

CURRICULUM VITAE

VANDAMME Anne-Mieke Irène

Private information

Born in Menen, Belgium on 17 september 1960

Belgian nationality

Married with two children : Karen born 31 July 1985, Tim born 11 December 1986.

Address:

Belgium:

Beatrijslaan 93
B-3110 Rotselaar
Belgium

Phone: +32-497-402888

Portugal:

Rua de Alcântara 45-2Esq
1300-025 Lisboa
Portugal

Phone: +351-964311167

Current assignments

Regular full professor at the Katholieke Universiteit Leuven, Faculty of Medicin, Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium

Address

Rega Institute for Medical Research
Minderbroedersstraat 10
B-3000 Leuven
Belgium

Phone: +32-16-332160

Fax : +32-16-332131

E-mail : annemie.vandamme@uzleuven.be

<http://regaweb.med.kuleuven.be/>

Invited full professore and head of the Biostatistics and Bioinformatics unit (BioSI) at the Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal

Address

IHMT
Rua da Junqueira 96

1349-008 Lisboa
Portugal
Phone: +351-21-3652685
Fax : +351-21-3632105

Founder and director of the companies IBEICO (International Biomedical Engineering and Informatics Consultancy Office) (since 2006) and MyBioData (Support for database solutions in the Biomedical sector) (2006-2014)

Address Beatrijslaan 93
 B-3110 Rotselaar
 Phone : +32-497 402 888
 E-mail : annemie.vandamme@mybiodata.eu

Education

June 1978: Secondary school : ASO Wet B, St-Niklaasinstituut, Kortrijk, Belgium.
July 1982: Master in Sciences, Katholieke Universiteit Leuven, Belgium, Faculty of Sciences, Chemistry department, specialisation Biochemistry, great distinction obtained during all four years.
March 1986: Doctor in Sciences, Katholieke Universiteit Leuven, Belgium, Faculty of Sciences, Chemistry department, Laboratory of Biochemistry, PhD obtained with the greatest distinction: "Study of the biosynthesis of hemocyanin in *Sepia officinalis*" Prof Lontie & Prof Préaux

Professional experience

October 1982 - October 1986

PhD student at the Katholieke Universiteit Leuven, Belgium, Chemistry department, Laboratory of Biochemistry, supervised by Prof R. Lontie and Prof G. Préaux : "Study of the biosynthesis of hemocyanin in *Sepia officinalis*"

Grants : "Aspirant NFWO" : October 1982 - October 1984
 October 1984 - October 1986

October 1986 - October 1987

Postdoctoral Scientist at the Katholieke Universiteit Leuven, Belgium, Chemistry department, Laboratory of Biochemistry, supervised by Prof G. Préaux : "Comparative study of the sequence, active site, bio-synthesis, antigenicity, and structure of biologically important proteins"

Grant : Postdoctoral grant of the Katholieke Universiteit Leuven

October 1987 - October 1990

Research assistant at the Katholieke Universiteit Leuven, Belgium, faculty of Medicine, Center for Thrombosis and Vascular Research (presently the Center for Vascular and Molecular Biology), supervised by Prof D. Collen : "Molecular biology of the fibrinolytic system and its involvement in pathogenic thrombo-embolic diseases"

Grant : "Aangesteld Navorsers NFWO" : October 1987 - October 1989

October 1990 – at present

Research associate (1990-1996), assistant professor (1996-1999), associate professor (1999-2002), full professor (2002-2005), regular full professor (2005-at present) at the Katholieke Universiteit Leuven, Faculty of Medicine, Department of Microbiology and Immunology, Belgium, Rega Institute for Medical Research, with several projects :

- Investigation of the molecular evolution of human viruses, HTLV, HIV, HCV, TTV.
- Evaluation of emerging antiviral drug resistance in clinical HIV and HCV strains using a genotyping and phenotyping approach
- Investigation on the factors that predict therapy response in HIV-infected patients using a database/datamining approach.
- Investigation of disease progression in HTLV or HIV infected patients.
- Evaluation and introduction of new molecular biology and bio-informatics based techniques and responsible for HIV drug resistance testing for the Belgian AIDS Reference laboratory in Leuven.

August 2006 – December 2007

Consultant at the Instituto Nacional de Saude Dr Ricardo Jorge, Portugal, Center for Bioinformatics.

Starting up and directing the Bioinformatics Unit.

- Setting up database systems.
- Providing bioinformatics support
- Giving bioinformatics training.

January 2008 – December 2009

Consultant at the 'Universidade de Lisboa', Bioinformatics support for the FCT center 'BioFIG'

January 2010 – at present

Invited full professor at the 'Universidade Nova de Lisboa', Bioinformatics support for the 'Instituto de Higiene e Medicina Tropical'

Invited lectures

1. *Comparison of reverse transcriptase gene sequences from HIV-1 strains with different sensitivity to TIBO derivatives.* Lecture given during my visit at the Henry M. Jackson Foundation, Rockville, Maryland, USA. 24/03/92-27/03/92.

2. *Comparison of reverse transcriptase gene sequences from HIV-1 strains with different sensitivity to TIBO derivatives.* Lecture given on 07/10/92 at the "Instituut voor Tropische Geneeskunde" in Antwerp, Belgium.
3. *Cell type-specific anti-HIV-1 activity of the transactivator inhibitor Ro5-3335.* Lecture given on 07/10/92 at the "Instituut voor Tropische Geneeskunde" in Antwerp, Belgium.
4. *Phylogenetic analysis of new types of primate T-lymphotropic viruses : implications for the origin of human retroviruses.* Lecture given on 16/08/94 during my visit at the Institute for Virus Research, Kyoto University, Japan. 13-16/08/94
5. *Phylogenetic analysis of primate T-lymphotropic viruses.* Lecture given on 25/01/96 during my visit at INSERM U271, Unité de Recherche sur les hépatites, le SIDA et les rétrovirus humains, Lyon, France. 25-26/01/96
6. *Genotypic resistance in HIV-1 isolates from patients treated with several combinations of ZDV, DDI, DDC and 3TC.* Lecture given on 07/11/96 on the INNO-LiPA HIV drug resistance satellite symposium during the Third International Congress on Drug Therapy in HIV Infection, Birmingham, UK, November 3-7, 1996
7. *Prevalence of multinucleoside analogue resistant HIV-1 strains in Europe.* Lecture given on 21/04/1997 during my visit at the Department of Internal Medicine, Institute of Clinical Immunology, Rheumatology, Hematology & Oncology, University of Erlangen-Nürnberg, Erlangen, Germany.
8. *Evolution of Primate T-lymphotropic Viruses.* Lecture given on 22/04/1997 during my visit at the laboratory for Medical Microbiology, Pettenkofer Institut, Munchen, Germany.
9. *Multi nucleoside analogue resistant HIV-1 in Europe.* Lecture given on 30/09/98 during the gathering of the clinical virologists of The Netherlands (NWKV) in Maastricht, The Netherlands.
10. *HTLV infection in individuals with indeterminate serologies.* Lecture given on 15/12/98 during my visit at the Centro de Hematologia e Hemoterapia do Ceara-Hemoce, Fortaleza, Brazil.
11. *The use of PCR in the study of HTLV-associated haematologic disorders.* Lecture given on 15/12/98 during my visit at the Centro de Hematologia e Hemoterapia do Ceara-Hemoce, Fortaleza, Brazil.
12. *Gene regulation for the human retroviruses HIV and HTLV, and possible interactions in cases of double infection.* Lecture given on 04/02/99 at the Department of Molecular Biology, University of Gent, Belgium.
13. *The multiple nucleoside analogue resistance mutations confer cross-resistance to Abacavir.* Lecture given on 12/02/1999 during my visit at the Institut für Klinische und Molekulare Virologie, University of Erlangen-Nürnberg, Erlangen, Germany.
14. *The simian origins of the human T-cell leukemia/lymphoma virus type 1.* Lecture given on 20/04/1999 during my visit at the Laboratoire de Rétrovirologie, CRP-Santé, Luxembourg.
15. *The simian origins of the pathogenic human T-cell lymphotropic virus type 1.* Lecture given on 28/05/1999 during my visit at the Institut für Virologie, Universität Köln, Germany.

16. *European guidelines for the clinical use of HIV-1 drug resistance testing*. Lecture given on 09/03/2000 at the "Instituut voor Tropische Geneeskunde" in Antwerp, Belgium.
17. *Methods for testing HIV-1 drug resistance*. Lecture given on 17/10/2000 at the "Max von Pettenkofer-Institut" in München, Germany.
18. *New Developments in anti-HIV Therapy: Potential Role for HIV Tat and Rev inhibitors*. Lecture given on 22/03/2001 at the "Instituut voor Tropische Geneeskunde" in Antwerp, Belgium.
19. *Impact of viral evolution on treatment outcome: viral load monitoring, viral subtypes and emergence of drug-resistance*. Lecture given on 03/05/2001 at the EATG meeting "Developments in HIV and treatment management of drug-related toxicities and side effects" in Brussels, Belgium.
20. *History of HIV*. Lecture given on 20/06/2001 at the University Hospital St Pieter, Brussels, Belgium.
21. *Phylogenetic analysis of new types of primate T-lymphotropic viruses: implications for the origin of human retroviruses*. Lecture given on 25/02/2002 at the Regional Primate Research Center, Seattle, USA.
22. *HTLV and HIV molecular epidemiology : dating their zoonotic origin*. Lecture given on 25/02/2004 at the 'Institut des Sciences de la Vie', Université Catholique de Louvain, Louvain-La-Neuve, Belgium.
23. *Evolution of viruses*. Lecture given on 09/03/2004 at the 'Rega Institute for Medical Research', Katholieke Universiteit Leuven, Leuven, Belgium.
24. *HIV-1 subtypes and drug resistance*. Lecture given on 07/12/2005 at the 'University of Antwerp', Antwerp, Belgium.
25. *HTLV and HIV molecular epidemiology: dating their zoonotic origin*. Lecture given on 11/10/2005 at the 'Biomedical Primate Research Centre', Rijswijk, The Netherlands.
26. *HTLV and HIV molecular epidemiology: dating their zoonotic origin*. Lecture given on 22/11/2005 at the 'Université de Liège', Sart Tilman, Belgium.
27. *HIV tropism determinants and how to measure them*. Lecture given on 04/12/2006 at the Belgian headquarters of Pfizer.
28. *HTLV and HIV molecular epidemiology: dating their zoonotic origin*. Lecture given on 20/04/2007 at the 'Laboratory of Aquatic Ecology', KULeuven, Belgium.
29. *RegaDB Collaborative System*. Lecture given on 04/05/2007 at the 'Cascade workshop', Robert Koch Institute, Berlin
30. *Molecular epidemiology as a forensic technique for HIV and HCV transmission investigation*. Lecture given on 29/11/2007 at the 'Instituto Nacional de Saúde', Lissabon, Portugal.
31. *The making of the Rega algorithm*. Lecture given on 14/12/2007 at the 'First International Consensus Conference about Inhibitory Quotients (ICCIQ), Paris Roissy Sheraton Hotel, France.
32. *Update on clinical use of co-receptor assays*. Lecture given on 06/03/2008 at the 'ECAB meeting of the European AIDS Treatment Group', Brussels, SAS radisson EU hotel, Belgium.

33. *Modelling HIV-1 Evolution under Drug Selective Pressure*. Lecture given on 16/01/2009 at the KDBIO, Instituto de Engenharia de Sistemas e Computadores, Lisbon, Portugal.
34. *Datamining for HIV resistance*. Lecture given on 28/04/2009 at the Institute of Microbiology, University Hospital Center, University of Lausanne, Switzerland.
35. *Molecular evolution and inferring phylogenies*. Presentation as part of the Bridge Meetings organized by the Erasmus Postgraduate School Molecular Medicine, given on 08/09/2009 at the Erasmus Medical Center, Rotterdam, The Netherlands.
36. *The HIV-1 pandemia*. Lecture given on 15/10/2009 at the National HIV Reference Center, Sheba Medical Center, Tel-Hashomer, and School of Public Health, Tel-Aviv University, Tel-Aviv, Israel
37. *The Origins of HIV*. Lecture given on 16/06/2010 at the MPL Lecture Theatre, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar-Es-Salaam, Tanzania.
38. *Kinshasa, the Cradle of the Current AIDS Pandemic*. Lecture given on 18/11/2010 at the Auditorium Museum M, Leuven, Belgium. This lecture was part of a series on 50 years independence of Congo.
39. *Forensic HIV research*. Lecture given on 03/12/2010 at the Laboratory for Forensic Genetics and Molecular Archeology, Katholieke Universiteit Leuven, Leuven, Belgium.
40. *Molecular epidemiology as a forensic technique for HIV and HCV transmission investigation*. Lecture given on 16/12/2010 at the Faculty of Medicine, Lund University, Sweden.
41. *Viral pathogen phylogenomics and disease dynamics: HIV as example*. ECDC Expert consultation: Breakthroughs in molecular epidemiology of human pathogens: how to translate into public health practice 22-23 November, 2011, Stockholm, Sweden.
42. *Comparison between genotypic interpretation algorithms*. Lecture given on 24/05/2012 at the 3rd Siemens Academy Scientific Day, Brussels, Belgium
43. *Could transmission of HIV drug resistance push the virus towards a more aggressive form?* Lecture given on 19/12/2012 at the Instituto de Higiene e Medicina Tropical, Lisbon, Portugal.
44. *Anomaly detection tool*. Lecture given on 3 March 2013 at the WHO ResNet meeting, Atlanta, USA.
45. *RegaDB: Virus data management and analysis environment*. Lecture given on 7 March 2013 at the CDC, Atlanta, USA.
46. *Origin and spread of the HIV pandemic*. Lecture given on 5 June 2014 at the National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
47. *HIV genetic sequences for forensic purposes*. Lecture given on 23 September 2014 at the Universidade Salvador "UNIFACS", Salvador, Bahia, Brazil.

Scientific distinctions

Award Jean-Servais Stas 1986, granted for my PhD thesis.

Award Franz Van Goidsenhoven for Clinical Medical Science, Period 1989-1991 :
Enhancement of the thrombolytic potency of urokinase-type plasminogen activator by
targeting with clot-specific monoclonal antibodies.

Special award of the Belgian Royal Academy of Medicine, Period 1991-1993 :
Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection.

Award Dr. & Mrs Schamelhout-Koettlitz for Medical Science, Period 1996-1997 :
Groeierende divergentie binnen de primate T-cel lymfotrope virussen.

Accepted for the 'EMBO Practical Course': "Sequence Analysis and Molecular
Evolution", Heidelberg, Germany, June 20-26, 1995.

Accepted for the 'Workshop on Molecular Evolution' at the Marine Biology Laboratory in
Woods Hole, MA, USA, August 6-18, 1995.

Travel grant of the NFWO for the VIIth International Conference on AIDS, Florence, Italy,
June 16-21, 1991.

Travel grant of the NFWO for the IXth International Conference on AIDS, Berlin,
Germany, June 7-11, 1993.

Travel grant of the NFWO for the 1st European Conference on Experimental AIDS
Research, Cannes, France, March 10-13, 1996.

Travel grant of the FWO for the VIIIth International Conference in Human Retrovirology :
HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.

Travel grant of the FWO for the 4th International Congress on Drug Therapy in HIV
Infection, Glasgow, Scotland, November 8-12, 1998

Travel grant of the FWO for the VIIIth International Conference in Human Retrovirology :
HTLV, Kagoshima, Japan, April 5-9, 1999.

Travel grant of the FWO for the XIIIth International AIDS Conference, Durban, South-
Africa, 9-14 July 2000.

Travel grant of the FWO for the Fifth International Workshop on HIV Drug Resistance
and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001.

Travel grant of the FWO for the 9th International Workshop on HIV Dynamics and
Evolution, Lake Arrowhead, USA, March 17-20, 2002.

Travel grant of the FWO for the 11th International Workshop on HIV Dynamics and Evolution, Stockholm, Sweden, April 29 – May 2, 2004.

Young researcher scholarship award for the abstract: **Vandamme A.-M.**, Schmit J.-C., Balzarini J., Witvrouw M., Van Laethem K., Hermans P., Kleim J.-P., Desmyter J., & De Clercq E. In vitro selection of high level quinoxaline (HBY097) resistance using a patient isolate displaying multidrug resistant phenotype. Third International Congress on Drug Therapy in HIV Infection, Birmingham, UK, November 3-7, 1996. AIDS 10, S20, 1996.

Young researcher award granted to Kristien Van Vaerenbergh for the abstract: Van Vaerenbergh K., Van Laethem K., Albert J., Albrecht H., Boucher C., Clotet B., Florida M., Nielsen C., Pedersen C., Perrin L., Ruiz L., Schmit J.C., Schneider F., Schoolmeesters A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerley S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Multinucleoside drug resistance among European HIV-1-infected patients. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, Oct 11-15, 1997

Best Poster award at the ECEAR meeting granted to Sonia Van Dooren for the abstract: Van Dooren S., Salemi M., Gotuzzo E., Watts D., Audenaert E., Duwe S., Ellerbrok H., Grassmann R., Desmyter J. & **Vandamme A.-M.** Post-Colombian introduction of HTLV-I in Latin-America. Third European Conference on Experimental AIDS Research, Munchen, Germany, Februari 28 -March 03, 1998.

Young researcher scholarship award granted to Kritsel Van Laethem for the abstract: Van Laethem K., Witvrouw M., Schmit J.C., Sprecher S., Hermans P., Leal M., Harrer T., Clotet B., Ruiz L., De Clercq E., Desmyter J., & **Vandamme A.-M.** The multiple nucleoside analogue resistance mutations confer cross-resistance to Abacavir. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 31 January-4 February 1999.

Young researcher scholarship award granted to Sonia Van Dooren for the abstract: Van Dooren S., Salemi M., Delaporte E., Pourrut X., Verschoor E., Van Goidsenhoven I., Desmyter J. & **Vandamme A.-M.** Analysis of the simian origin of the HTLV-I subtypes. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999.

Young researcher scholarship award granted to Marco Salemi for the abstract: Salemi M., Desmyter J., & **Vandamme A.-M.** Estimation of the divergence time for the major human and simian T-lymphotropic virus (HTLV/STLV) lineages by analysing full genome sequences. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999.

Best Poster award at the 13de Wetenschappelijke Vergadering van de Belgische Vereniging voor Infectiologie en Klinische Microbiologie granted to Gaëtan Muyltermans toegekend aan voor de poster: Muyltermans G., Debaisieux L., Fransen K., Marissens D., Miller K., Vaira D., **Vandamme A.-M.**, Vandenbroucke A.T., Verhofstede

C., Schuurman R., Zisis G., Lauwers S. Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories. 13de Wetenschappelijke Vergadering van de Belgische Vereniging voor Infectiologie en Klinische Microbiologie, Sint-Niklaas, Belgium, 11 December 1999.

Young researcher scholarship award granted to Sonia Van Dooren for the abstracts: Van Dooren S., Gessain A. & **Vandamme A.-M.** Full Genome Analysis of the Current Most Divergent STLV-I Strain Present in a *Macaca arctoides*. - Van Dooren S., Pourrut X., Peeters M., Delaporte E. & **Vandamme A.-M.** A second divergent 'STLV-L'-like strain detected in a *Cercopithecus nictans* from Cameroon. - Van Dooren S., Salemi M., Liu H.-F., Goubau P., Prims M., Vancuyck D., Remondegui C., Bouzas M.B., Talarmin A., Gotuzzo E., Gurtsevitch V. & **Vandamme A.-M.** Low HTLV-I evolutionary rate confirmed in cases of vertical intrafamilial HTLV-I transmission. - Van Dooren S., Prims M., Verschoor E., Langenhuijzen S., Pourrut X., Peeters M., Delaporte E. & **Vandamme A.-M.** Phylogenetic Characterization of STLV-I Strains from Various Asian and African Monkey Species. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001..

Award for the 'Best scientific papers originating in Ireland', Period 2000-2001: obtained with the paper 'Salemi M., Strimmer K., Hall W.W., Duffy M., Delaporte E., Mboup S., Peeters M. & **Vandamme A.-M.** Dating the radiation of HIV-1 group M in 1930s using a new method to uncover clock-like molecular evolution. *FASEB Journal* online 10.1096/fj.00-0449fje, 2000. *FASEB Journal* 15: 276-278, 2001'

Educational assignments

Assistance in teaching :

- "Genetische en chemische manipulatie van antilichamen" (2 hours); 2nd year postgraduate education in Biotechnology (20 students), KULeuven, academic year 1989-1990 and 1990-1991, substituting for Prof. D. Collen as part of the course "Cellulaire immunologie en biotechnologie in de medische wetenschappen, E514, 15 uur".
- Practical courses for the 2nd year postgraduate education in Biotechnology (2 weeks), assisting Dr. Luc Nelles, KULeuven academic year 1989-1990 and 1990-1991;

Teaching :

- "Molecular epidemiology of viruses" (1 hour/week one semester); 3rd year Medical School at the Katholieke Universiteit Leuven, Belgium, 1996-2001.
- "Evolution moléculaire des virus : théorie et applications" (2 times 2 hours in total); Université Catholique de Louvain, Brussels, Belgium 1996-1999.

- "Phenotypic Resistance Assays – Technical overview and description" From Laboratory To Patient: Course in HIV Resistance and Resistance Assays. University Medical Center Utrecht; Virology Education. 5-6 Juni, 2000.
- "Scientific Research Education" (1 hour/week one semester); 2nd and 3rd year Medical School at the Katholieke Universiteit Leuven, Belgium, 2001-2007.
- "Genetics, Genetic Evolution Mechanisms and Genetic Nomenclature" (Team-teaching with 4 teachers). Master in Sciences Bioinformatics at the Katholieke Universiteit Leuven, Belgium, 2001-2014.
- "Introduction to Genetics" (Team-teaching with 4 teachers). Master in Sciences Bioinformatics at the Katholieke Universiteit Leuven, Belgium, since 2014.
- "Bioinformatics" (Team-teaching with 4 teachers). Postgraduate Bioinformatics at the Katholieke Universiteit Leuven, Belgium, 2001-2007.
- "Molecular epidemiology of HIV and HTLV" (4 hours) Postgraduate course: "Epidemiology of Infectious Diseases", at the Municipal Health Service, Amsterdam, The Netherlands, 18-22 February 2002.
- "Fundamentals of molecular evolution", "Construction of phylogenetic trees: powers and pitfalls of tree construction methods", "Practical computer session 1: Construction and interpretation of phylogenetic trees" during the "First Brazilian workshop on virus evolution and molecular epidemiology", Bahia, Brazil, 25-27 maart 2002.
- "Bio-informatics: Evolutionary and Quantitative Genetics" (Team-teaching with 3 teachers). Master in Sciences Bioinformatics at the Katholieke Universiteit Leuven, Belgium, 2008-2012.
- "Bioinformatics and systems biology" (Team-teaching with 4 teachers). Master in Biomedical Sciences at the Katholieke Universiteit Leuven, Belgium, since 2008.
- "Phylogenetic Investigation in Forensic Sciences" at the Egas Moniz - Cooperativa de Ensino Superior, Lisbon, Portugal, teaching in the "Erasmus Mundus Msc in Forensic Sciences", 2012.
- "Computational biology and Bioinformatics" (Team-teaching with 9 teachers). Postgraduate in human genetics and infectious diseases at the Universidade Nova de Lisboa, Lisboa, Portugal, since 2013.

Training and advising researcher for PhD students :

- Christine De Greef : 1984 - 1989 (Promoter Prof. G. Préaux). "Afzonderen, fractioneren en kloneren van hemocyanine-mRNA-rijke fracties uit de cefalopood *Sepia officinalis*", Faculty of Sciences.
- Lieve Declercq : 1986 - 1990 (Promoter Prof. G. Préaux). "Partiële sekwentiebepaling van het hemocyanine bij *Sepia officinalis* en lokalisatie van de

hemocyanine-biosyntheseplaats bij *Helix pomatia* via de rekombinant-DNA technologie", Faculty of Sciences.

- Hsin-Fu Liu : 1991 - 1996 (Promoter Prof. J. Desmyter, co-promoter Prof P Goubau). "Genomic diversity and molecular phylogeny of human and simian T-cell lymphotropic viruses", Faculty of Medicine.

Copromoter for PhD students :

- Jean-Claude Schmit : 1993 - 1998 (Promoter Prof. E. De Clercq, co-promoter Prof **Anne-Mieke Vandamme**): "Clinical relevance of human immunodeficiency virus (HIV) type 1 drug resistance", Faculty of Medicine.
- Marianne Van Brussel : 1992 - 1998 (Promoter Prof. J. Desmyter, co-promoters Prof **Anne-Mieke Vandamme** and Prof Roger Huybrechts): "Isolation and genomic characterization of two new simian T- lymphotropic viruses", Faculty of Sciences.
- Dirk Daelemans : 1996 - 2000 (Promoter Prof. E. De Clercq, co-promoters Prof. J. Vanderleyden, and Prof **Anne-Mieke Vandamme**): "HIV-1 gene regulation inhibitors: mechanism and target of action", Faculty of Agriculture and Applied Biological Sciences.
- Kris Covens: 2004 - 2010. Biomedical Sciences. "HIV-1 drug resistance pathways: new methodologies and application to fusion inhibitors" (promoter: Kristel Van Laethem, co-promotor: **Anne-Mieke Vandamme**)
- Nuno Faria: 2009-2013. Uncovering the patterns of gene flow in viral epidemic history. (Promoter Philippe Lemey, co-promoter **Anne-Mieke Vandamme**).
- Bram Vrancken: 2009-present. "Een populatiegenomisch perspectief op persistente virale infecties." (Promoter Philippe Lemey, co-promoter **Anne-Mieke Vandamme**).
- Sarah Megens: 2009-present. Genetische determinanten van coreceptor gebruik en resistentie tegen entry inhibitoren in HIV-1 groep M. (Promoter Kristel Van Laethem, co-promoter **Anne-Mieke Vandamme**).
- Lize Cuypers: 2012-present. HCV..... (Promoter Kristel Van Laethem, co-promoter **Anne-Mieke Vandamme**).

Promoter for PhD students :

- Marco Salemi: 1995-1999 (Promoter **Anne-Mieke Vandamme**, co-promoters Y. Engelborghs and J. Desmyter): "Molecular investigation of the origin and genetic stability of the human T-cell lymphotropic viruses", KU Leuven, Faculty of Sciences.
- Kristien Van Vaerenbergh: 1996-2001 (Promoter **Anne-Mieke Vandamme**, co-promoter E. De Clercq): "Study of the impact of HIV genotypic drug resistance testing on therapy efficacy", KU Leuven, Faculty of Medicine.
- Kristel Van Laethem: 1997-2001 (Promoter **Anne-Mieke Vandamme**, co-promoter E. De Clercq): "*In vitro* investigation of the correlation between genotype and phenotype in clinical HIV-1 isolates", KULeuven, Faculty of Medicine.

- Philippe Lemey: 2000-2005 (Promoter **Anne-Mieke Vandamme**, co-promoter Marc Van Ranst): “Molecular investigation of evolutionary and population genetic processes in human retroviruses”, KU Leuven, Faculty of Medicine.
- Joke Snoeck: 2000-2005 (Promoter **Anne-Mieke Vandamme**, co-promoter R. Huybrechts): “HIV-1 genetic diversity and anti-HIV-1 drug resistance”, KU Leuven, Faculty of Sciences.
- Inge Derdelinckx: 2000-2005 (Promoter **Anne-Mieke Vandamme**, co-promoter E. Van Wijngaerden): “Resistance among untreated HIV infected patients: methods for detection, prevalence in Belgium and impact on treatment response”, KU Leuven, Faculty of Medicine.
- Sonia Van Dooren: 1998-2005 (Promoters **Anne-Mieke Vandamme** and M Horzinek, co-promoter E. Verschoor): “Molecular investigation of the evolutionary history and diversity of primate T-lymphotropic virus types 1 and 3”, University of Utrecht, Faculty of Veterinary Sciences.
- Koen Deforche: 2003-2008. Biomedical Sciences. “Modeling HIV resistance evolution under drug selective pressure” (Promoter **Anne-Mieke Vandamme**, co-promoters H. Blockeel and Y Moreau)
- Ana Abecasis: 2004-2009. Biomedical Sciences. “The impact of genetic diversity on HIV-1 molecular epidemiology and antiviral drug resistance” (Promoter: **Anne-Mieke Vandamme**, co-promoter Ricardo Camacho)
- Jurgen Vercauteren: 2004-2009. Biomedical Sciences. “The epidemiology of HIV-1 drug resistance” (promoter: **Anne-Mieke Vandamme**, co-promoter Eric Van Wijngaerden)
- Kristof Theys: 2005-2010. Biomedical Sciences. “HIV-1 evolutionary dynamics. Individualized prediction of antiretroviral resistance” (promoter: **Anne-Mieke Vandamme**, co-promoter Hendrik Blockeel)
- Britta Moens: 2006-2012. Biomedical Sciences. “*In vitro* and *ex vivo* evaluation of currently used and novel therapeutic strategies in HTLV-1 infection” (Promoter **Anne-Mieke Vandamme**, co-promoters Johan Van Weyenbergh, Christophe Pannecouque)
- Ana Carolina Palma: 2007–2012. Biomedical Sciences. “The influence of HIV-1 genetic background on antiviral drug resistance pathways” (promoter: **Anne-Mieke Vandamme**, co-promoters Ricardo Camacho and Kristel Van Laethem)
- Raphael Sangeda: 2007–2013. Biomedical Sciences. “Challenges for monitoring HIV-1 therapy response in resource-limited settings” (Promoter **Anne-Mieke Vandamme**, co-promoters Eric Van Wijngaerden and Eligius F. Lyamuya)
- Fausta Mosha: 2010-2014. Biomedical Sciences. “Socio-demographic factors associated with success of antiretroviral treatment among HIV patients in Dar es Salaam, Tanzania. (Promoter **Anne-Mieke Vandamme**, co-promoter Eligius Lyamuya)

- Guangdi Li: 2009-2014. Biomedical Sciences. "HIV genome-wide diversity, interaction and coevolution" (promotor: **Anne-Mieke Vandamme**, co-promoter Jan Ramon)
- Andrea Clemencia Pineda Pena: 2010-2014. Biomedical Sciences. "The Dynamics of Local HIV-1 Epidemics. The Colombian and Belgian cohorts." (Promoter **Anne-Mieke Vandamme**, co-promoter Kristel Van Laethem, co-promoter Arley Gomez Lopez)
- Soo-Yon Rhee: 2010-2015. Biomedical Sciences. "Identifying Genetic Correlates of HIV-1 Drug Resistance Using a Multifaceted Approach: Genotype-Treatment, Genotype-Phenotype, and Genotype-Clinical Outcome Correlations" (Promoter **Anne-Mieke Vandamme**, co-promoter Robert W. Shafer)
- Ricardo Khouri: 2009-present. Biomedical Sciences. "Immune activation in Immune activation in HIV-1 and HTLV-1 infection: a candidate gene and systematic approach" (Promoter **Anne-Mieke Vandamme**, co-promoter Johan Van Weyenbergh)
- João Sousa: 2010-present. Biomedical Sciences. "Understanding the factors involved in the origin and epidemic emergence of the HIV strains" (Promoter **Anne-Mieke Vandamme**, co-promoters Philippe Lemey and Viktor Müller)
- Soraya Maria Menezes: 2011-present. Biomedical Sciences. "Identification of biomarkers and novel therapeutic targets in HTLV-1-associated pathologies" (Promoter **Anne-Mieke Vandamme**, co-promoter Johan Van Weyenbergh)
- Carolina Alvarez: 2012-present. Biomedical Sciences. "Use of data mining to identify clinical markers of disease progression in HTLV-1-associated myelopathy (HAM/TSP)" (Promoter **Anne-Mieke Vandamme**, co-promoter Eduardo Gotuzzo and Kristien Verdonck)

Co-promoter of several master theses :

- Darek Krzywania: 2001-2002, "Licentie informatica". "Datamining in HIV-onderzoek".
- Anneleen Vanassche: 2001-2002, "Licentie informatica". "Datamining in HIV-onderzoek".
- Tom Moerman: 2001-2002, "Licentie informatica". "Datamining in AIDS-onderzoek".

Promoter of several master theses :

- Kristel Van Laethem : 1993-1994, "Industriëel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Toepassing van de polymerase chain reaction (PCR) bij de diagnose van HIV-infecties".

- Christophe Van Vaeck : 1994-1995, "Licentie Biologie". "Analyse van het genotypische resistentiepatroon bij het humaan immunodeficiency virus type 1 (HIV-1) geïsoleerd uit patiënten tijdens hun behandeling met reverse transcriptase (RT) inhibitoren."
- Robert Rousseau : 1994-1995, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Nucleotidesequentie en genomische organisatie van het Primaat T-lymfotroop virus type Leuven."
- Dirk Daelemans : 1995-1996, "Ingenieur in de scheikunde en landbouwindustrieën". "De genregulatie van HIV als doelwit voor antivirale therapie".
- Jan Gabriëls : 1995-1996, "Ingenieur in de scheikunde en landbouwindustrieën". "De genomische organisatie van twee nieuwe types primate T-lymfotrope virussen".
- Ilse Van der Linden : 1995-1996, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Detectie van HIV-1 resistentiemutaties via diverse genetische technieken."
- Elke Audenaert : 1996-1997, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "De evolutie en moleculaire epidemiologie van het humaan T-cel lymfotroop virus (HTLV-I)"
- Veronique De Vroey : 1996-1997, "Ingenieur in de scheikunde en landbouwindustrieën". "Genotypisch resistentieprofiel van HIV-1 bij patiënten behandeld met een combinatie van anti-HIV-1 middelen"
- Machteld Deconinck : 1997-1998, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Kloneren van het volledig genoom van een nieuw humaan T-cel lymfotroop virus subtype IId uit lymfocyt DNA"
- Lisbet Willems : 1997-1998, "Licentiaat biomedische wetenschappen". "De genregulatie van HIV als doelwit voor antivirale therapie"
- Inge Van Goidsenhoven: 1998-1999, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Moleculaire epidemiologie van humane en apen T-cel lymfotrope virussen type I"
- Kristel Declercq: 1998-1999, "Ingenieur in de scheikunde en landbouwindustrieën". "Evaluatie van genotypische resistentietechnieken bij de opvolging van patiënten besmet met HIV-1"
- Bart Maes: 1999-2000, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Evaluatie en gebruik van genotypische resistentietechnieken bij de opvolging van patiënten besmet met HIV-1"
- Luc Vandenberghe: 1999-2000 "Ingenieur in de scheikunde en landbouwindustrieën". "Evaluatiemethoden voor inhibitoren van de HIV-1 genregulatie: ontwikkeling, optimalisatie en toepassing"
- Marie Prims: 2000-2001, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Studie van de moleculaire evolutie van humane en apen T-cell lymfotrope virussen HTLV-I en STLV-I"
- Kirsten De Schouwer: 2001-2002, "Industrieel ingenieur" De Naeyer Instituut, St Kathelijne Waver, Belgium. "Het belang van resistente mineure varianten bij HIV-infectie"

- Koen Deforche: 2002-2003, Masters of Science in Bioinformatics, KULeuven. "Development of a sliding window tool for phylogenetic analysis using a Bayesian algorithm"
- Fausta Shakiwa Moshia: 2002-2003, 'Master in Medical Sciences', KULeuven, "Characterisation of a possible new circulating recombinant form (CRF) of HIV-1"
- Stéphanie Dumont: 2002-2003, "Industrieel ingenieur", De Naeyer Instituut, St Kathelijne Waver, Belgium. "Reconstructie van een HIV-1 transmissieketen met behulp van moleculair biologische technieken"
- Kim Steegen: 2002-2003, 'Master in Biomedical Sciences', KULeuven, "Optimalisatie van genotypische resistentietesten voor klinische HIV-1 stammen van diverse subtypes"
- Katarina Seghers: 2002-2003, 'Master in Biomedical Sciences', KULeuven, "Op punt stellen en toepassen van moleculair biologische technieken bij het onderzoek naar antiretrovirale resistentie in klinische HIV-1 isolaten"
- Steve Vermeulen: 2002-2003, Master in Biomedical Sciences', KULeuven, "Karakterisatie van een HIV-1 transmissieketen aan de hand van genetische informatie"
- Lies Vanheeswijck: 2004-2005, 'Master in Biomedical Sciences', KULeuven, "Optimalisatie en validatie van genotypische testen voor klinische HIV-1 stammen van diverse subtypes"
- Raphael Sangeda: 2006-2008, 'Master of Science in Bioinformatics', KULeuven, "Estimating the Human Immunodeficiency Virus (HIV) fitness landscape under indinavir treatment pressure from observed evolution in longitudinal sequence data."
- Leonidas Salichos: 2005-2006, 'Master of Science in Bioinformatics', KULeuven, "Classification of HIV-1 strains using the automated REGA HIV-1 Subtyping Tool V1.0 and further phylogenetic analysis"
- Yunpeng Wang: 2008-2009, 'Master of Bio-informatics', KULeuven, "Comparative study of REGA HIVsubtyping Tool version 1 and version 2"
- Gertjan Beheydt: 2008-2009, 'Master of Bio-informatics', KULeuven, "Automating the process of estimating genetic fitness landscapes for HIV under drug selective pressure"
- Joris De Ranter: 2009-2010, 'Master of Bio-informatics', KULeuven, "Automated clustering of endogenous retroviruses using their DNA sequences"
- Raf Winand: 2010-2011, 'Master of Bio-informatics', KULeuven, "Development of a phylogenetic framework for the detection of HIV-1 drug resistance transmission chains"
- Ewout Vanden Eynden: 2013-2014, 'Master of Bio-informatics', KULeuven, "Development of a bioinformatics framework for detection of HIV-1 transmission. Application to the subtype G epidemic" (co-promotor Ana Abecasis).
- Abbas Jariani: 2013-2014, 'Master of Bio-informatics', KULeuven, 'Investigating HIV-1 Evolutionary Dynamics Using a Forward-in-Time Evolution Simulator: Selective Pressure, Mutation and Recombination' (Promoters Anne-Mieke Vandamme, Kristof Theys, Ana Abecasis). KU Leuven 2014.

-

Jury member of PhD theses abroad:

- Mehdi Gasmi : “Analyse génotypique du rétrovirus HTLV-1 sous l’influence de l’origine géographique, des facteurs d’hôte et du traitement par l’AZT”, 26 Januari 1996, Université Claude Bernard Lyon I, INSERM, France.
- Marleen Vanden Haesevelde : “Genetic evidence for additional phylogenetic subtypes within the human immunodeficiency virus type 1 lineage”, June 1996, Vrije Universiteit Brussel, Fakulteit van de Wetenschappen, Brussels, Belgium.
- Zuojiang Gong: “In vitro infection of hepatitis B virus : a direct involvement of human Annexin V and an in vitro test system for development of antiviral drugs”, June 1998, KULeuven, Fakulteit Geneeskunde, Leuven, Belgium.
- Bernadette Trentin: “Transcriptase inverse du HTLV-I: expression, structure et rôle dans l’infectiosité”, Januari 1999, Université Victor Segalen Bordeaux 2, France.
- Karine Triques: “Diversité génétique due VIH-1. Impact sur le diagnostic moléculaire et la variabilité génétique intra-patient”, December 2000, Université de Montpellier II, France
- Fengxia Xiao: “Reconstruction of the evolution of chinese populations by the study of human genome diversity”, June 2001, KULeuven, Fakulteit Geneeskunde, Leuven, België.
- Rui Mang: “Endogenous retrovirus and xenotransplantation”, juni 2001, Department of Human Retrovirology, June 2001, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- Jun Lin: “Positional cloning of XLMR genes”, June 2001, KULeuven, Fakulteit Geneeskunde, Leuven, België.
- Chris Verslype: “Detection of Hepatitis C virus-core and –envelope (E2) proteins in the liver. A tool to study patients with non-A to E Hepatitis”, May 2002, KULeuven, Fakulteit Geneeskunde, Leuven, België.
- Morgane Rolland : ‘Etude des relations phylogénétiques entre les lentivirus des petits ruminants’, July 2003, Université Victor Segalen Bordeaux 2, France.
- Laurence Vergne: ‘Génotypes et phenotypes du HIV-1 en Afrique: implications biologiques et thérapeutiques de la diversité génétique’, November 2003, Université de Montpellier II, France.
- Laurent Meertens: ‘La diversité génétique des STLV-1 et des STLV-3 et l’étude des mécanismes de répression de l’activité transcriptionnelle de la protéine suppresseur de tumeur p53 par la protéine Tax d’HTLV-2 de sous-type B.’, December 2003, Université Paris 7-Denis Diderot, Institut Pasteur Paris, France.

- Ana Margarida Domingos Tavares de Sousa : 'Generation and reconstruction of experimental phylogenies', January 2008, Universidade de Lisboa, Lisbon, Portugal.
- Etiène Simon-Lorière: 'Caractérisation des premières étapes de génération de formes recombinantes chez le VIH-1', December 2008, Université Pierre et Marie Curie, Paris, France.
- Joakim Esbjörnsson : 'HIV-1 evolution, disease progression and molecular epidemiology of HIV-1 single and HIV-1 and HIV-2 dual-infected individuals in Guinea-Bissau', December 2010, Faculty of Medicine, Lund University, Sweden.
- Carla Van Tienen : 'Molecular epidemiology of HIV-1, HIV-2 and HTLV-1 in Guinea Bissau', December 2011, Faculty of Medicine, University of Amsterdam, The Netherlands.

Other scientific contributions

Evaluator of grant applications :

- The Israel Science Foundation, 1995.
- US National Science Foundation, 1996.
- Italian Association for Cancer Research, 1998.
- The Wellcome Trust, 1999, 2001, 2002, 2003, 2004.
- Postdoctoral grants of the Flemish Institute Supporting Scientific Technological Research in Industry (IWT), 1998-1999, 2003-2004.
- European Commission, Framework Program 5 (FP5), 1999-2001. FP6 Marie Curie, 2007.
- Agence Nationale de Recherches sur le SIDA. Membre du Comité Scientifique Sectoriel N° ¾: "Recherches cliniques et physiopathologiques", 1999-2001.
- Predoctoral grants of the Flemish Institute Supporting Scientific Technological Research in Industry (IWT) (Veterinary Medicine), November 1999.
- National Program for Basic Research in Microbiology, Infectious and Parasitic Diseases; France, 2000.
- Premier's Research Excellence Award (PREA), University of Ottawa, Canada, 2003.
- Evaluator for faculty positions at many international universities (European, American, Middle-East, Africa)
- Service for Research, International and Public Relations, Cyprus, 2004
- University of Cyprus, Medicine, 2007.
- University of Liège, Bioinformatics, 2007

- Fonds pour la formation à la Recherche dans l'Industrie et dans l'Agriculture, Belgium, 2007
- Onderzoekskoördinatie, IDO, Katholieke Universiteit Leuven, 2008
- Member of FWO (Flemish Fund for Scientific Research) commission MED6 « Clinical and Epidemiological Research », Belgium, 2009.
- The Royal Society, Newton International Fellowships, 2010
- Dutch AIDS FONDS, HIV/AIDS RESEARCH GRANT APPLICATION, 2010
- Evaluator for professor position, University of Arizona, US, 2010.
- Chair of FWO (Flemish Fund for Scientific Research) commission MED8 « Health Sciences », Belgium, since 2010.
- Evaluator for the Portuguese National Science Foundation (FCT), regarding an FCT center, 2011.

Invited expert for :

- Forensic medicine: HIV and HCV transmission investigations through molecular epidemiological techniques since 2005.
- HIV drug resistance testing and advice on genotypic drug resistance interpretation systems since 2000
- Euroguidelines initiative, Chairman of workgroup 2: Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up; 1999-2000. Chairman for the guidelines on drug resistance testing: Updated European recommendations for the clinical use of HIV drug resistance testing; 2002-2010. Member of the expert panel for HIV treatment guidelines; 2002-2006.
- Member of the WHO HIV drug resistance network since 2005 (WHO ResNet)
- First International Consensus Conference about Inhibitory Quotients” (ICCIQ) 2007
- Member of the Belgian deontological commission for laboratory animals – 2007-2014
- Member of the expert group for the “Development of ECDC roadmap for integration of molecular typing into European surveillance and epidemic preparedness”. Stockholm, Sweden, 2011-2013.
- Expert group advising the Belgian Superior Health Council “Conseil supérieur de la Santé - Hoge Gezondheidsraad”, invited expert in 2011, assigned member since 2014.
- Member of the “HIV Drug Resistance Technical Working Group” for the government of South-Africa, since 2012.

- Member of the working group to draft the 'National Plan for the Management of HIV and AIDS' for the Belgian government, since 2012.
- Occasional member of advisory boards for pharmaceutical and diagnostic industry

Organizer of international meetings:

Organizer of the Series "Virus Evolution and Molecular Epidemiology":

- Annual European workshop on phylogenetic analysis of HTLV. Leuven, Belgium:
 - 1st: September 18, 1995;
 - 2nd: October 7-8, 1996;
 - 3rd: September 29- October 1, 1997.
- Annual European workshop on virus evolution and molecular epidemiology. Leuven, Belgium. Abstracts published in 'The Infectious Disease Review':
 - 4th: September 1-4, 1998;
 - 5th: August 30-September 4, 1999;
 - 6th: September 4-9, 2000; Proceedings published in 'Virus Research' Vol 85, 2002
 - 7th: September 5-12, 2001;
 - 8th: September 4-11, 2002. Abstracts published in 'Infection, Genetics and Evolution (MEEGID)'. Proceedings published in 'FEMS Immunology and Medical Microbiology' Vol 1616, 2003
- Annual International workshop on virus evolution and molecular epidemiology. Abstracts and proceedings published in 'Infection, Genetics and Evolution (MEEGID)'
 - 9th: Stanford, USA, August 13-23, 2003.
 - 10th: Helsinki, Finland, August 30-Sept 3, 2004.
 - 11th: Petrópolis, Brazil, September 5– 9, 2005.
 - 12th: Cape Town, South Africa, 1– 5 September, 2008. Vol. 10, issue 3, April 2010
- Annual International bioinformatics workshop on virus evolution and molecular epidemiology. Teaching "Fundamentals of Molecular Evolution: Theory", "Alignment Algorithms: Theory", "Methods for Phylogenetic Tree Reconstruction: Theory". Proceedings published in 'Infection, Genetics and Evolution (MEEGID)'
 - 13th: Athens, Greece, September 11– 15, 2006.
 - 14th: Lisbon, Portugal, September 9– 14, 2007.
 - 15th: Rotterdam, The Netherlands, September 7– 11, 2009.

- 16th: Rockville, USA, August 29 - September 3, 2010.
- 17th: Belgrade, Serbia, August 27-31, 2012. Teaching also “RegaDB: Practice”
- 18th: Gainesville, Florida USA, August 25-30, 2013. Teaching also “RegaDB: Practice”, “Q&A Session: Power and Pitfalls of Phylogeny Inference”
- 19th: Rome, Italy, September 7-12, 2014. Teaching also “RegaDB: Practice”, “Q&A Session: Power and Pitfalls of Phylogeny Inference”
- 20th: St Augustine, Trinidad & Tobago, 10-14 August, 2015.

Member of the organizing committee for the Series on “Treatment Strategies & Antiviral Drug Resistance”:

- ‘Annual European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications’.
 - 1st : Luxembourg, Luxembourg, March 6-8, 2003.
 - 2nd: Rome, Italy, March 11-13, 2004.
 - 3rd: Athens, Greece, March 30-April 1, 2005.
 - 4th : Monaco, March 29 – 31, 2006.
 - 5th: Cascais, Portugal, March 28-30, 2007.
 - 6th: Budapest, Hungary, March 26-28, 2008.
 - 7th: Stockholm, Sweden, March 25-27, 2009.
 - 8th: Sorrento, Italy, March 17-19, 2010.
- Annual European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. Member of the organizing committee.
 - 9th: Paphos, Cyprus, 23-25 March 2011, member of the Program Committee
 - 10th: Barcelona, Spain, 28-30 March 2012.
 - 11th: Rome, Italy, 20-22 March 2013, member of the Program Committee.
 - 12th: Barcelona, Spain, 26-28 March 2014.
 - 13th: Barcelona, Spain, 3-5 June 2015, member of the Program Committee.

Organizer of the Series on “Virus Drug Resistance Training”:

- Workshop on HIV & HCV Drug Resistance Training: “Advanced Training in the Clinical Interpretation of Drug Resistance Testing Results”, Leuven, Belgium.
 - 1st: 13-15 May 2009.
 - 2nd: 13-15 October 2010.
 - 3rd: 16-18 November 2011.

- 4th: 4-6 July 2012.
- 5th: 19-21 June 2013.
- 6th: 2-4 July 2014.
- 7th: 17-19 June 2015.

15th International Conference on Human Retrovirology, HTLV and Related Viruses. Leuven/Gembloux 5-8 June 2011. Abstracts published in 'Retrovirology'. Co-organizer.

Organizer of national meetings :

- Clinical use of HIV-1 drug resistance testing in Belgium, 8 May 2001, Leuven, Belgium. Sponsored by Visible Genetics. Organized by **AM Vandamme**.
- 2002 Symposium of the Belgian AIDS Reference Laboratories and Centers "Treatment and follow-up of HIV infected patients in Belgium", 24 mei 2002, Neerijse, Belgium. Organized by **AM Vandamme**.
- 2006 annual meeting of the Belgian AIDS Reference Laboratories (ARL) and AIDS Reference Centers (ARC), 9 June 2006, Brussels, Belgium. Organized by N Clumeck and D Pierard. Co-organized by **AM Vandamme** (workshop 1: Virology).
- First Bioinformatics Workshop – Belém – Pará – Brazil, 8-12 September, 2011. Organized by Ana Abecasis and Marcio Nunez. Co-organized by **AM Vandamme**
- First BREACH (Belgian Research Consortium on AIDS and HIV) Symposium, 30 Sept 2011, Leuven, Belgium. Co-organizer

Invited chairman on international meetings:

- International Conference on HIV and Iron. Brugge, Belgium, 14-15 March 1997.
- International meeting on blood borne viral infections, Riga, Latvia, 26-27 May 1998.
- Spanish Consensus Conference on Drug Resistance Testing in Clinical Practice, Madrid, Spain, 20 Februari 1999.
- Second European Standards of HIV Clinical Care Meeting. HIV drug resistance: implications for European clinical care, Brussels, Belgium, 29 April 1999. Euroguidelines initiative, Chairman of workgroup 2: Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
- Bristol-Myers Squibb Virology Symposium, Barcelona, Spain, 10-12 March 2000.

- 2nd Spanish Consensus Conference on Drug Resistance Testing in Clinical Practice, Madrid, Spain, 18 March 2000.
- 3rd European Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 23-25 February 2001.
- HIV Dynamics and Evolution Discussion Meeting, Paris, France, 27-29 April 2001.
- First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. March 6-8, 2003, Luxembourg, Luxembourg.
- Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. March 11-13, 2004, Rome, Italy.
- Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. March 30-April 1, 2005, Athens, Greece
- Fourth European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. 29 - 31 March 2006, Monaco
- Fifth European HIV Drug Resistance Workshop. From basic science to clinical implications. Cascais Portugal, 28-30 March 2007.
- Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008.
- Seventh European HIV Drug Resistance Workshop. From basic science to clinical decision making. 25-27 March 2009, Stockholm, Sweden.
 - Round table discussion: Guidelines on Resistance Analysis & Tropism Testing. Discussants: **A-M Vandamme**, C Boucher & Writing Committee. Moderator: AM Geretti.
 - Round table discussion: The power and limitations of large database analyses. Panel members: B Shafer, **A-M Vandamme**, AM Geretti. Moderator: M Zazzi.
 - **A-M Vandamme** and D Paraskevis. Chairs of Session 10: Clinical Implications of HIV Drug Resistance.
- 14th International Conference on Human Retrovirology: HTLV and related retroviruses. Session 'Epidemiology and Phylogenesis'. July 1-4, 2009, Salvador-Bahia, Brazil.
- Eighth European HIV Drug Resistance Workshop. From basic science to clinical decision making. 17-19 March 2010, Sorrento, Italy. Session 9: HIV diversity/variation and drug resistance epidemiology.
- Ninth European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 23-25 March 2011, Paphos, Cyprus. Session 2. Resistance to the RT and Pro HIV Inhibitors

- 6th Southern African HIV/TB Drug Resistance & Clinical Management Workshop, November 7-8, 2011, Gaborone, Botswana. Session 4: Use of genotyping to assess HIV & TB resistance in Southern Africa. Session 12: Bioinformatics tools.
- Tenth European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 28-30 March 2012, Barcelona, Spain. Session 1. Viral Evolution and Transmission.
- SA HIV Clinicians Society Conference 2012. Cape Town, South Africa, November 25-28, 2012. Chairman of SATuRN workshop session 'State of the ART: HIV & TB Resistance, Epidemiology and Clinical Cases'
- 11th European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 20-22 March 2013, Rome, Italy. Session 2. Transmission and Evolution of Drug Resistance (HIV, HCV and HBV).
- International Meeting on Microbial Epidemiological Markers (IMMEM-10). Paris, France. 2-5 October 2013. Session: "Molecular epidemiology of viral zoonoses".
- 12th European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 26-28 March 2014, Barcelona, Spain. Session 8. Bringing generics into the clinic now.
- European HTLV Research Meeting (HERN). A Translational Approach. 4-6 June 2014, Rome, Italy. Session 4.
- 13th European Workshop on HIV & Hepatitis. Treatment Strategies & Antiviral Drug Resistance. 3-5 June 2015, Barcelona, Spain. Session 9. HIV Epidemiology.
-

Scientific Committee member on international meetings :

- 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000.
- From Laboratory To Patient: Course in HIV Resistance and Resistance Assays. University Medical Center Utrecht; Virology Education. 5-6 June, 2000.
- 3rd European Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 23-25 February 2001.
- The HIV Data Management and Data Mining for Antiretroviral Resistance Workshop, Durban, South Africa, 13-17 December 2004. <http://www.bioafrica.net/dataminingworkshop.html>
- 1st Workshop Internacional de Bioinformática em Evolução e Biologia Molecular Viral, Bahia, Brazil, 22-26 July 2013. Teaching "Fundamentals of molecular evolution", "Alignment algorithms: theory"
- 16th International Conference on Human Retrovirology HTLV and Related Viruses. Montréal Québec Canada. June 26- 30, 2013.

Scientific Committee member on national meetings :

- First Brazilian workshop on virus evolution and molecular epidemiology, Salvador, Bahia, Brazil, 25-27 maart 2002. Teaching “Fundamentals of molecular evolution”, “Construction of phylogenetic trees: powers and pitfalls of tree construction methods”, “Practical computer session 1: Construction and interpretation of phylogenetic trees”
- Second Brazilian workshop on virus evolution and molecular epidemiology, Slavador, Bahia, Brazil, November 8-13, 2004. Teaching ‘Fundamentals of molecular evolution’, ‘How to Interpret Phylogenetic Trees Theoretical Lecture’, ‘Simian to human transmission of retroviruses - holistic view’
- First South-African workshop on virus evolution and molecular epidemiology, Durban, South Africa, 1-6 juli 2003. Teaching “Fundamentals of molecular evolution”, “Construction of phylogenetic trees: powers and pitfalls of tree construction methods”, “Practical computer session 1: Construction and interpretation of phylogenetic trees”
<http://www.bioafrica.net/Africanworkshop.html>
- 2003 Annual meeting of the Belgian AIDS Reference Laboratories and AIDS Reference Centers, 23 May 2003, Antwerp, Belgium.
- 2004 Annual meeting of the Belgian AIDS Reference Laboratories and AIDS Reference Centers, 18 March 2004, Liège, Belgium.
- 2006 Annual meeting of the Belgian AIDS Reference Laboratories and AIDS Reference Centers, 19 June 2006; Brussels, Belgium.
- First South-African workshop on ‘HIV Drug Resistance in Clinical Practice’, University of the Western Cape, Cape Town, South Africa, 5 Sept 2008. Teaching: ‘Drug Resistance Interpretation Tools’.
-

Responsibilities for journals:

Invited reviewer for numerous international journals

Member of the editorial board of the following journals: The Infectious Disease Review (1998 - 2002), Journal of Medical Virology (2004-2007), HIV Therapy (2006-2010), Antiviral Chemistry and Chemotherapy (2000-2013), Antiviral Therapy Reviews (since 2006), Future HIV Therapy (since 2006), The Open Infectious Diseases Journal (since 2007), The Open AIDS Journal (since 2007), Retrovirology (since 2009), Infection, Genetics and Evolution (since 2009), Current Opinion in Virology (since 2013), Virus Evolution (since 2014)

Editor of AIDS Reviews (since 1999)

Guest editor for Virus Research (2002)

Guest editor for FEMS Immunology and Medical Microbiology (2003)

Guest editor for *Infection, Genetics and Evolution* (2004, 2005, 2007, 2008, 2009, 2010, 2012, 2013). Each time a special issue dedicated to the "Proceedings of the International workshop on virus evolution and molecular epidemiology"

Guest editor of *Retrovirology*. A special issue dedicated to "15th International Conference on Human Retroviruses: HTLV and Related Viruses. Leuven and Gembloux, Belgium. 5-8 June 2011". (Vandamme, A., Ed., Willems, L., Ed.). Springer
Guest editor for *PLOS Computational Biology* (2013)

Member of scientific organizations:

American Association for the Advancement of Science (AAAS, since 1996)

American Society for Biochemistry and Molecular Biology (ASBMB, since 2004)

Belgian Society for Biochemistry and Molecular Biology

Belgian Society for Microbiology (since 2002)

European AIDS Clinical Society (since 2002)

European Society for Clinical Virology (since 2001)

European Society for Emerging Infections

Federation of European Microbiological Societies (FEMS)

International AIDS Society (since 2001)

International Retrovirology Association (2000-2009)

International Society for Antiviral Research

Society for General Microbiology (since 2001)

Royal Academy of Medicine of Belgium (2002-2014)

European Society for translational Antiviral Research (ESAR) (since 2010)

Editor of books:

- Editor of 'The Phylogenetic Handbook. A Practical Approach to DNA and Protein Phylogeny' (Salemi M. & **Vandamme A.-M.**, eds). Cambridge University Press, 2003, 1st edition.
- Editor of 'The Phylogenetic Handbook. A Practical Approach to Phylogenetic Analysis and Hypothesis Testing' (Lemey P, Salemi M. & **Vandamme A.-M.**, eds). Cambridge University Press, 2009, 2nd edition. ISBN:9780521877107 (Hardback); ISBN:9780521730716 (Paperback)
- Guide to management of HIV resistance and pharmacokinetics of drug therapy" (B. Clotet, L. Menéndez-Arias, L. Ruiz, C. Tural, **A.-M. Vandamme**, D. Burger, J.M. Shapiro, C.A. Boucher, R. D'Aquila, D.D. Richman, eds), Editorial TAISA, S.L., Barcelona, Spain (yearly new edition)
- Guest editor of a special issue of "Virus Research", dedicated to "Virus evolution and molecular epidemiology": *Virus Research* 85, 2002.
- Guest editor of a special issue of "FEMS Immunology and Medical Microbiology", dedicated to "Virus evolution and molecular epidemiology": *FEMS Immunology and Medical Microbiology* 39(2), 2003.

- Editor of 'Combination Therapy of AIDS', in the series 'Milestones in Drug Therapy (MDT)' (De Clercq E. & **Vandamme A.-M.**, eds). Birkhäuser Verlag AG, Basel, Switzerland, 2004.
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", 2004
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", 2005
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", June 2007
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", July 2009
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", April 2010
- Editor of a special issue of "Retrovirology", dedicated to "15th International Conference on Human Retroviruses: HTLV and Related Viruses Leuven and Gembloux, Belgium. 5-8 June 2011", Retrovirology, Volume 8, Supplement 1. Supplement Editors: **Anne-Mieke Vandamme** and Luc Willems
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", Oct 2013
- Guest editor of a special issue of "Infection, Genetics and Evolution", dedicated to "Virus evolution and molecular epidemiology", Dec 2014
-

Contributor to software:

- Development of an educational software package "AIDS in Belgium" in collaboration with the University Health Services, University of Alberta, Canada; Medica Leuven; Universitair Rekencentrum Leuven.
- Retrogram: "Decision support system for the treatment of HIV-infected patients". C. Boucher, J. Shapiro, B. Shafer and **A.-M. Vandamme**. A software developed by Virology Networks, Utrecht, Amsterdam; with financial support from Hoffman-La Roche Ltd.
- CDrom of the symposium "Clinical use of HIV-1 drug resistance testing in Belgium" organized by **A.-M. Vandamme** with the Belgian AIDS Reference Laboratories, 8 May 2001, Leuven, Belgium. Sponsored by Visible Genetics.
- The Rega Algorithm "Clinical decision support software for the interpretation of genotypic HIV drug resistance". Available on-line from several websites worldwide.
- The Rega HIV-1 Subtyping tool "Automated tool for classifying HIV-1 strains using phylogenetic analysis". Available on-line from several websites worldwide.
- RegaDB: An Open Source, Community-Driven virus Data and Analysis Management Environment

Academic responsibilities:

- Permanent member of the department council (Microbiology and Immunology), Faculty of Medicine, KULeuven, Belgium.
- Permanent member of the faculty council (Medicine), Faculty of Medicine, KULeuven, Belgium.

Patents:

- Witvrouw M., Fikkert V., Pannecouque C., Cherepanov P., Van Laethem K., De Clercq E., **Vandamme A.M.**, Debyser Z. "HIV-1 resistance assay" Patent number WO0157245-A/27, 09-AUG-2001. K.U.Leuven Research & Development (BE).
- G Vuagniaux, JM Dumont, Snoeck J, Van Dooren S, **A-M Vandamme**. "Near full-genome assay of HCV drug resistance." patent application No PCT/IB2007/003304

Projects and funding

GOA 90/95-1

Subject : Fibrinolysis : molecular and cellular mechanisms and clinical applications.

Period : October 1990 - August 1995

Promoter : Prof. D. Collen

Funding organisation : Ministerie van de Vlaamse Gemeenschap - Onderwijs

Financial support : 45 205 000 BEF (in total)

My contribution : Research scientist

NFWO/AIDS 3.3010.91

Subject : Molecular targets for chemotherapy of HIV infections.

Period : September 1991 - August 1995, October 1996 - September 1997

Promoters : Prof. E. De Clercq, Prof. J. Desmyter, Prof. J. Balzarini, Prof. P. Herdewijn, Prof. J. Anné.

Funding organisation : Belgische Nationaal Fonds voor Wetenschappelijk Onderzoek

Financial support : 55 000 000 BEF + 13 000 000 BEF (in total)

My contribution : Principal investigator

AIDS Basic Research Program of the European Community

Subject : Design, synthesis and evaluation of new HIV-antivirals.

Period : 1991-1998

Promoters : Prof. E. De Clercq/ Prof. J. Desmyter, Universitaire Ziekenhuizen en Rega Instituut, KULeuven

Funding organisation : European Community DG XII

Financial support: 11 000 000 BEF (every year)

My contribution: Research scientist

Industrial support

Subject : Evaluation of the NASBA technology for the detection of HIV-RNA in plasma and serum in comparison with RNA-PCR.

Period : September-October 1993

Funding organisation : Akzo Organon-Teknika, Boxtel, Nederland

Financial support: 140 000 BEF

My contribution: Promoter

FGWO 3.0098.94 + extension

Subject: Vergelijkende virologie van humane en primaten T-lymfotrope virussen (HTLV en PTLV)

Period : January 1994 - December 1999

Promoters : Prof. J. Desmyter, Prof. P. Goubau (until 1997), Prof. A-M. Vandamme (from 1997) Universitaire Ziekenhuizen en Rega Instituut, KULeuven

Funding organisation : Belgisch Nationaal Fonds voor Wetenschappelijk Onderzoek en Collen Research Foundation

Financial support: 10 000 000 BEF (NFWO) and 4 000 000 BEF (Collen Res Foundation); 1 500 000 BEF (NFWO) for the extension

My contribution: Copromoter since 1997

FGWO 3.0180.95

Subject: Development of new compounds with selective antiviral or antitumor activity

Period : January 1995 - December 1998

Promoters : Prof. E. De Clercq, Prof. J. Desmyter, Prof. J. Balzarini, Prof. P. Herdewijn, Prof. J. Anné.

Funding organisation : Belgisch Nationaal Fonds voor Wetenschappelijk Onderzoek

Financial support: 17 000 000 BEF

My contribution: Principal investigator

GOA 95/5

Subject: Moleculaire targets voor antivirale (anti-HIV) en antitumorale chemotherapie.

Period : January 1995 - December 1999

Promoters : Prof. E. De Clercq, Prof. J. Balzarini, Prof. J. Anné, Dr. R. Pauwels, Dr. D. Schols.

Funding organisation : Ministerie van de Vlaamse Gemeenschap - Onderwijs

Financial support: 50 000 000 BEF

My contribution: Principal investigator

BIOMED 2 BMH4-CT96-0409

Subject: An European Network for the Virological evaluation of international clinical trials for new Anti-HIV therapies.
Period: June 1996 - December 1998
Funding organisation : European Commission
Financial support: 300 000 ECU (in total) for 9 partners
My contribution: Promoter for the Belgian partner at the Rega-Institute

FWO G.0140.98

Subject : Molecular targets for chemotherapy of AIDS and viral infections associated with immunodeficiency.
Period : January 1998 - December 2001
Promoters : Prof. E. De Clercq, Prof. J. Balzarini, Prof. D. Schols, Prof. A.-M. Vandamme, Dr G. Andrei, Dr L. Naesens, Dr J Neyts, Dr R Snoeck, Dr M Van Ranst.
Funding organisation : Vlaams Fonds voor Wetenschappelijk Onderzoek
Financial support : 45 000 000 BEF
My contribution : Copromoter

GOA 00/12

Subject : Molecular targets for the chemotherapy of virus infections, AIDS and cancer.
Period : januari 2000 - december 2004
Promoters : Prof. E. De Clercq, Prof. J. Balzarini, Prof. D. Schols, Prof. A.-M. Vandamme, Dr G. Andrei, Dr L. Naessens, Dr J. Neyts, Dr R. Snoeck, Rega Instituut, KULeuven.
Funding organisation : Ministerie van de Vlaamse Gemeenschap - Onderwijs
Financial support : 60 000 000 BEF
My contribution : Copromoter

4FP, TMR , ERBFMBICT950138

Subject: Postdoctoral fellow on the project: "Molecular investigation on the origin and genetic stability of human T-lymphotropic virus type II (HTLV-II)"
Period: February 1996 - January 1999
Funding organisation : European Commission
Financial support: Salary and consumables of one postdoctoral fellow
My contribution: Promoter

4FP, TMR, BMH4-98-4830

Subject: European Workshop on Virus Evolution and Molecular Epidemiology
Period: 1-4 September 1998
Funding organisation : European Commission
Financial support: 5400 ECU

My contribution: Promoter

DB/98/40

Subject: Final year for foreign PhD student (Marco Salemi):
“Molecular investigation of the origin and genetic stability
of the human T-cell lymphotropic viruses”
Period: February 1999 - January 2000
Funding organisation : Onderzoeksraad KULeuven
Financial support: Salary for one PhD student
My contribution: Promoter

PDM/99/123

Subject: Postdoctoral fellow on the project (Marco Salemi):
“Molecular evolution of human retroviruses”
Period: February 2000 - January 2001
Funding organisation : Onderzoeksraad KULeuven
Financial support: Salary for one postdoctoral fellow
My contribution: Promoter

5FP, Accompanying Measures, QLAM-PL1999-00008

Subject: 5th European Workshop on Virus Evolution and Molecular
Epidemiology
Period: 30 August-4 September 1999
Funding organisation : European Commission
Financial support: 9600 Euro
My contribution: Promoter

FWO G.0288.01

Subject: Evolutie en moleculaire epidemiologie van humane
virussen
Period: januari 2001 - december 2004
Promoters Prof. A.-M. Vandamme, KULeuven; Prof. M. Van Ranst,
KULeuven.
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 11 820 000 BEF
My contribution: Promoter

5FP, Accompanying Measures, QLAM-2000-00002

Subject: 6th European Workshop on Virus Evolution and Molecular
Epidemiology
Period: 4-9 September 2000
Funding organisation: European Commission
Financial support: 28 324 Euro
My contribution: Promoter

FWO K.7..059.00N

Subject: 6th European Workshop on Virus Evolution and Molecular Epidemiology
Period: 4-9 September 2000
Funding organisation : Vlaams Fonds voor Wetenschappelijk Onderzoek
Financial support: 175 000 BEF
My contribution: Promoter

Derde Cyclus Programma DCP/00/08

Subject: 6th European Workshop on Virus Evolution and Molecular Epidemiology
Period: 4-9 September 2000
Funding organisation : Onderzoeksfonds KULeuven
Financial support: 50 000 BEF
My contribution: Promoter

Postdoctoral grant

Name of grantholder : Marco Salemi
Period : oct 2000 - dec 2003
Funding organisation: Vlaams Fonds voor Wetenschappelijk Onderzoek
My contribution: Promotor

IWT PhD grant

Name of grantholder: Philippe Lemey
Period: sept 2000 - sept 2002
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promotor

IWT postdoctoral grant

Name of grantholder: Inge Derdelinckx
Period: jan 2000 - jan 2002
Funding organisation: IWT
My contribution: Promotor

5FP, Quality of Life, QLK2-CT-2001-01344

Subject: SPREAD: "Strategy To Control Spread Of Resistance To Anti Retroviral Drugs"
Period: January 2002-December 2005
Funding organisation: European Commission
Financial support: 112 118 Euro
My contribution: Partner

5FP, Accompanying Measures, QLAM-2001-00016

Subject: 7th European Workshop on Virus Evolution and Molecular Epidemiology
Period: 5-12 September 2001
Funding organisation: European Commission
Financial support: 40 000 Euro
My contribution: Promotor

Industrial support

Subject: Genotyping of Brazilian TTV isolates
Period: September-October 2000
Funding organisation: Innogenetics, Gent
Financial support: 200 000 BEF
My contribution: Promotor

Contract research

Subject: Development of a genotypic drug resistance interpretation system based on HIV-1 LiPA
Period: May-June 2001
Funding organisation: Innogenetics, Gent
Financial support: 200 000 BEF
My contribution: Promotor

Marie-Curie fellowship

Name of grantholder: Dimitris Paraskevis
Period : Jan 2002 - Dec 2004
Funding organisation: EC FP5
My contribution: Promotor

Contract research

Subject: Modeling drug-resistance mutations in the HIV-1 RT and PRO
Period: Oct 2001-Sept 2003
Funding organisation: AlgoNomics, Gent
Financial support: 2 200 000 BEF
My contribution: Promotor

IWT-010445

Subject: DMax: Integrated drug/target discovery and development through integration of data mining techniques. Application in virology research and development
Period: Oct 2001- Sept 2003
Funding organisation: IWT-Vlaanderen (Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen)
Financial support: 23224,94 Euro

My contribution: Research partner

VIS/01/014

Subject: Onderzoek naar de factoren die therapie respons bepalen bij HIV geïnficeerden, gebruik makende van relationele data mining technieken

Period: Jan 2002- July 2004

Funding organisation: Onderzoeksfonds Katholieke Universiteit Leuven

Financial support: 186 000 Euro

My contribution: Promotor

Symposium sponsoring

Subject: 2002 symposium of the Belgian AIDS Reference Laboratories and Centers "Treatment and follow-up of HIV infected patients in Belgium"

Period: 24 mei 2002, Neerijse, Belgium

Funding organisation: Several Pharmaceutical and Diagnostic companies

Financial support: 18 000 Euro

My contribution: Organizer

5FP, Accompanying Measures, QLAM-2001-00470

Subject: 8th European Workshop on Virus Evolution and Molecular Epidemiology

Period: 4-11 September 2002

Funding organisation: European Commission

Financial support: 54 000 Euro

My contribution: Promotor

Onderzoeksraad – bilateral collaboration South Africa

Subject: Investigating the determinants of therapy response in HIV infected patients using a datamining approach, with special focus on drug resistance and virus subtype.

Period: Jan 2003- Dec 2004

Funding organisation: Onderzoeksraad KULeuven, Belgium

Financial support: 57958 Euro

My contribution: Promotor

NATO Advanced Study Institute

Subject: 9th International Workshop on Virus Evolution and Molecular Epidemiology

Period: 13-23 Aug 2003

Funding organisation: NATO

Financial support: 70 000 Euro

My contribution: Promotor

ANRS 1257

Subject: Observatory of HIV-1 resistance in developing countries of Africa and Asia
Period: March 2003 – Febr 2004
Funding organisation: ANRS
Financial support: 34647.5 Euro
My contribution: Subcontractor

FWO G.0266.04

Subject: Investigation of the clinical prognostic value for therapy failure of HIV-1 drug resistance results and its interaction with other factors, using new datamining technologies
Period: januari 2004 - december 2007
Promoters: Prof. A.-M. Vandamme, KULeuven; Prof. E. Van Wijngaerden, KULeuven, Prof. H. Blockeel, KULeuven.
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 353 800 Euro
My contribution: Promoter

IWT PhD grant

Name of grantholder: Koen Deforche
Period: dec 2003 - dec 2007
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promotor

Leerstoel infectieziekten in de derde wereld

Subject: Investigation of HTLV replication strategies and its associations with leucemia and paralysis in Latin- America
Period: Sept 2004 - August 2009
Promoters: Prof. A.-M. Vandamme, KULeuven.
Funding organisation: Mecenat
Financial support: 200 000 Euro
My contribution: Promoter

Onderzoekstoelage OT/04/43

Subject: Investigation of the contribution of antiviral drug resistance and other factors to the failure of antiviral therapy in HIV patients, using datamining technology
Period: Oct 2004 - Sept 2008
Promoters: Prof. A.-M. Vandamme, KULeuven; Prof. E. Van Wijngaerden.
Funding organisation: University of Leuven
Financial support: 250 000 Euro

My contribution: Promoter

VLIR ZEIN2005PR311

Subject: Host genetic, immune and viral factors in transmission and diseases expression of Human T-lymphotropic Virus type 1 (HTLV-1) in Peru
Period: April 2005 - March 2009
Promoter: Prof. G Vanham (ITG – UA).
Funding organisation: VLIR
Financial support: 307040 Euro
My contribution: copromotor

EF/05/015

Subject: Virus infections, cancer and inflammatory diseases: Molecular insights and targets for intervention
Period: November 2005 – September 2010
Promoter: Prof Jan Balzarini
Funding organisation: KULeuven
Financial support: total: 2 460 000 Euro, our lab: 256.250 Euro
My contribution: partner

IWT PhD grant

Name of grantholder: Kris Covens
Period: Jan 2006 - Dec 2009
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promoter

FWO G.0513.06

Subject: Molecular evolution and epidemiology of HIV and papillomaviruses
Period: januari 2006 - december 2009
Promoters: Prof. A.-M. Vandamme, Prof. M. Van Ranst, KULeuven
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 546 980 Euro (total budget)
My contribution: Promoter

VIROLAB 6FP, 027446

Subject: VIROLAB: “A virtual laboratory for decision support in viral diseases treatment”
Period: March 2006- August 2009
Promoter: Prof Peter Sloot, Amsterdam, The Netherlands
Funding organisation: European Commission
Financial support: 131100 Euro (Leuven)
My contribution: Partner

6FP, LSHP-CT-2006-518211

Subject: EuropeHIVResistance (EHR): “European Cohort coordinating network on HIV drug resistance”
Period: March 2006-Februari 2010
Promoter: Prof Charles Boucher, Utrecht, The Netherlands
Funding organisation: European Commission
Financial support: 27 000 Euro (Leuven partners)
My contribution: Partner

IWT PhD grant

Name of grantholder: Kristof Theys
Period: Jan 2007 - Dec 2010
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promotor

IUAP P6/41

Subject: Inhibition of HIV replication
Period: Jan 2007-Dec 2011
Promoter: Prof Zwi Berneman, Antwerp
Funding organisation: Belgian Science Policy
Financial support: 600 000 Euro (Leuven partner)
My contribution: Partner

FCT

Subject: Organisation of the 13th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology 2007
Period: 10-14 September 2007
Promoter: Anne-Mieke Vandamme
Funding organisation: Fundação para a Ciência e a Tecnologia
Financial support: 1500 Euro
My contribution: Promotor

CREA

Subject: Targeting cancer through telomerase and shelterin-directed inhibition in an oncogenic retroviral 'human T-lymphotropic virus type 1 model
Period: Oct 2007- Sept 2009
Promoter: Sonia Van Dooren
Funding organisation: KULeuven
Financial support: 200 000 Euro
My contribution: co-promotor

IWT PhD grant

Name of grantholder: Britta Moens
Period: Jan 2008 - Dec 2011
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promotor

IWT PhD grant

Name of grantholder: Bram Vrancken
Period: Jan 2009 - Dec 2013
Funding organisation: Flemish Institute for Science and Technology (IWT)
My contribution: Promotor

Onderzoekstoelage OT/08/047

Subject: Impact of hepatitis C virus evolution on epidemiology, disease progression and development of resistance
Period: Oct 2008 - Sept 2012
Promoters: Prof. A.-M. Vandamme, Prof M Van Ranst, KULeuven;
Funding organisation: University of Leuven
Financial support: 275 000 Euro
My contribution: Promoter

FCT center BioFIG

Subject: Center for Biodiversity Functional and Integrative Genomics
Period: Januari 2008 - December 2012
Promoters: Rui Manuel Santos Malho, Fundação da Faculdade de Ciências - Faculdade de Ciências da Universidade de Lisboa
Funding organisation: Fundação de Ciências é Tecnologias - Portugal
Financial support: 4000 Euro per PhD participant
My contribution: participant

VLIR ZEIN2008PR358

Subject: HIV drug resistance testing in Cuba
Period: September 2008 - Februari 2014
Promoter: Prof.A-M Vandamme, V Kouri (Pedro Kouri Institute Havana).
Funding organisation: VLIR
Financial support: 309611,50 Euro
My contribution: promotor

FWO G.0611.09N

Subject: Investigation of the clinical prognostic value for therapy failure of HIV-1 drug resistance results combined with other clinical, virological and immunological parameters
Period: Januari 2009 - December 2012
Promoters Prof. A.-M. Vandamme, Prof. E. Van Wijngaerden, KULeuven
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 176 800 Euro (total budget)
My contribution: Promoter

FWO WO.025.09N

Subject: Belgian AIDS Research Consortium (BREACH)
Period: Januari 2009 - December 2014
Promoters Prof. Dirk Vogelaers, UGent, Gent, Belgium
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 62 500 Euro (total budget)
My contribution: Partner

7FP, 223131

Subject: Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)
Period: April 2009-March 2014
Promoter Prof Deenan Pillay, London, UK
Funding organisation: European Commission
Financial support: 375 122 Euro (Leuven partners)
My contribution: Partner

FWO G.0778.10

Subject: Identification of biomarkers and new therapeutic targets in HTLV-1-associated pathologies
Period: Januari 2010 - December 2014
Promoters Prof. A.-M. Vandamme, Prof C Pannecouque
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 280134 Euro (total budget)
My contribution: Promoter

VLIR ZEIN2011PR376

Subject: Host genetic, immune and viral factors in transmission and diseases expression of Human T-lymphotropic Virus type 1 (HTLV-1) in Peru
Period: May 2010 - April 2014
Promoter Prof.A-M Vandamme, Prof E Gotuzzo.
Funding organisation: VLIR
Financial support: 329888,20 Euro

My contribution: promotor

FWO G.A.029.11.N.10

Subject: Onderzoek naar de virale evolutie van HCV in functie van ziekteprogressie en antivirale therapierespons
Period: Januari 2011 - December 2015
Promoters Prof. A.-M. Vandamme, Prof. F. Nevens, Prof. P. Lemey
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 265000 Euro (total budget)
My contribution: Promoter

FWO K8.012.12N

Subject: Sabbatical grant:
Period: Januari 2012 - September 2012
Promoters Prof. A.-M. Vandamme
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 22500 Euro
My contribution: Promoter

FWO G.0692.14

Subject: Modeling and predicting HIV-1 transmission chains and therapy response
Period: Januari 2014 - December 2017
Promoters Prof. A.-M. Vandamme, Prof. K. Van Laethem, Prof. E. Van Wijngaerden
Funding organisation: Fonds voor Wetenschappelijk Onderzoek - Vlaanderen
Financial support: 550824 Euro (total budget)
My contribution: Promoter

VES/14/031

Subject: Preparation of a European Project: Virogenesis
Period: May 2014 – August 2014
Promoters Prof. A.-M. Vandamme
Funding organisation: BIJZONDER ONDERZOEKSFONDS
Financial support: 15000 Euro (total budget)
My contribution: Promoter

H2020, 634650-2

Subject: Virus discovery and epidemic tracing from high throughput metagenomic sequencing (VIROGENESIS)
Period: June 2015-May 2018
Promoter Prof Anne-Mieke Vandamme, KU Leuven, BE
Funding organisation: European Commission
Financial support: 2 995 969 Euro (entire consortium)

My contribution: Co-ordinator

Publications (with impact factor in the year of publication)

On 6 October 2015 (Web of Science): H-index=56, Total number of citations=10248, Average citation per item: 22.33, ResearchID: I-4127-2012, ORCID: 0000-0002-6594-2766, ResearchGate score 47.49 (>97.5%)

1. **Vandamme A.-M.**, Cleuter Y., Marbaix G., Préaux G., & Lontie R. Isolation of haemocyanin-synthesizing polysomes from the branchial glands of *Sepia officinalis*. Arch. Int. Physiol. Biochim. 93, B115, 1985.
2. Préaux G., **Vandamme A.-M.**, de Béthune B., Jacobs M.-P., & Lontie R. Haemocyanin-mRNA-rich fractions of cephalopodan decabrachia and of crustacea, their in vivo and in vitro translation. In 'Invertebrate Oxygen Carriers' (Linzen B., ed.), Springer-Verlag, Berlin, p 485-488, 1986.
3. **Vandamme A.-M.**, De Greef C., Préaux G., & Lontie R. Relative molecular mass of the mRNA for the haemocyanin subunit of *Sepia officinalis*. Arch. Int. Physiol. Biochim. 94, B44, 1986.
4. **Vandamme A.-M.**, Préaux G., & Lontie R. Isolation of mRNA from membrane-bound polysomes synthesizing *Sepia officinalis* haemocyanin in *Xenopus laevis* oocytes. Biochemistry International 14, 27-35, 1987.
5. Declercq L., **Vandamme A.-M.**, & Préaux G. Construction of a cDNA library for the haemocyanin of *Sepia officinalis* in the expression vector lambdagt11. Arch. Int. Physiol. Biochim. 97, B136, 1989.
6. Collen D., Lijnen H.R., Bulens F., **Vandamme A.-M.**, Tulinsky A., & Nelles L. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. Journal of Biological Chemistry 265(21), 12184-12191, 1990.(1998 IF= 7.199)
7. **Vandamme A.-M.**, Bulens F., Bernar H., Nelles L., Lijnen H.R., & Collen D. Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment D-dimer. European Journal of Biochemistry 192, 767-775, 1990.(1998 IF= 3.249)
8. **Vandamme A.-M.**, Deleersnijder W., Witters R., & Lontie R. The decomposition of the nitrosylhaemocyanin of *Helix pomatia*. In 'Proceedings of the Symposium on Invertebrate Dioxygen Carriers', Leuven, p 433-436, 1991.

9. Bulens J., **Vandamme A.-M.**, Bernar H., Nelles L., Lijnen H.R., & Collen D. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer. *European Journal of Biochemistry* 195, 235-242, 1991. (1998 IF= 3.249)
10. **Vandamme A.-M.**, Dewerchin M., Lijnen H.R., Bernar H., Bulens F., Nelles L., & Collen D. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase. *European Journal of Biochemistry* 205, 139-146, 1992. (1998 IF= 3.249)
11. Dewerchin M., **Vandamme A.-M.**, Holvoet P., De Cock F., Lemmens G., Lijnen H.R., Stassen J.-M., & Collen D. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. *Thrombosis and Haemostasis*, 68(2), 170-179, 1992.(1998 IF= 3.726)
12. De Vreese K., Debyser Z., **Vandamme A.-M.**, Pauwels R., Desmyter J., De Clercq E., Anné J. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. *Virology* 188, 900-904, 1992. (1998 IF=3.550)
13. Debyser Z., **Vandamme A.-M.**, Pauwels R., Baba M., Desmyter J., & De Clercq E. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcriptase by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1jk][1,4]-benzodiazepin-2(1H)-thione, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. *Journal of Biological Chemistry* 267(17), 11769-11776, 1992. (1998 IF= 7.199)
14. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Schols D., Perno C.-F., **Vandamme A.-M.**, Camarasa M.-J., & De Clercq E. 2',5'-Bis-O-(tert-butylidimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)pyrimidine (TSAO) nucleoside analogues : Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. *Proceedings of the National Academy of Sciences of the USA* 89, 4392-4396, 1992. (1998 IF=9.821)
15. Witvrouw M., Pauwels R., **Vandamme A.-M.**, Schols D., Reymen D., Yamamoto N., Desmyter J., & De Clercq E. Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. *Antimicrobial Agents and Chemotherapy* 36(12), 2628-2633, 1992.(1998 IF= 3.761)
16. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Velazquez S., Camarasa M.-J., **Vandamme A.-M.**, Karlsson A., & De Clercq E. TSAO derivatives : a novel class of HIV-1-specific inhibitors. In "Antibiotics and Antiviral Compounds : Chemical

Synthesis and Modification", VCH Verlagsgesellschaft mbH, Weinheim.- K. Krohn, H. Kirst, H. Maas (Eds), p403-420, 1993.

17. Balzarini J., Karlsson A., Pérez-Pérez M.-J., Vrang L., Walbers J., Zhang H., Öberg B., **Vandamme A.-M.**, Camarasa M.-J., & De Clercq E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. *Virology* 192, 246-253, 1993. (1998 IF=3.550)
18. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese K., Woestenborghs R., **Vandamme A.-M.**, Janssen C.G.M., Anné J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., & Janssen P.A.J. Potent and highly selective HIV-1 inhibition by a new series of alpha-anilino phenyl acetamide (alpha-APA) derivatives targeted at HIV-1 reverse transcriptase. *Proceedings of the National Academy of Sciences of the USA* 90, 1711-1715, 1993.(1998 IF= 9.821)
19. Balzarini J., Karlsson A., **Vandamme A.-M.**, Pérez-Pérez M.-J., Vrang L., Öberg B.,Walbers J., San-Félix A., Velazquez S., Camarasa M.-J., & De Clercq E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the novel class of HIV-1-specific TSAO nucleoside analogues retain sensitivity to HIV-1-specific non-nucleoside inhibitors. *Proceedings of the National Academy of Sciences of the USA* 90, 6952-6956, 1993.(1998 IF= 9.821)
20. Goubau P., Liu H.-F., De Lange G.G., **Vandamme A.-M.**, & Desmyter J. Endemic HTLV-II in pygmies across Africa since 1970. *AIDS Research and Human Retroviruses* 9, 709-713, 1993.(1998 IF= 2.609)
21. De Clercq E., **Vandamme A.-M.**, Schols D. & Debyser Z. Potential chemotherapeutic targets in the replicative cycle of HIV. In "Design of Enzyme Inhibitors as Drugs : Vol. II" Chapter 6 (Enzyme targets as an approach to therapy for HIV infections). M. Sandler & H.J. Smith (Eds), Oxford University Press, p192-225, 1994.
22. **Vandamme A.-M.**, Debyser Z., Pauwels R., De Vreese K., Goubau P., Youle M., Gazzard B., Stoffels A., Cauwenbergh G.F., Anné J., Andries K., Janssen P.A.J., Desmyter J., & De Clercq E. Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. *AIDS Research and Human Retroviruses* 10, 39-45, 1994. (1998 IF=2.609)
23. Goubau P., Van Brussel M., **Vandamme A.-M.**, Liu H.-F., & Desmyter J. A primate T-lymphotropic virus, PTLV-L, different from human T-lymphotropic viruses types I and II in a wild caught baboon (*Papio hamadryas*). *Proceedings of the National Academy of Sciences of the USA* 91, 2848-2852, 1994. (1998 IF= 9.821)

24. **Vandamme A.-M.**, Liu H.-F., Goubau P., & Desmyter J. Primate T-lymphotropic virus type I LTR sequence variation and its phylogenetic analysis : compatibility with an African origin of PTLV-I. *Virology* 202, 212-223, 1994. (1998 IF=3.550)
25. Liu H.-F., **Vandamme A.-M.**, Kazadi K., Carton H., Desmyter J., & Goubau P. Familial transmission and minimal sequence variability of human T-lymphotropic virus type I (HTLV-I) in Zaire. *AIDS Research and Human Retroviruses* 10, 1135-1142, 1994. (1998 IF=2.609)
26. **Vandamme A.-M.** Polymerase chain reaction (PCR) as a diagnostic tool in HIV infection. *Verhandelingen van de Koninklijke Academie voor Geneeskunde van België*, LVI nr.3, 231-265, 1994.
27. Liu H.-F., **Vandamme A.-M.**, Van Brussel M., Desmyter J., & Goubau P. New retroviruses in human and simian T-lymphotropic viruses. *Lancet* 344, 265-266, 1994. (1998 IF=11.793)
28. **Vandamme A.-M.**, Fransen K., Debaisieux L., Marissens D., Sprecher S., Vaira D., Vandembroucke A.T., Verhofstede C., & the Belgian AIDS Reference Laboratories. Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. *Journal of Virological Methods* 51, 305-316, 1995. (1998 IF= 1.551)
29. de Castro Costa C.M., Goubau P., Liu H.-F., **Vandamme A.-M.**, da Cunha F.M.B., Santos T.J.T., Desmyter J., & Carton H. HTLV-negative and HTLV type I-positive tropical spastic paraparesis in Northeastern Brazil. *AIDS Research and Human Retroviruses* 11, 315-318, 1995. (1998 IF=2.609)
30. **Vandamme A.-M.**, Van Dooren S., Kok W., Goubau P., Fransen K., Kievits T., Schmit J.-C., De Clercq E., & Desmyter J. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. *Journal of Virological Methods* 52, 121-132, 1995. (1998 IF= 1.551)
31. Esté J., Witvrouw M., Tu J., Desmyter J., De Clercq E., & **Vandamme A.-M.** Inhibition of HIV-1 Tat mediated transactivation by Oncostatin M in HL-Tat cells. *AIDS Research and Human Retroviruses* 11, 1355-1358, 1995. (1998 IF=2.609)
32. Van Brussel M., Goubau P., Rousseau R., Desmyter J., & **Vandamme A.-M.** The genomic structure of a new primate T-lymphotropic virus, STLV-PH969, differs from that of human T-lymphotropic virus types I and II. *Journal of General Virology* 77, 347-358, 1996. (1998 IF= 2.645)
33. Liu H.-F., Goubau P., Van Brussel M., Van Laethem K., Chen Y.-C., Desmyter J., & **Vandamme A.-M.** The three human T-lymphotropic virus type I subtypes arose

- from three geographically distinct simian reservoirs. *Journal of General Virology* 77, 359-368, 1996.(1998 IF= 2.645)
34. **Vandamme A.-M.**, Liu H.-F., Van Brussel M., De Meurichy W., Desmyter J., and Goubau P. The presence of a divergent T-lymphotropic virus in a wild-caught *Pan paniscus* supports an African origin for the HTLV/STLV group of viruses. *Journal of General Virology* 77, 1089-1099, 1996. (1998 IF= 2.645)
 35. Salemi M., **Vandamme A.-M.**, Guano F., Gradozzi C., Cattaneo E., Casoli C., & Bertazzoni U. Complete sequence of the Italian human T-cell lymphotropic virus type II (HTLV-II) isolate Gu and phylogenetic identification of a possible origin of South European epidemics. *Journal of General Virology* 77, 1193-1201, 1996. (1998 IF= 2.645)
 36. Goubau P., **Vandamme A.-M.**, Beuselinc K. & Desmyter J. Proviral HTLV-I and HTLV-II in the Efe pygmies of Northeastern Zaire. *Journal of AIDS and Human Retroviruses* 12, 208-209, 1996. (1998 IF= 2.667)
 37. Esté J.A., De Vreese K., Witvrouw M., Schmit J.C., **Vandamme A.-M.**, Anné J., Desmyter J., Henson G.W., Bridger G., & De Clercq E. Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. *Antiviral Research* 29, 297-307, 1996.(1998= 2.152)
 38. Goubau P., **Vandamme A.-M.**, & Desmyter J. Questions on the evolution of Primate T-lymphotropic viruses raised by molecular and epidemiological studies of divergent strains. *Journal of AIDS and Human Retroviruses* 13, S242-S247, 1996. (1998 IF= 2.667)
 39. Beuselinc K., **Vandamme A.-M.**, Reynders M., Desmyter J., & Goubau P. Diagnosis of herpes simplex encephalitis and typing by polymerase chain reaction followed by endonuclease cleavage. *Medical Microbiology Letters* 5, 217-224, 1996.
 40. **Vandamme A.-M.**, Schmit J.-C., Van Dooren S., Van Laethem K., Gobbers E., Kok W., Goubau P., Witvrouw M., Peetermans W., De Clercq E. & Desmyter J. Quantification of HIV-1 RNA in plasma : comparable results with the NASBA[®] HIV-1 RNA QT and with the AMPLICOR[®] HIV MONITOR test. *Journal of AIDS and Human Retroviruses* 13, 127-139, 1996. (1998 IF= 2.667)
 41. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J.M., Desmyter J., De Clercq E. & **Vandamme A.-M.** Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). *AIDS* 10, 995-999, 1996. (1998 IF=6.109)

42. **Vandamme A.-M.** BaEV is a relic from an ancient retrovirus that crossed species barriers. *Trends in Microbiology* 4, 478, 1996. (1998 IF=4.953)
43. Van Brussel M., Goubau P., Desmyter J., & **Vandamme A.-M.** Genomic analysis of a new type of primate T-lymphotropic virus : PTLV-L. *Archives of Physiology and Biochemistry* 104:3, B53, 1996. (1998 IF=0.186)
44. Schmit J.-C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E., & **Vandamme A.-M.** Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. *Journal of Infectious Diseases* 174, 962-968, 1996. (1998 IF=4.966)
45. Ruiz L., Romeu J., Martinez-Picado J., Schmit J.C., **Vandamme A.-M.**, Balagué M., Cabrera C., Puig T., Tural C., Segura A., Sirera G., De Clercq E., & Clotet B. Efficacy of a triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. *AIDS* 10, F61-F66, 1996. (1998 IF=6.109)
46. Witvrouw M., Schmit J.-C., Van Remoortel B., Daelemans D., Esté J., **Vandamme A.-M.**, Desmyter J., & De Clercq E. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type I replication in vitro. *AIDS Research and Human Retroviruses* 13, 187-192, 1997. (1998 IF=2.609)
47. Witvrouw M., Balzarini J., Pannecouque C., Jhaumeer-Laulloo S., Esté J.A., Schols D., Cherepanov P., Schmit J.-C., Debyser Z., **Vandamme A.-M.**, Desmyter J., Ramadas S.R. & De Clercq E. SRR-SB3, a disulfide containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. *Antimicrobial Agents and Chemotherapy* 41, 262-268, 1997. (1998 IF= 3.761)
48. Saksena N., Srinivasan A., Ge Y.C., Xiang S.-H., Azad A., Bolton W., Herve V., Reddy S., Diop O., Miranda-Saksena M., Rawlinson W.D., **Vandamme A.-M.**, & Barré-Sinoussi F. Simian T cell leukemia virus type I from naturally infected feral monkeys from Central and West Africa encodes a 91-amino acid p12 (ORF-1) protein as opposed to a 99-amino acid protein encoded by HTLV type I from humans. *AIDS Research and Human Retroviruses*,13, 425-432, 1997. (1998 IF=2.609)
49. **Vandamme A.-M.**, Van Laethem K., Liu H.-F., Van Brussel M., Delaporte E., de Castro Costa C.M., Fleischer C., Taylor G., Bertazzoni U., Desmyter J. & Goubau P. Use of a generic PCR assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serologies. *Journal of Medical Virology* 52, 1-7, 1997.(1998 IF= 2.594)
50. **Vandamme A.-M.** Finally, a specific Tat transactivation inhibitor? *International Antiviral News* 5, 114, 1997.

51. Van Brussel M., Goubau P., Rousseau R., Desmyter J., & **Vandamme A.-M.** Complete nucleotide sequence of the new simian T-lymphotropic virus, STLV-PH969 from a hamadryas baboon, and unusual features of its long terminal repeat. *Journal of Virology* 71, 5464-5472, 1997. (1998 IF= 5.828)
52. Esté J.A., Schols D., De Vreese K., Van Laethem K., **Vandamme A.-M.**, Desmyter J., & De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. *Molecular Pharmacology* 52, 98-104, 1997. (1998 IF= 5.428)
53. Ellerbrok H., Fleischer C., **Vandamme A.-M.**, Kücherer C., & Pauli G. Sequence analysis of two HTLV type I infections imported to Germany. *AIDS Research and Human Retroviruses* 13, 1255-1258, 1997. (1998 IF=2.609)
54. Pelemans H., Esnouf R., Dunkler A., Parniak M.A., **Vandamme A.-M.**, Karlsson A., De Clercq E., Kleim J.-P., & Balzarini J.. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. *Journal of Virology*, 71, 8195-8203, 1997. (1998 IF=5.828)
55. Liu H.-F., Goubau P., Van Brussel M., Desmyter J., & **Vandamme A.-M.** Phylogenetic analysis of a simian T-lymphotropic virus type I from a Hamadryas baboon. *AIDS Research and Human Retroviruses*, 13, 1545-1548, 1997. (1998 IF=2.609)
56. Daelemans D., Esté J., Witvrouw M., Pannecouque C., Jonckheere H., Perno C.-F., De Clercq E. & **Vandamme A.-M.** S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. *Molecular Pharmacology* 52, 1157-1163, 1997. (1998 IF= 5.428)
57. Witvrouw M., Arranz M.E., Pannecouque C., Declercq R., Jonckheere H., Schmit J.-C., **Vandamme A.-M.**, Diaz J.A., Ingate S.T., Desmyter J., Esnouf R., Van Meervelt L., Vega S., Balzarini J., & De Clercq E. 1,1,3-trioxo-2*H*,4*H*-thieno[3,4-*e*][1,2,4]thiadiazine (TTD) derivatives : a new class of non-nucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. *Antimicrobial Agents and Chemotherapy* 42, 618-623, 1998. (1998 IF= 3.761)
58. Daelemans D., **Vandamme A.-M.**, Shuto S., Matsuda A., & De Clercq E. Stereospecificity of 6'-neplanocin A analogues as inhibitors of S-adenosylhomocysteine hydrolase activity and human immunodeficiency virus replication. *Nucleosides & Nucleotides*, 17, 479-486, 1998. (1998 IF= 0.649)

59. Debyser Z., Van Wijngaerden E., Van Laethem K., Beuselinck K., Reynders M., De Clercq E., Desmyter J., & **Vandamme A.-M.** Failure to quantify viral load with two of the three commercial methods in a pregnant woman harbouring an HIV-1 subtype G strain. *AIDS Research and Human Retroviruses*, 14, 453-459, 1998. (1998 IF=2.609)
60. **Vandamme A.-M.**, Salemi M., Van Brussel M., Liu H.F., Van Laethem K., Van Ranst M., Michels L., Desmyter J., Goubau P. African origin of human T-lymphotropic virus type II (HTLV-II) supported by a potential new subtype HTLV-IIId in Congolese Bambuti Efe pygmies. *Journal of Virology* 72, 4327-4340, 1998.(1998 IF= 5.828)
61. Van Brussel M., Salemi M., Liu H.-F., Gabriëls J., Goubau P., Desmyter J., & **Vandamme A.-M.** The simian T-lymphotropic virus STLV-PP1664 from *Pan paniscus* is distinctly related to HTLV-2 but differs in genomic organization. *Virology* 243, 366-379, 1998. (1998 IF=3.550)
62. Salemi M., **Vandamme A.-M.**, Gradozzi C., Van Laethem K., Cattaneo E., Taylor G., Casoli C., Goubau P., Desmyter J. & Bertazzoni U. Evolutionary rate and genetic heterogeneity of human T-cell lymphotropic virus type II (HTLV-II) using isolates from European injecting drug users. *Journal of Molecular Evolution* 46, 602-611, 1998.(1998 IF= 3.271)
63. Pelemans H., Esnouf R.M., Parniak M.A., **Vandamme A.-M.**, De Clercq E., & Balzarini J. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152. *Journal of General Virology* 79, 1347-1352, 1998. (1998 IF= 2.645)
64. **Vandamme A.-M.**, Van Vaerenbergh K., and De Clercq E. Anti-HIV drug combination strategies. *Antiviral Chemistry & Chemotherapy* 9, 187-203, 1998.(1998 IF= 1.653)
65. Salemi M., Van Dooren S., Audenaert E., Delaporte E., Goubau P., Desmyter J. & **Vandamme A.-M.** Two new human T-lymphotropic virus type I phylogenetic subtypes in seroindeterminates, a Mbuti Pygmy and a Gabonese, have closest relatives among African STLV-I strains. *Virology* 246, 277-287, 1998. (1998 IF=3.550)
66. Van Laethem K., Beuselinck K., Van Dooren S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Diagnosis of human immunodeficiency virus infection by a polymerase chain reaction assay evaluated in patients harbouring strains of diverse geographical origin. *Journal of Virological Methods* 70, 153-166, 1998. (1998 IF= 1.551)

67. Schmit J.C., Martinez-Picado J., Ruiz L., Tural C., Van Laethem K., Cabrera C., Ibanez A., Puig T., Witvrouw M., Desmyter J., De Clercq E., Clotet B & **Vandamme A.-M.**. Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. *Antiviral Therapy* 3, 81-88, 1998. (2000 IF=4.510)
68. Schmit J.C., Ruiz L., Stuyver L., Van Laethem K., Van der Linden I., Puig T., Rossau R., Desmyter J., De Clercq E., Clotet B & **Vandamme A.-M.** Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. *Journal of Virological Methods* 73, 77-82, 1998. (1998 IF=1.551)
69. Schmit J.C., Van Laethem K., Ruiz L., Hermans P., Sprecher S., Sönnerborg A., Leal M., Harrer T., Clotet B., Arendt V., Lissen E., Witvrouw M., Desmyter J., De Clercq E., & **Vandamme A.-M.** Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. *AIDS* 12, 2007-2015, 1998. (1998 IF=6.109)
70. Ellerbrok H., Fleischer C., Salemi M., Reinhardt P., Ludwig W.-D., **Vandamme A.-M.**, & Pauli G. Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas. *AIDS Research and Human Retroviruses* 14, 1199-1203, 1998. (1998 IF=2.609)
71. Van Dooren S., Gotuzzo E., Salemi M., Watts D., Audenaert E., Duwe S., Ellerbrok H., Grassmann R., Hagelberg E., Desmyter J. & **Vandamme A.-M.** Evidence for a post-Columbian introduction of human T-cell lymphotropic virus type I in Latin-America. *Journal of General Virology* 79, 2695-2708, 1998. (1998 IF= 2.645)
72. Witvrouw M., Daelemans D., Pannecouque C., Neyts J., Andrei G., Snoeck R., **Vandamme A.-M.**, Balzarini J., Desmyter J., Baba M. & De Clercq E. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. *Antiviral Chemistry and Chemotherapy* 9, 403-411, 1998.
73. **Vandamme A.-M.**, Salemi M., & Desmyter J. The simian origins of the pathogenic human T-cell lymphotropic virus type I. *Trends in Microbiology* 6, 477-483, 1998. (1998 IF=4.953)
74. **Vandamme A.-M.**, Van Laethem K., Van Vaerenbergh K. & De Clercq E. Anti-HIV combination therapy and resistance management. *International Antiviral News* 6:10, 182-187, 1998.
75. **Vandamme A.-M.**, Van Laethem K., & De Clercq E. Managing resistance to anti-HIV drugs: An important consideration for effective disease management . *Drugs* 57, 337-361, 1999 (1999 IF=4.150).

76. Oelrichs R.B., **Vandamme A.-M.**, Van Laethem K., Debyser Z., McCutchan F.E. & Deacon N.J. Full-length genomic sequence of an HIV type 1 subtype G from Kinshasa. *AIDS Research and Human Retroviruses* 15, 585-589, 1999. (1999 IF=2.499)
77. Van Brussel M., & **Vandamme A.-M.** Groeiende divergentie binnen de primate T-cel lymfotrope virussen. *Verhandelingen van de Koninklijke Academie voor Geneeskunde van België* LXI (1), 39-63, 1999.
78. **Vandamme A.-M.**, Van Laethem K., Schmit J.-C., Van Wijngaerden E., Reynders M., Debyser Z., Witvrouw M., Van Ranst M., De Clercq E. & Desmyter J. Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. *European Journal of Clinical Investigation* 29, 445-452, 1999.
79. Salemi M., **Vandamme A.-M.**, Desmyter J., Casoli C. & Bertazzoni U. The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy. *Gene* 234, 11-21, 1999.
80. Walter H., Schmidt B., Korn K., **Vandamme A.-M.**, Harrer T. & Überla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. *Journal of Clinical Virology* 13, 71-80, 1999.
81. Witvrouw M., Pannecouque C., Van Laethem K., Desmyter J., De Clercq E. & **Vandamme A.-M.**, Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. *AIDS* 13, 1477-1483, 1999.(1999 IF= 6.931)
82. Van Brussel M., Salemi M., Liu H.-F., Goubau P., Desmyter J., & **Vandamme A.-M.** The discovery of two new divergent STLVs has implications for the evolution and epidemiology of HTLVs. *Reviews in Medical Virology* 9, 155-170, 1999.
83. **Vandamme A.-M.** Highlights of the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA 23-26 June 1999. *International Antiviral News* 7, 92-97, 1999.
84. Salemi M., Van Dooren S. & **Vandamme A.-M.** Origin and evolution of human and simian T-cell lymphotropic viruses. *AIDS Reviews* 1, 131-140, 1999. (2006 IF= 4.022)
85. **Vandamme A.-M.**, Witvrouw M., Pannecouque C., Balzarini J., Van Laethem K., Schmit J.-C., Desmyter J. & De Clercq E. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In "Methods in Molecular Medicine, vol 24: Antiviral Methods and Protocols" (D. Kinchington & R.F. Schinazi, eds), Humana Press Inc., Totowa, NJ, USA, pp223-258, 1999.
86. Salemi M., Lewis M., Egan J.F., Hall W., Desmyter J. & **Vandamme A.-M.** Different population dynamics of human T-cell lymphotropic virus type II in intravenous

- drug users compared with endemically infected tribes. Proceedings of the National Academy of Sciences of the USA 96, 13253-13258, 1999. (1999 IF=10.260)
87. Van Laethem K., Van Vaerenbergh K., Schmit J.-C., Sprecher S., Hermans P., De Vroey V., Schuurman R., Harrer T., Witvrouw M., Van Wijngaerden E., Stuyver L., Van Ranst M., Desmyter J., De Clercq E. & **Vandamme A.-M.** Phenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic populations. *Journal of AIDS and Human Retroviruses* 22, 107-118, 1999. (1999 IF= 2.712)
 88. Daelemans D., **Vandamme A.-M.** & De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. *Antiviral Chemistry & Chemotherapy* 10, 1-14, 1999.(1999 IF= 1.843)
 89. Soriano, V., Ledesma, E., Aguilera, A., Antela, A., Arribas, J., Barreiro, P., Blanco, F., Briones, C., Clotet, B., Dalmau, D., Gatell, J.M., Gonzales-Lahoz, J., Leal, M., Martinez-Picado, X., De Mendoza, C., Miro, J.M., Moreno, S., Pedreina, J., Podzamczek, D., Pumarola, T., Rodriguez, C., Rodriguez-Rosado, R., Del Romero, J., Rubio, R., Ruiz, L., Havlir, D., **Vandamme, A.-M.**, Wainberg, M., Youle, M. Second Spanish Consensus on the Use of Drug Resistance Testing in Clinical Practice (Madrid, March 2000) (Conference Paper) *AIDS Reviews* 2, 111-118, 2000.(2006 IF= 4.022)
 90. **Vandamme A.-M.** Evolving viruses and virologists. *Trends in Microbiology* 8, 8-10, 2000. (2000 IF=6.006)
 91. Daelemans D., Schols D., Witvrouw M., Pannecouque C., Hatse S., Van Dooren S., Hamy F., Klimkait T., De Clercq E. & **Vandamme A.-M.** A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXCR4-chemokine receptor 4-mediated virus entry. *Molecular Pharmacology* 57, 116-124, 2000. (2000 IF= 5.678)
 92. Fontaine E., Van Vaerenbergh K., **Vandamme A.-M.** & Schmit J.-C. Multidrug resistant human immunodeficiency virus type I. *AIDS Reviews* 1, 231-237, 2000.(2006 IF= 4.022)
 93. **Vandamme A.-M.**, Hall W.W., Lewis M.J., Goubau P. & Salemi M. Origins of HTLV-I in South-America. Reply. *Nature Medicine* 6, 232-233, 2000. (2000 IF= 27.905)
 94. Salemi M., Desmyter J. & **Vandamme A.-M.** Tempo and mode of human and simian T-lymphotropic virus (HTLV/STLV) evolution revealed by analyses of full-genome sequences. *Molecular Biology and Evolution* 17, 374-386, 2000.
 95. Van Laethem K., Witvrouw M., Balzarini J., Schmit J.-C., Sprecher S., Hermans P., Leal M., Harrer T., Ruiz L., Clotet B., Van Ranst M., Desmyter J., De Clercq E. &

- Vandamme A.-M.** Patient HIV-1 strains carrying the multiple nucleoside analogue resistance mutations are cross-resistant to abacavir. *AIDS* 14, 469-471, 2000. (2000 IF= 8.018)
96. Allain J.-P., Dong Y., **Vandamme A.-M.**, Moulton V. & Salemi M. Evolutionary rate and genetic drift of Hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. *Journal of Virology* 74, 2541-2549, 2000. (2000 IF=5.930)
97. Van Vaerenbergh K., Van Laethem K., Van Wijngaerden E., Schmit J.-C., Schneider F., Ruiz L., Clotet B., Verhofstede C., Van Wanzele F., Muyltermans G., Simons P., Stuyver L., Hermans P., Evans C., De Clercq E., Desmyter J. & **Vandamme A.-M.** Baseline HIV Type-1 genotypic resistance to a newly added nucleoside analog is predictive for virologic failure of the new therapy. *AIDS Research and Human Retroviruses* 16, 529-537, 2000. (2000 IF= 2.870)
98. Muyltermans G., Debaisieux L., Vaira D., Fransen K., Marissens D., Miller K., **Vandamme A.-M.**, Vandenbroucke A., Verhofstede C., Schuurman R., Zisis G., Lauwers S. Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories. *Clinical Microbiology and Infection* 6, 213-217, 2000.
99. Lewis M.J., Novoa P., Salemi M., Ishak M., Ishak R., **Vandamme A.-M.**, Kaplan M.H. & Hall W.W. Isolation, cloning, and complete nucleotide sequence of a phenotypically distinct Brazilian isolate of human T-lymphotropic virus type II (HTLV-II). *Virology* 271, 142-154, 2000. (2000 IF=3.507)
100. **Vandamme A.-M.** Possible genotypic and phenotypic algorithm for the clinical use of HIV-1 drug resistance testing. In "Guide to management of HIV resistance and pharmacokinetics of drug therapy" (B. Clotet, L. Menéndez-Arias, L. Ruiz, C. Tural, **A.-M. Vandamme**, D. Burger, J.M. Schapiro, C.A. Boucher, R. D'Aquila, D.D. Richman, eds), Editorial TAISA, S.L., Barcelona, Spain, pp85-89, 2000.
101. Van Laethem K., Schmit J.-C., Balzarini J., Witvrouw M., Pérez-Pérez M.J., Camarasa M.-J., Esnouf R., Aquaro S., Cenci A., Perno C.F., Hermans P., Sprecher S., Ruiz L., Clotet B., Van Wijngaerden E., Van Ranst M., Desmyter J., De Clercq E. & **Vandamme A.-M.** Presence of TSAO-resistant virus strains in TSAO-unexperienced patients. *AIDS Research and Human Retroviruses* 16, 825-833, 2000. (2000 IF=2,870)
102. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C., Clotet B., Florida M., Gerstoft J., Nielsen C., Pannecouque C., Perrin L., Pirillo MF., Ruiz L., Schmit JC., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Remoortele B., Van Wijngaerden E., Vella S., Witvrouw M., Yerly S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence and characteristics

- of multinucleoside resistant HIV-1 among European patients receiving combinations of nucleoside analogues. *Antimicrobial Agents and Chemotherapy* 44, 2109-2117, 2000. (2000 IF = 4.215)
103. Schmidt B., Walter H., Moschik B., Paatz C., Van Vaerenbergh K., **Vandamme A.-M.**, Schmitt M., Harrer T., Überla K. & Korn K. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. *AIDS* 14, 1731-1738, 2000. (2000 IF=8.018)
 104. Daelemans D., De Clercq E. & **Vandamme A.-M.** Control of RNA initiation and elongation at the HIV-1 promoter. *AIDS Reviews* 2, 229-240, 2000. (2006 IF= 4.022)
 105. Salemi M., Strimmer K., Hall W.W., Duffy M., Delaporte E., Mboup S., Peeters M. & **Vandamme A.-M.** Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. *FASEB Journal online* 10.1096/fj.00-0449fje, 2000. *FASEB Journal print* 15: 276-278, 2001. (2001 IF=8.817)
 106. **Vandamme A.-M.**, Bertazzoni U. & Salemi M. Evolutionary strategies of human T-cell lymphotropic virus type II. *Gene* 261, 171-180, 2001. (2001 IF=3.041)
 107. Pelemans H., Aertsen A., Van Laethem K., **Vandamme A.-M.**, De Clercq E., Pérez-Pérez M.-J., San-Félix A., Velazquez S., Camarasa M.-J., & Balzarini J. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. *Virology* 280, 97-106, 2001. (2001 IF=3.270)
 108. Miller V., **Vandamme A.-M.**, Loveday C., Staszewski S., Lundgren J., Youle M., Ait-Khaled M., Boucher C., Brun-Vézinet F., Dedes N., Giaquinto C., Hertogs K., Houyez F., Perrin L., Pillay D., Schmit J.-C., Schuurman R. & Lange J. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management – recommendations for the European setting. *AIDS* 15, 309-320, 2001. (2001 IF=6.881)
 109. **Vandamme A.-M.**, Houyez F., Bânhegyi D., Clotet B., De Schrijver G., De Smet K.A.L., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Holtzer C., Larder B., Pillay D., Race E., Schmit J.-C., Schuurman R., Shulse E., Sönnernborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. *Antiviral Therapy* 6, 21-40, 2001. (2001 IF=9.240)
 110. Van Vaerenbergh K., Debaisieux L., De Cabooter N., Declercq C., Desmet K., Fransen K., Maes B., Marissens D., Miller K., Muyldermans G., Sprecher S., Stuyver L., Vaira D., Verhofstede C., Zisis G., Van Ranst M., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence of genotypic resistance among Belgian antiretroviral drug-naïve HIV-1 infected patients and its consequences for therapy response. *Antiviral Therapy* 6, 63-70, 2001. (2001 IF=9.240)

111. Van Dooren S., Salemi M. & **Vandamme A.-M.** Dating the origin of the African Human T-Cell Lymphotropic Virus Type-I (HTLV-I) subtypes. *Molecular Biology and Evolution* 18, 661-671, 2001. (2001 IF=5.357)
112. Van Laethem K., Witvrouw M., Pannecouque C., Van Remoortel B., Schmit J.C., Esnouf R., Kleim J.-P., Balzarini J., Desmyter J., De Clercq E. & **Vandamme A.-M.** Mutations in the non-nucleoside binding pocket interfere with the multi-nucleoside resistance phenotype. *AIDS* 15, 553-561, 2001. (2001 IF=6.881)
113. Paraskevis D., Magiorkinis G., **Vandamme A.-M.**, Kostrikis L.G. & Hatzakis A. Re-analysis of human immunodeficiency virus type 1 isolates from Cyprus and Greece, initially designated as 'subtype I', reveals a unique complex A/G/H/K/? mosaic pattern. *Journal of General Virology*. 82, 575-80, 2001. (2001 IF=3.248)
114. **Vandamme A.-M.** & De Clercq E. Clinical usefulness of human immunodeficiency virus drug resistance monitoring. Chapter 12 in "Antiviral Therapy" (E. De Clercq, ed.) ASM Press, Washington, US, pp. 243-277, 2001.
115. Daelemans D., De Clercq E. & **Vandamme A.-M.** A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. *Journal of Virological Methods* 96, 183-188, 2001. (2001 IF=1.768)
116. Paraskevis D., Magiorkinis E., Magiorkinis G., Anastassopoulou C., Lazanas M., Chrysos G., **Vandamme A.-M.** & Hatzakis A. Molecular Characterization of a complex recombinant HIV-1 isolate (A/G/J/K/?): evidence to support the existence of a novel HIV-1 subtype. *Journal of General Virology* 82, 2509-2514, 2001. (2001 IF=3.248)
117. Balotta C., Facchi G., Violin M., Van Dooren S., Cozzi-Lepri A., Forbici F., Bertoli A., Riva C. Senese D., Caramello P., Carnevale G., Rizzardini G., Cremonini L., Monno L., Rezza G., Perno C.F., Ippolito G., d'Arminio Monforte A., **Vandamme A.-M.**, Moroni M., for the IcoNA Study Group. Increasing prevalence of non-clade B HIV-1 strains heterosexuals, as monitored by the analysis of the RT and protease sequences. *Journal of AIDS* 27, 499-505, 2001. (2001 IF=3.586)
118. International HIV Expert Commission. (**Vandamme A.-M.** 2nd last author of 100 authors ordered alphabetically) *Enjeux en 2001 des stratégies thérapeutiques et de la prise en charge de l'infection par VIH*. *Immuno-Deficiency Forum* 1, 1-8, (Bouchaud O. & Plique O., editors), 2001.
119. Van Dooren S., Salemi M., Pourrut X., Peeters M., Delaporte E., Van Ranst M., & **Vandamme A.-M.** Evidence for a second simian T-Cell lymphotropic virus type 3 in *Cercopithecus nictans* from Cameroon. *Journal of Virology* 75, 11939-11941, 2001. (2001 IF=5.622)

120. Fontaine E., Riva C., Peeters M., Schmit J.-C., Delaporte E., Van Laethem K., Van Vaerenbergh K., Van Wijngaerden E., Van Ranst M., De Clercq E. & **Vandamme A.-M.** Evaluation of two commercial kits for the detection of genotypic drug-resistance on a panel of HIV-1 subtypes A-J. *Journal of AIDS* 28, 254-258, 2001. (2001 IF=3.586)
121. Rijnders B.A., Van Wijngaerden E., **Vandamme A.-M.** Therapiefalen bij HIV en AIDS: Belang en aanpak van de onderliggende factoren. *Tijdschr voor Geneeskunde* 57, 782-787, 2001.
122. Salemi M. & **Vandamme A.-M.** Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. *Journal of Molecular Evolution* 54, 62-70, 2002. (2002 IF=3.041)
123. Shindo N., Alcântara L.C., Van Dooren S., Salemi M., Costa M.C., Kashima S., Covas D.T., Teva A., Pellegrini M., Brito I., **Vandamme A.-M.** & Galvão-Castro B. Human Retroviruses (HIV and HTLV) in Brazilian Indians: Seroepidemiological Study and Molecular Epidemiology of HTLV Type 2 Isolates. *AIDS Research and Human Retroviruses* 18, 71-77, 2002. (2002 IF=2.278)
124. Van Dooren S., Switzer W.M., Heneine W., Goubau P., Verschoor E., Parekh B., De Meurichy W., Furley C., Van Ranst M. & **Vandamme A.-M.** Lack of evidence for infection with simian immunodeficiency virus in bonobos. *AIDS Research and Human Retroviruses* 18, 213-216, 2002. (2002 IF=2.278)
125. Leyssen P., Charlier N., Lemey P., Billoir F., **Vandamme A.-M.**, De Clercq E., de Lamballerie X., and Neyts J. Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the modoc virus, a Flavivirus with No Known Vector. *Virology* 293, 125-140, 2002. (2002 IF=3.363)
126. Van Vaerenbergh K., Harrer T., Schmit J.-C., Carbonez A., Fontaine E., Kurowski M., Grünke M., Löw P., Rascu A., Schmidt B., Schmitt M., Thoelen I., Walter H., Van Laethem K., Van Ranst M., Desmyter J., De Clercq E., & **Vandamme A.-M.** Initiation of HAART in drug-naïve HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. *AIDS Research and Human Retroviruses* 18, 419-426, 2002. (2002 IF=2.278)
127. Snoeck J., Van Dooren S., Van Laethem K., Derdelinckx I., Van Wijngaerden E., De Clercq E. & **Vandamme A.-M.** Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. *Virus Research* 85, 95-108, 2002. (2002 IF=1.597)
128. Lemey P., Salemi M., Bassit L. & **Vandamme A.-M.** Phylogenetic classification of TT virus groups based on the N22 region is unreliable. *Virus Research* 85, 47-60, 2002. (2002 IF=1.597)

129. **Vandamme A.-M.** Virus evolution and molecular epidemiology. *Virus Research* 85, 1-3, 2002. (2002 IF=1.597)
130. Lewis M.J., Sheehy N., Salemi M., **Vandamme A.-M.** & Hall W.W. Comparison of CREB- and NF- κ B-mediated transactivation by human T lymphotropic virus type II (HTLV-II) and type I (HTLV-I) Tax proteins. *Virology* 295, 182-189, 2002. (2002 IF=3.363)
131. Magiorkinis G., Paraskevis D., Magiorkinis E., **Vandamme A.-M.**, Hatzakis A. Re-analysis of the HIV-1 Circulating Recombinant Form A/E (CRF01_AE): Evidence of A/E/G Recombination. *Journal of AIDS* 30, 124-129, 2002. (2002 IF=3.586)
132. Clotet B., **Vandamme A.-M.**, Tural C., Moreno S., Gatell J.M., Ruiz L. Implications of resistance testing for HIV-1 patient management: role in when selecting an initial regimen and use of resistance testing when changing therapy. In "Guide to management of HIV resistance and pharmacokinetics of antiretroviral therapy" 2nd Edition (B. Clotet, L. Menéndez-Arias, L. Ruiz, C. Tural, F. Brun-Vézinet, C. Loveday, D. Burger, J. Shapiro, C.A. Boucher, R. D'Aquila, D.D. Richman, eds), Editorial TAISA, S.L., Barcelona, Spain, 2002.
133. Van Wijngaerden E., De Saar V., De Graeve V., **Vandamme A.-M.**, Van Vaerenbergh K., Bobbaers H., Deschamps A., Ceunen H. & De Geest S. Non-adherence to highly active antiretroviral therapy: clinically relevant patient categorisation based on electronic event monitoring. *AIDS Research and Human retroviruses* 18, 327-330, 2002. (2002 IF=2.278)
134. Charlier N., Leyssen P., Pleij C.W.A., Lemey P., Billoir F., Van Laethem K., **Vandamme A.-M.**, De Clercq E., de Lamballerie X. and Neyts J. Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vector. *Journal of General Virology*, 83 1875-1885, 2002. (2002 IF=3.300)
135. Courgnaud V., Salemi M., Pourrut X., Mpoudi-Ngole E., Abela B., Auzel P., Bibollet-Ruche F., Hahn B., **Vandamme A.-M.**, Delaporte E. & Peeters M. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (*Cercopithecus nictitans*) provides new insights into simian/human immunodeficiency virus phylogeny. *Journal of Virology* 76, 8298-8309, 2002. (2002 IF=5.241)
136. Van Laethem K., De Luca A., Antinori A., Cingolani A., Perno C.-F. and **Vandamme A.-M.** A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. *Antiviral Therapy* 7, 123-129, 2002. (2002 IF=6.565)

137. Fikkert V., Cherepanov P., Van Laethem K., Hantson A., Van Remoortel B., Pannecouque C., De Clercq E., Debyser Z., **Vandamme A.-M.**, Witvrouw M. A new phenotypic assay to evaluate HIV susceptibility towards entry inhibitors. Proceedings of the XIV International AIDS Conference, Barcelona, Spain, July 7-12, Monduzzi Editore, Bologna, Italy, 2002.
138. Qari S.H., Winters M., **Vandamme A.-M.**, Merigan T., Heneine W. A rapid phenotypic assay for detecting multiple nucleoside analog reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 in plasma. *Antiviral Therapy* 7, 131-139, 2002. (2002 IF=6.565)
139. Duffy M., Salemi M., Sheehy N., **Vandamme A.-M.**, Hegarty J., Curry M., Nolan N., Kelleher D., McKiernan S., Hall W.W. Comparative Rates of Nucleotide Sequence Variation in the Hypervariable Region of E1/E2 and the NS5b Region of Hepatitis C Virus in Patients with a Spectrum of Liver Disease Resulting from a Common Source of Infection. *Virology* 301, 354-364, 2002. (2002 IF=3.363)
140. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De Clercq E., Pavlakis G.N. & **Vandamme A.-M.** A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proceedings of the National Academy of Sciences of the USA 99, 14440-14445, 2002. (2002 IF=10.700)
141. Fikkert V., Cherepanov P., Van Laethem K., Hantson A., Van Remoortel B., Pannecouque C., De Clercq E., Debyser Z., **Vandamme A.-M.** and Witvrouw M. *env* chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. *Antimicrobial Agents and Chemotherapy* 46, 3954-3962, 2002. (2002 IF=4.215)
142. Van Vaerenbergh K., De Geest S., Derdelinckx I., Bobbaers H., Carbonez A., Deschamps A., De Graeve V., De Saar V., Ceunen H., De Smet K., Maes B., Peetermans W., Schrooten Y., Desmyter J., De Clercq E., Van Ranst M., Van Wijngaerden E. & **Vandamme A.-M.** A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. *Antiviral Chemistry & Chemotherapy* 13, 231-240, 2002. (2001 IF=1.414)
143. Charlier N., Molenkamp R., Leyssen P., **Vandamme A.-M.**, De Clercq E., Bredenbeek P. and Neyts J. A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses. *Journal of Virological Methods* 108, 67-74, 2003. (2003 IF=1.826)
144. Vergne L., Paraskevis D., **Vandamme A.-M.**, Delaporte E., Peeters M. High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. *AIDS* 17:1-14, 2003. (2003 IF=5.521)

145. Ravela J., Betts B.J., Brun-Vézinet F., **Vandamme A.-M.**, Descamps D., Van Laethem K., Smith K., Schapiro J.M., Winslow D.L., Reid C., Shafer R.W. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. *Journal of AIDS* 33, 8-14, 2003. (2003 IF=3.586)
146. Lemey P., Pybus O.G., Wang B., Saksena N.K., Salemi M. & **Vandamme A.-M.** Tracing the origin and history of the HIV-2 epidemic. *Proceedings of the National Academy of Sciences of the USA* 100, 6588-6592, 2003. (2003 IF= 10.272)
147. Robbins K.E., Lemey P., Pybus O.G., Jaffe H.W., Saekhou A.M., Brown T.M., Salemi M., **Vandamme A.-M.**, Kalish M.L. U.S. human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. *Journal of Virology* 77, 6359-6366, 2003. (2003 IF=5.225)
148. Salemi M., De Oliveira T., Courgnaud V., Moulton V., Holland B., Cassol S., Switzer W.M., and **Vandamme A.-M.** Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. *Journal of Virology* 77, 7202-7213, 2003. (2003 IF=5.225)
149. **Vandamme A.-M.** Basic Concepts Of Molecular Evolution. In "The Phylogenetic Handbook" (M. Salemi & A.-M. Vandamme, eds), Cambridge University Press, UK, pp 1-23, 2003.
150. Magiorkinis G., Paraskevis D., **Vandamme A.-M.**, Magiorkinis E., Sypsa V., & Hatzakis A. In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of the hot spots and correlation with sequence similarity. *Journal of General Virology* 84, 2715-2722, 2003. (2003 IF=3.036)
151. de Jesus Teixeira Santos T., de Castro Costa C. M., Goubau P., **Vandamme A.-M.**, Desmyter J., Van Dooren S., Saleni Mota R.M., Bovy de Castro Costa F., Oliveira A.C.S., Gomes V.B.A.F., Carneiro-Proietti A.B., Sales de Bruin V.M., Florenço de Sousa F.C., & Barreto Oriá R. Western blot Seroindeterminate Individuals for Human T-lymphotropic Virus 1/2 (HTLV-1/2) in Fortaleza (Brazil): A Serological and Molecular Diagnostic and Epidemiological Approach. *The Brazilian Journal of Infectious Diseases*;7, 203-211, 2003.
152. **Vandamme A.-M.** Virus evolution and molecular epidemiology – evolving viruses and evolving analysis techniques. *FEMS Immunology and Medical Microbiology* 39, 95-96, 2003. (2003 IF= 1.789)
153. Lemey P., Salemi M., Wang B., Duffy M., Hall W.W., Saksena N.K., & **Vandamme A.-M.** Site stripping based on likelihood ratio reduction is a useful tool to evaluate the impact of non-clock-like behavior on viral phylogenetic

- reconstructions. *FEMS Immunology and Medical Microbiology* 39, 125-132, 2003. (2003 IF= 1.789)
154. Alcantara L.C. Jr., Shindo N., Van Dooren S., Salemi M., Ramos Costa M.C., Kashima S., Tadeu Covas D., **Vandamme A.-M.**, Galvão-Castro B. Brazilian HTLV type 2a strains from intravenous drug users (IDUs) appear to have originated from two sources: Brazilian Amerindians and European/North American IDUs. *AIDS Research and Human Retroviruses* 19, 519-523, 2003. (2003 IF= 2.291)
 155. Alcantara L.C. Jr., Van Dooren S., Gonçalves M.S., Kashima S., Ramos Costa M.C., Santos F.L.N., Bittencourt A.L., Dourado I., Filho A.A., Tadeu Covas D., **Vandamme A.-M.**, Galvão-Castro B. Globin haplotypes of human T-cell lymphotropic virus type I-infected individuals in Salvador, Bahia, Brazil, suggest a post-Columbian African origin of this virus. *Journal of AIDS* 33, 536-542, 2003. (2003 IF= 2.291)
 156. The EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. *AIDS* 17, S3-S27, 2003. (2003 IF=5.521)
 157. Wolf K., Walter H., Beerenwinkel N., Keulen W., Kaiser R., Hoffmann D., Lengauer T., Selbig J., Schnell T., **Vandamme A.-M.**, Korn K., and Schmidt B. Tenofovir resistance and resensitization. *Antimicrobial Agents and Chemotherapy* 47, 3478-3484, 2003. (2003 IF= 4.246)
 158. Derdelinckx I., Van Laethem K., Maes B., Schrooten Y., De Schouwer K., Dewit S., Franssen K., García Ribas S., Moutschen M., Vaira D., Zisis G., Van Ranst M., Van Wijngaerden E. and **Vandamme A.-M.** Performance of the VERSANT HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naïve patients infected with different HIV-1 subtypes. *FEMS Immunology and Medical Microbiology* 39, 119-124, 2003. (2003 IF= 1.789)
 159. Paraskevis D., Lemey P., Salemi M., Suchard M., Van de Peer Y., **Vandamme A.-M.** Analysis of the evolutionary relationships of HIV-1 and SIVcpz sequences using Bayesian inference: Implications for the origin of HIV-1. *Molecular Biology and Evolution* 20, 1986-1996, 2003. (2003 IF= 6.050)
 160. Sanchez-Palacios C, Gotuzzo E, **Vandamme A.-M.**, Maldonado Y. Seroprevalence and risk factors for human T-cell lymphotropic virus (HTLV-I) infection among ethnically and geographically diverse Peruvian women. *Int J Infect Dis.* 2003 Jun;7(2):132-7.
 161. **Vandamme A.-M.** HIV drug resistance testing in clinical practice: how far are we? In "Resistenz in der HIV-Therapie-Diagnostik und Management" (M Oette, R Kaiser, D Häussinger, eds), UNI-MED Verlag AG, Bremen, Vorwort, 2003.

162. Van Dooren S., Shanmugam V., Bhullar V., Parekh B., **Vandamme A.-M.**, Heneine W., and Switzer W.M. Identification in gelada baboons (*Theropithecus gelada*) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. *Journal of General Virology* 85, 507-517, 2004. (2004 IF=3.327)
163. Van Dooren S., Pybus O.G., Salemi M., Liu H.-F., Goubau P., Remondegui C., Talarmin A., Gotuzzo E., Alcantara L.C.J., Galvão-Castro B. and **Vandamme A.-M.**, The low evolutionary rate of Human T-Cell Lymphotropic Virus type-1 confirmed by analysis of vertical transmission chains. *Molecular Biology and Evolution* 21, 603-611, 2004. (2004 IF=6.355)
164. Snoeck J., Van Laethem K., Hermans P., Van Wijngaerden E., Derdelinckx I., Schrooten Y., van de Vijver D.A.M.C, De Wit S., Clumeck N., and **Vandamme A.-M.** Rising prevalence of HIV-1 non-B subtypes in Belgium : 1983-2001. *Journal of AIDS* 35, 279-285, 2004. (2004 IF=4.100)
165. Maes B, Schrooten Y, Snoeck J, Derdelinckx I, Van Ranst M, **Vandamme A-M**, Van Laethem K. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. *J Virol Methods*. 2004 Jul;119(1):45-9. (2004 IF=1.729)
166. Courgnaud V, Van Dooren S, Liegeois F, Pourrut X, Abela B, Loul S, Mpoudi-Ngole E, **Vandamme A-M**, Delaporte E, Peeters M. Simian T-cell leukemia virus (STLV) infection in wild primate populations in Cameroon: evidence for dual STLV type 1 and type 3 infection in agile mangabeys (*Cercocebus agilis*). *J Virol*. 2004 May;78(9):4700-9. (2004 IF=5.398)
167. Zlateva KT, Lemey P, **Vandamme A-M**, Van Ranst M. Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. *J Virol*. 2004 May;78(9):4675-83. (2004 IF=5.398)
168. Thoelen I, Moës E, Lemey P, Mostmans S, Wollants E, Lindberg AM, **Vandamme A-M**, Van Ranst M. Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species. *J Clin Microbiol*. 2004 Mar;42(3):963-71. (2004 IF=3.439)
169. de Oliveira T., Salemi M., Gordon M., **Vandamme A.-M.**, van Rensburg E.J., Engelbrecht S., Coovadia H.M., and Cassol S. Mapping Sites of Positive Selection and Amino Acid Diversification in the HIV Genome: An Alternative Approach to Vaccine Design? *Genetics* 167, 1047-1058, 2004. (2004 IF=4.138)
170. Lemey P., Pybus O.G., Rambaut A., Drummond A.J., Robertson D.L., Roques P., Worobey M., and **Vandamme A.-M.** The molecular population genetics of HIV-1 group O. *Genetics* 167, 1059-1068, 2004. (2004 IF=4.138)

171. Balzarini J., Van Laethem K., Hatse S., Vermeire K., De Clercq E., Peumans W., Van Damme E., **Vandamme A.-M.**, Böhmstedt A., Schols D. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. *Journal of Virology* 78, 10617-10627, 2004. (2004 IF=5.398)
172. Gotuzzo E., Cabrera J. , Deza L. , Verdonck K., **Vandamme A.-M.**, Cairampoma, R., Vizcarra D., Cabada M., Narvarte G. and De las Casas C. Clinical characteristics of patients in Peru with Human T Cell Lymphotropic Virus Type 1-Associated Tropical Spastic Paraparesis. *Clinical Infectious Diseases* 39, 939-944, 2004. (2004 IF=5.594)
173. Ziermann R., Celis L., Derdelinckx I., Lambert Ch., Veeck J., Rizzo M.G., Vanderborgh B., Zissis G., Clumeck N., Fransen K., Vaira D., Hendricks D., Van Laethem K., **Vandamme A.-M.**, Schmit J.-C., Knechten H., De Luca A., Louwagie J., Segers P., De Boeck K., Pottel H., De Brauwier A., Hulstaert F. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. *Journal of Clinical Virology* 2004: 31S: S7-S15. (2004 IF=2.447)
174. Magiorkinis G., Magiorkinis E., Paraskevis D., **Vandamme A.M.**, Van Ranst M, Moulton V, Hatzakis A.. Phylogenetic analysis of the full-length SARS-CoV sequences: evidence for phylogenetic discordance in three genomic regions. *Journal of Medical Virology* 74, 369-72, 2004. (2004 IF=2.331)
175. **Vandamme A.-M.**, Sönnnerborg A., Ait-Khaled M., Albert J., Asjo B., Bacheler L., Banhegyi D., Boucher C., Brun-Vézinet F., Camacho R., Clevenbergh P., Clumeck N., Dedes N., De Luca A., Doerr H.W., Faudon J.-L., Gatti G., Gerstoft J., Hall W.W., Hatzakis A., Hellmann N., Horban A., Lundgren J.D., Kempf D., Miller M., Miller V., Myers T.W., Nielsen C., Opravil M., Palmisano L., Perno C.F., Phillips A., Pillay D., Pumarola T., Ruiz L., Salminen M., Schapiro J., Schmidt B., Schmit J.-C., Schuurman R., Shulse E., Soriano V., Staszewski S., Vella S., Youle M., Ziermann R., Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. *Antiviral Therapy* 9, 829-848, 2004. (2004 IF=6.036)
176. Derdelinckx I., Van Laethem K., Maes B., Schrooten Y., De Wit S., Florence E., Fransen K., García Ribas S., Marissens D., Moutschen M., Vaira D., Zissis G., Van Ranst M., Van Wijngaerden E., and **Vandamme A.-M.** Current levels of drug resistance among therapy-naïve HIV-infected patients have significant impact on treatment response. *Journal of AIDS* 37 (5), 1664-1666, 2004. (2004 IF=4.100)
177. Abecasis A, Paraskevis D, Epalanga M, Fonseca M, Burity F, Bartolomeu J, Carvalho AP, Gomes P, **Vandamme AM**, Camacho R. HIV-1 genetic variants circulation in the North of Angola. *Infect Genet Evol.* 2005 Apr;5(3):231-7. Epub 2004 Dec 2.

178. Deschamps A., De Graeve V., Van Wijngaerden E., De Saar V., **Vandamme A.-M.**, Van Vaerenbergh K., Ceunen H., Bobbaers H., Peetermans W., De Vleeschouwer P., De Geest S. Prevalence and correlates of non-adherence to antiretroviral therapy in a population of HIV-patients using Medication Event Monitoring System[®]. *AIDS Patient care and STDs* 18 (11), 644-657, 2004. (2004 IF=1.600)
179. Paraskevis D., Magiorkinis E., Magiorkinis G., Kiosses V.G., Lemey P., **Vandamme A.-M.**, Rambaut A., & Hatzakis A. Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods. *Journal of Molecular Evolution* 59 (5), 709-717, 2004. (2004 IF=2.751)
180. Potter S.J., Lemey P., Achaz G., Chew C.B., **Vandamme A.-M.**, Dwyer D.E. & Saksena N.K. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. *Journal of leucocyte biology* 76(3), 562-570, 2004. (2004 IF=4.224)
181. Van Laethem K., Schrooten Y., Lemey P., Van Wijngaerden E., De Wit S., Van Ranst M., and **Vandamme A.-M.** A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelop gene. *Journal of Virological Methods* 123, 25-34, 2005. (2005 IF=1.886)
182. Vijgen L., Keyaerts E., Moës E., Thoelen I., Wollants E., Lemey P., **Vandamme A.-M.** and Van Ranst M. Complete genomic sequence of human coronavirus OC43: Molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. *Journal of Virology* 79 (3), 1595-1604, 2005. (2005 IF=5.178)
183. **Vandamme A.-M.** Phylogenetic techniques improve our understanding of virus evolution. *Infection, Genetics and Evolution* 5 (3), 197, 2005. (2007 IF=2.407)
184. Magiorkinis, G., Paraskevis D., Magiorkinis E., **Vandamme A.-M.**, Hatzakis A. Reanalysis of thirty-four full-length HIV-1 intersubtype recombinant sequences. *Infection, Genetics and Evolution* 5 (3), 225-229, 2005. (2007 IF=2.407)
185. Lemey P., Pybus O.G., Van Dooren S., **Vandamme A.-M.** A bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates. *Infection, Genetics and Evolution* 5 (3), 291-298, 2005. (2007 IF=2.407)
186. Paraskevis D., Deforche K., Abecasis A., Camacho R., **Vandamme A.-M.** Analysis of complex HIV-1 intersubtype recombinants using a Bayesian scanning method. *Infection, Genetics and Evolution* 5 (3), 219-224, 2005. (2007 IF=2.407)
187. Paraskevis D., Deforche K., Lemey P., Magiorkinis G., Hatzakis A., & **Vandamme A.-M.** SlidingBayes: Exploring recombination using a sliding window approach based on Bayesian phylogenetic inference. *Bioinformatics* 21(7), 1274-1275, 2005. (2005 IF=6.019)

188. Lemey P., Van Dooren S. and **Vandamme A.-M.** Evolutionary dynamics of human retroviruses investigated through full genome scanning. *Molecular Biology and Evolution* 22(4), 942-951, 2005. (2005 IF=6.233)
189. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Soares M.A., Snoeck J., Pillay C., Rudich H., Rodrigues R., Holguin A., Ariyoshi K., Bouzas M.B., Cahn P., Sugiura W., Soriano V., Brigido L.F., Grossman Z., Morris L., **Vandamme A.-M.**, Tanuri A., Phanuphak P., Weber J.N., Pillay D., Harrigan P.R., Camacho R., Schapiro J.M. & Shafer R.W. Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. *PLoS medicine/ Public Library of Science* 2(4), e112, 2005. (2005 IF=8.389)
190. Abecasis AB, Deforche K, Snoeck J, Bachelier LT, McKenna P, Carvalho AP, Gomes P, Camacho RJ, **Vandamme AM.** Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. *AIDS*. 2005 Nov 4;19(16):1799-1806. (2005 IF=5.835)
191. Lemey P, Van Dooren S, Van Laethem K, Schrooten Y, Derdelinckx I, Goubau P, Brun-Vezinet F, Vaira D, **Vandamme AM.** Molecular testing of multiple HIV-1 transmissions in a criminal case. *AIDS*. 2005 Oct 14;19(15):1649-1658. (2005 IF=5.835)
192. Lemey P, Derdelinckx I, Rambaut A, Van Laethem K, Dumont S, Vermeulen S, Van Wijngaerden E, **Vandamme AM.** Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. *J Virol*. 2005 Sep;79(18):11981-9. (2005 IF=5.178)
193. Meersseman W, Van Laethem K, Lagrou K, Wilms G, Sciote R, Van Ranst M, **Vandamme A**, Van Wijngaerden E. Fatal brain necrosis in primary HIV infection. *Lancet*. 2005 Sep 3-9;366(9488):866. (2005 IF=23.878)
194. Lemey P, **Vandamme AM.** Exploring full-genome sequences for phylogenetic support of HIV-1 transmission events. *AIDS*. 2005 Sep 23;19(14):1551-2. (2005 IF=5.835)
195. Hantson A, Fikkert V, Van Remoortel B, Pannecouque C, Cherepanov P, Matthews B, Holan G, De Clercq E, **Vandamme AM**, Debyser Z, Witvrouw M. Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology. *Antivir Chem Chemother*. 2005;16(4):253-66.
196. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul

- EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, **Vandamme AM**, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. *J Infect Dis*. 2005 Sep 15;192(6):958-66. (2005 IF=4.953)
197. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de Vijver DA, Boucher CA, Camacho R, **Vandamme AM**. An automated genotyping system for analysis of HIV-1 and other microbial sequences. *Bioinformatics*. 2005 Oct 1;21(19):3797-800. (2005 IF=6.019)
 198. Zlateva KT, Lemey P, Moes E, **Vandamme AM**, Van Ranst M. Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. *J Virol*. 2005 Jul;79(14):9157-67. (2005 IF=5.178)
 199. Mikhail M, Wang B, Lemey P, Beckholdt B, **Vandamme AM**, Gill MJ, Saksena NK. Full-length HIV type 1 genome analysis showing evidence for HIV type 1 transmission from a nonprogressor to two recipients who progressed to AIDS. *AIDS Res Hum Retroviruses*. 2005 Jun;21(6):575-9. (2005 IF=2.531)
 200. Mikhail M, Wang B, Lemey P, Beckthold B, **Vandamme AM**, Gill MJ, Saksena NK. Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. *Retrovirology*. 2005 Jun 29;2:41. (2005 IF= 4.040)
 201. Salemi M, de Oliveira T, Soares MA, Pybus O, Dumans AT, **Vandamme AM**, Tanuri A, Cassol S, Fitch WM. Different epidemic potentials of the HIV-1B and C subtypes. *J Mol Evol*. 2005 May;60(5):598-605. (2005 IF=2.703)
 202. Van Dooren S, Meertens L, Lemey P, Gessain A, **Vandamme AM**. Full-genome analysis of a highly divergent simian T-cell lymphotropic virus type 1 strain in *Macaca arctoides*. *J Gen Virol*. 2005 Jul;86(Pt 7):1953-9. (2005 IF=3.013)
 203. Vijgen L, Keyaerts E, Lemey P, Moes E, Li S, **Vandamme A-M**, Van Ranst M. Circulation of genetically distinct contemporary human coronavirus OC43 strains. *Virology*. 2005 Jun 20;337(1):85-92. (2005 IF=5.178)
 204. Snoeck J, Riva C, Steegen K, Schrooten Y, Maes B, Vergne L, Van Laethem K, Peeters M, **Vandamme A-M**. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. *J Virol Methods*. 2005 Sep;128(1-2):47-53. (2005 IF=1.886)
 205. Van Laethem K, & **Vandamme A-M** "HAART Therapy—Antiretroviral Resistance Genotyping" in *Encyclopedia of Diagnostic Genomics and Proteomics*, Marcel Dekker, Inc. pp550-554, 2005.

206. Vergne L, Snoeck J, Aghokeng A, Maes B, Valea D, Delaporte E, **Vandamme AM**, Peeters M, Van Laethem K. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. *FEMS Immunol Med Microbiol.* 2006 Feb 1;46(1):53-62. (2006 IF= 2.281)
207. Van Laethem K, Schrooten Y, Dedecker S, Van Heeswijck L, Deforche K, Van Wijngaerden E, Van Ranst M, **Vandamme AM**. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. *Journal of Virological Methods* 2006 Mar;132(1-2):181-6. Epub 2005 Nov 4. (2006 IF= 2.097)
208. Babic DZ, Zelnikar M, Seme K, **Vandamme AM**, Snoeck J, Tomazic J, Vidmar L, Karner P, Poljak M. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. *Virus Research* 2006 Jun;118(1-2):156-63. Epub 2006 Jan 14. (2006 IF= 2.783)
209. Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vezinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, **Vandamme AM**. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. *Antimicrob Agents Chemother.* 2006 Feb;50(2):694-701. (2006 IF=4.153)
210. Van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, Macrae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, **Vandamme AM**, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. *J Acquir Immune Defic Syndr.* 2006 Mar;41(3):352-360. (2006 IF= 3.946)
211. Potter SJ, Lemey P, Dyer WB, Sullivan JS, Chew CB, **Vandamme AM**, Dwyer DE, Saksena NK. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. *Virology* 2006 Apr 25;348(1):35-46. Epub. 2006 Jan 30. (2006 IF=3.525)

212. Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, **Vandamme AM**. Use of Electronic Monitoring Induces a 40-Day Intervention Effect in HIV Patients. *J Acquir Immune Defic Syndr*. 2006 Oct 1;43(2):247-248. (2006 IF= 3.946)
213. Abecasis AB, Deforche K, Bacheler LT, McKenna P, Carvalho AP, Gomes P, **Vandamme AM**, Camacho RJ. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. *Antivir Ther*. 2006;11(5):581-9. (2006 IF= 4.982)
214. Gifford R, de Oliveira T, Rambaut A, Myers RE, Gale CV, Dunn D, Shafer R, **Vandamme AM**, Kellam P, Pillay D; UK Collaborative Group on HIV Drug Resistance. Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. *AIDS*. 2006 Jul 13;20(11):1521-9. (2006 IF=5.632)
215. Vercauteren J, **Vandamme AM**. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. *Antiviral Res*. 2006 Sep;71(2-3):335-42. Epub 2006 May 30. (2006 IF= 2.878)
216. Van Laethem K, **Vandamme AM**. Interpreting resistance data for HIV-1 therapy management--know the limitations. *AIDS Rev*. 2006 Jan-Mar;8(1):37-43. Review. (2006 IF= 4.022)
217. Deforche K, Silander T, Camacho R, Grossman Z, Soares M, Van Laethem K, Kantor R, Moreau Y, **Vandamme AM**., non-B workgroup. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. *Bioinformatics* 2006 Dec 15;22(24):2975-9. Epub. 2006 Oct 4. (2006 IF=4.894)
218. **Vandamme A.-M.**, Camacho R. Useful websites for the management of HIV infected patients. In "Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects" 6th Edition (B. Clotet, L. Menéndez-Arias, J. Shapiro, D. Kuritzkes, D. Burger, A. Telenti, F. Brun-Vézinet, A.M. Geretti, C.A. Boucher, D.D. Richman, eds), Ediciones Gráficas Rey, S.L., Barcelona, Spain, 2006.
219. Katzenstein DA, Camacho RJ, Abecasis AB, **Vandamme A-M** and Shafer RW for the HIV-1 Non-Subtype B Working Group. Authors Reply to: Role for Geographical Location and Founder Effects in Describing HIV-1 Subtype-Specific Polymorphisms. *Plos Medicine* 2006. Published online 4 Dec 2006. (2006 IF=13.75)
220. **Vandamme A-M**, Ait-Khaled M, Albert J, Åsjö B, Bacheler L, Banhegyi D, Bates M, Boucher C, Brun-Vézinet F, Camacho R, Colonna RJ, Clumeck N, de Béthune M-P, Dedes N, de Luca A, Doerr H.W., Faudon J-L, Gatell J, Gatti G, Gerstoft J, Hall WW, Hanna G, Hazuda D, Heilek-Snyder G, Horban A, Lundgren JD, Marlowe N, Mayers D, Miller M, Miller V, Nielsen C, Opravil M, Palmisano L,

- Paraskevis D, Pattick A, Perno CF, Phillips A, Pillay D, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit J-C, Schuurman R, Sönnnerborg A, Soriano V, Staszewski S, Youle M, Ziermann R, Perrin L. European HIV Drug Resistance Guidelines 2006 update. The European HIV Drug Resistance Guidelines Panel March 2007. <http://www.rega.kuleuven.be/cev/>
221. Resik S, Lemey P, Ping LH, Kouri V, Joanes J, Perez J, **Vandamme AM**, Swanstrom R. Limitations to Contact Tracing And Phylogenetic Analysis in Establishing HIV Type 1 Transmission Networks in Cuba. *AIDS Res Hum Retroviruses*. 2007 Mar;23(3):347-56 (2007 IF=2.022)
 222. Verdonck K, Gonzalez E, Van Dooren S, **Vandamme AM**, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. *Lancet Infect Dis*. 2007 Apr;7(4):266-81(2007 IF= 12.058)
 223. Camacho R J and **Vandamme A.M**. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. *Current Opinion in HIV and AIDS*. 2007 (2): 123-129 (IF=)
 224. Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, Van Wijngaerden E, **Vandamme AM**. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs. *J Clin Virol*. 2007 May;39(1):43-7. Epub 2007 Mar 21(2007 IF= 3.468)
 225. Van Dooren S, Verschoor EJ, Fagrouch Z, **Vandamme AM**. Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains. *Infection Genetics and Evolution* 2007 Jun;7(3):374-81. Epub 2006 Aug 23. (2007 IF= 2.407)
 226. Deforche K, Camacho R, Grossman Z, Silander T, Soares M.A., Moreau Y, Shafer RW, Van Laethem K, Carvalho AP, Wynhoven B, Cane P, Snoeck J, Clarke J, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas M.B, Cahn P, Brigido L.F., Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan P.R., Shapiro J.M., Katzenstein D.A., Kantor R & **Vandamme A.-M**. Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. *Infection Genetics and Evolution* 2007 Jun;7(3):382-90. Epub 2006 Nov 28.(2007 IF= 2.407)
 227. Bernard E, Azad Y, **Vandamme A-M**, Weait M, Geretti A. HIV forensics: pitfalls and acceptable standards in the use of phylogenetic analysis as evidence in criminal investigations of HIV transmission. *HIV Med*. 2007 Sep;8(6):382-7.(2007 IF=3.347)

228. Bittencourt AL, Barbosa HS, Requiao C, da Silva AC, **Vandamme AM**, Van Weyenbergh J, Farre L. Adult T-cell leukemia/lymphoma with a mixed CD4+ and CD8+ phenotype and indolent course. *J Clin Oncol*. 2007 Jun 10;25(17):2480-2. (2007 IF= 15.484)
229. Abecasis AB, Lemey P, Vidal N, de Oliveira T, Peeters M, Camacho R, Shapiro B, Rambaut A, **Vandamme AM**. Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. *J Virol*. 2007 Aug;81(16):8543-51. Epub 2007 Jun 6. (2007 IF= 5.332)
230. Mota AC, Van Dooren S, Fernandes FM, Pereira SA, Queiroz AT, Gallazzi VO, **Vandamme AM**, Galvao-Castro B, Alcantara LC. The close relationship between South African and Latin American HTLV type 1 strains corroborated in a molecular epidemiological study of the HTLV type 1 isolates from a blood donor cohort. *AIDS Res Hum Retroviruses*. 2007 Apr;23(4):503-7. (2007 IF=2.022)
231. Snoeck J, **Vandamme A-M** & Camacho RJ. Impact of genetic variation of HIV-1 on drug resistance development. *Future Virology* May 2007, Vol. 2, No. 3, Pages 303-310 . (2007 IF=0.612)
232. **Vandamme A.-M.**, Camacho R. Useful websites for the management of HIV infected patients. In "Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects" 7th Edition (B. Clotet, L. Menéndez-Arias, J. Shapiro, D. Kuritzkes, D. Burger, A. Telenti, F. Brun-Vézinet, A.M. Geretti, C.A. Boucher, D.D. Richman, eds), Ediciones Gráficas Rey, S.L., Barcelona, Spain, pp 465-466, 2007.
233. Deforche K, Camacho R, Van Laethem K, Shapiro B, Moreau Y, Rambaut A, **Vandamme AM**, Lemey P. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. *J Comput Biol*. 2007 Oct;14(8):1105-14. (2007 IF= 2.109)
234. Gifford RJ, de Oliveira T, Rambaut A, Pybus OG, Dunn D, **Vandamme AM**, Kellam P, Pillay D; UK Collaborative Group on HIV Drug Resistance. Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. *J Virol*. 2007 Dec;81(23):13050-6. Epub 2007 Sep 26. (2007 IF= 5.167)
235. Van Laethem K, Pannecouque C, **Vandamme AM**. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. *Infect Genet Evol*. 2007 Sep;7(5):600-3. Epub 2007 May 13. (2007 IF=2.407)

236. Arrais TC, Van Dooren S, **Vandamme A-M**, Brechot C, Rimlinger F, Silva AE, Perez RM, Ferraz ML, Thiers V. Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy-relapse or re-infection? *J Med Virol*. 2008 Jan;80(1):80-6. (2008 IF=2.576)
237. Deforche K.; R. Camacho; K. Van Laethem; P. Lemey; A. Rambaut; Y. Moreau; **A.-M. Vandamme**. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. *Bioinformatics* 2008, 24: 34-41. Epub 2007 Nov 17 (2008 IF=4.328)
238. Gotuzzo E, Moody J, Verdonck K, Cabada MM, González E, Van Dooren S, **Vandamme AM**, Terashima A, Vermund SH. Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1-associated myelopathy/tropical spastic paraparesis or strongyloidiasis. *Rev Panam Salud Publica*. 2007 Oct;22(4):223-230.
239. Abecasis AB, **Vandamme A-M**. New insights in the early evolutionary history of HIV-1: on the origin of CRF02_AG and subtype G. VIII Virtual Congress HIV-AIDS. Nov 2007. http://www.aidscongress.net/article.php?id_comunicacao=344.
240. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC Jr, Van Dooren S, Galvão-Castro B, **Vandamme AM**, Van Weyenbergh J. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. *J Leukoc Biol*. 2008 Jan;83(1):220-2. Epub 2007 Oct 25. (2008 IF=4.605)
241. Ho YS, Abecasis AB, Theys K, Deforche K, Dwyer DE, Charleston M, **Vandamme AM**, Saksena NK. HIV-1 gp120 N-linked glycosylation differs between plasma and leukocyte compartments. *Virol J*. 2008 Jan 23;5:14. (2008IF=1.882)
242. Farre L, de Oliveira M de F, Primo J, **Vandamme AM**, Van Weyenbergh J, Bittencourt AL. Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. *Clin Infect Dis*. 2008 Feb 1;46(3):440-2. (2008IF=8.266)
243. Matheï C, Van Dooren S, Lemey P, Van Damme P, Buntinx F, **Vandamme AM**. The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. *J Viral Hepat*. 2008 Jun;15(6):399-408. Epub 2008 Jan 28. (2008 IF=3.326)
244. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, **Vandamme AM**, Camacho R. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. *Retrovirology*. 2008 Feb 1;5(1):12. (2008 IF=4.042)

245. The SPREAD programme (Wensing AM.J., Jurgen Vercauteren, David A. van de Vijver, Jan Albert, Birgitta Asjö, Claudia Balotta, Ricardo Camacho, Suzie Coughlan, Zehava Grossman, Andrzej Horban, Claudia Kücherer, Claus Nielsen, Dimitris Paraskevis, Wei C. Loke, Gabrielle Poggensee, Elisabeth Puchhammer-Stöckl, Chiara Riva, Lidia Ruiz, Jean-Claude Schmit, Rob Schuurman, Mika Salminen, Anders Sonnerborg, Maja Stanojevic, Daniel Struck, **Vandamme A-M**, Charles A.B. Boucher). Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. *AIDS*. 22(5):625-635, March 12, 2008. (2008 IF=5.460)
246. Lemey P., K. Deforche and **A-M. Vandamme**. Comparative Genomics in AIDS Research. In 'Comparative Genomics. Basic and Applied Research', (J.R. Brown, ed.), CRC Press, Taylor & Francis Group, pp219-244, 2008.
247. Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Franssen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Van Den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, **Vandamme AM**, Van Laethem K. Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006. *AIDS Res Hum Retroviruses* 24 (3) , 355-362, 2008. (2008 IF=2.024)
248. Abecasis AB, **Vandamme A-M**, Lemey P (2007). Sequence alignment in HIV computational analysis. pp. 12-16 in HIV Sequence Compendium 2006/2007. Edited by: Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B. Published by: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos. <http://www.hiv.lanl.gov/content/sequence/TUTORIALS/Tutorials.html>
249. Theys K, **Vandamme AM**. Understanding the changing prevalence of K65R. *AIDS Rev*. 2008 Apr-Jun;10(2):125. (editorial). (2008 IF=3.268)
250. Gonzalez LMF, Santos AF, Abecasis AB, Van Laethem K, Soares EA, Deforche K, Tanuri A, Camacho R, **Vandamme A-M**, Soares MA. Impact of HIV-1 protease mutations A71V/1 T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. *Journal of Antimicrobial Chemotherapy*, 2008 Jun;61(6):1201-4. Epub 2008 Mar 20. (2008 IF=4.328)
251. Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, **Vandamme AM**; EuroSIDA Study Group. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. *Antivir Ther*. 2008;13(3):399-407. (2008 IF=4.105)

252. Sloot P, Coveney P, Bubak MT, **Vandamme AM**, O Nualláin B, van de Vijver D, Boucher C. Multi-Science Decision Support for HIV Drug Resistance Treatment. *Stud Health Technol Inform.* 2008;138:188-98.
253. Zimmer JM, Roman F, Lambert C, Jonckheer A, Vazquez A, Plesséria JM, Servais JY, Covens K, Weber J, Van Laethem K, Schmit JC, **Vandamme AM**, Quinones-Mateu ME, De Maeyer M. Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. *J Acquir Immune Defic Syndr.* 2008 Jul 1;48(3):255-62. (2008 IF=4.570)
254. Deschamps AE, De Geest S, **Vandamme A-M**, Bobbaers H, Peetermans WE, and Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virological failure as reference standards. *AIDS Patient Care and STDs* 2008 Sep;22(9):735-43. (2008 IF=2.392)
255. Sloot P., P Coveney, MT Bubak, **AM Vandamme**, B. O'Nuallian, D van de Vijver and C. Boucher. Virolab: A collaborative decision support system in viral disease treatment. *Reviews in Antiviral Therapy*, 3:4-7,2008.
256. Mascolini M., F Brun-Vézinet, B Clotet, A De Luca, S Dressler, A.M. Geretti, J Minarovits, C Nielsen, J Schapiro, J-C Schmit, **A-M Vandamme** and C Boucher. Report to new antiretrovirals and clinical implications of resistance. Report on the 6th European HIV Drug Resistance Workshop, 26-28 March 2008, Budapest, Hungary. *Reviews in Antiviral Therapy*, 2: 22-45, 2008.
257. Deforche K, Camacho RJ, Grossman Z, Soares MA, Van Laethem K, Katzenstein DA, Harrigan PR, Kantor R, Shafer R, **Vandamme AM**; non-B Workgroup. Bayesian network analyses of resistance pathways against efavirenz and nevirapine. *AIDS.* 2008 Oct 18;22(16):2107-15. (2008 IF=5.460)
258. Van Laethem K, Schrooten Y, Covens K, Dekeersmaeker N, De Munter P, Van Wijngaerden E, Van Ranst M, **Vandamme AM**. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. *J Virol Methods.* 2008 Nov;153(2):176-81. Epub 2008 Sep 2. (2008 IF=2.077)
259. **Vandamme A-M**. The origins of human retroviruses. In 'Lectures for the XXIst Century' (ed. Bart Raymaekers) Leuven University Press, 2008, pp 127-141.
260. Theys K, Vercauteren J, Abecasis A, Libin P, Deforche K, **Vandamme AM** and Camacho R. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of Tenofovir. *Infection, Genetics and Evolution* 2009 Jul;9(4):683-8. Epub 2008 Nov 6. (2008 IF=2.792)
261. Schietgat L, K Theys, J Ramon, H Blockeel, and **AM Vandamme**. Distinguishing epidemiological dependent from treatment (resistance) dependent HIV

mutations: Problem Statement. Proceedings of the 1st International Workshop on Statistical and Relational Learning in Bioinformatics 18. 19th European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases. Antwerp; 15-19 September 2008.

262. Sloot P.M.A.; P.V. Coveney; M.T. Bubak; **A.-M. Vandamme**; B. Ó Nualláin; D. van de Vijver and C.A.B. Boucher: Multi-Science Decision Support for HIV Drug Resistance Treatment, in T. Solomonides; J.C. Silverstein; J. Saltz; Y. Legré; M. Kratz; I. Foster; V. Breton and J.R. Beck, editors, Global Healthgrid: e-Science Meets Biomedical Informatics - Proceedings of HealthGrid 2008, in series Studies in Health Technology and Informatics, vol. 138, pp. 188-198. IOS Press, 2008. ISBN: 978-1-58603-874-8.
263. Verdonck K, González E, Maldonado F, Agapito D, Van Dooren S, **Vandamme AM**, Silva-Santisteban A, Vanham G, Clark D, Gotuzzo E. Comparison of three ELISAs for the routine diagnosis of human T-lymphotropic virus infection in a high-prevalence setting in Peru. *Trans R Soc Trop Med Hyg.* 2009 Apr;103(4):420-2. Epub 2009 Jan 19.
264. Santos AF, Abecasis AB, **Vandamme AM**, Camacho RJ, Soares MA. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. *J Antimicrob Chemother.* Mar;63(3):593-9. Epub 2009 Jan 10. (2009 IF= 4.352)
265. Covens K, Kabeya K, Schrooten Y, Dekeersmaeker N, Van Wijngaerden E, **Vandamme AM**, De Wit S, Van Laethem K. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. *J Clin Virol.* 2009 Apr;44(4):325-8. Epub 2009 Feb 23. (2009 IF= 3.124)
266. Clement J, Vercauteren J, Verstraeten WW, Ducoffre G, Barrios JM, **Vandamme AM**, Maes P, Van Ranst M. Relating increasing hantavirus incidences to the changing climate: the mast connection. *Int J Health Geogr.* 2009 Jan 16;8:1.
267. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, **Vandamme AM**, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. *PLoS ONE.* 2009;4(3):e4724. Epub 2009 Mar 6. (2009 IF= 4.351)
268. Assel M, D van de Vijver, P Libin, K Theys, D Harezlak, B Ó Nualláin, P Nowakowski, M Bubak, **A-M Vandamme**, S Imbrechts, R Sangeda, T Jiang, D Frenzt and P Sloot. A Collaborative Environment Allowing Clinical Investigations on Integrated Biomedical Databases. *Stud Health Technol Inform.* 2009;147:51-61.

269. **Vandamme A.-M.** Basic Concepts Of Molecular Evolution. In “The Phylogenetic Handbook” (P. Lemey, M. Salemi & A.-M. Vandamme, eds, 2nd edition), Cambridge University Press, UK, pp 3-29, 2009.
270. Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman IM, Horban A, Korn K, Kuecherer C, Leitner T, Loveday C, Macrae E, Maljkovic I, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schuurman R, Soriano V, Stanczak J, Stanojevic M, Struck D, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CA, **Vandamme AM**, Programme SPREAD. Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. *Retrovirology*. 2009 May 20;6(1):49. (2009 IF= 4.105)
271. Covens K, Dekeersmaecker N, Schrooten Y, Weber J, Schols D, Quiñones-Mateu ME, **Vandamme AM**, Van Laethem K. Novel recombinant virus assay for measuring susceptibility to clinically approved drugs in HIV-1 group M subtypes. *J Clin Microbiol*. 2009 Jul;47(7):2232-42. Epub 2009 Apr 29. (2009 IF= 4.162)
272. **Vandamme AM**. Bioinformatics tools for the investigation of emerging and re-emerging infectious diseases. Introduction. *Infect Genet Evol*. 2009 Jul;9(4):671. Epub 2009 Apr 17. (IF 2009 = 3.223)
273. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, **Vandamme AM**, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. *J Infect Dis*. 2009 Aug 1;200(3):453-463. (2009 IF=5.15)
274. Alcantara LC, Cassol S, Libin P, Deforche K, Pybus OG, Van Ranst M, Galvão-Castro B, **Vandamme AM**, de Oliveira T. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. *Nucleic Acids Res*. 2009 Jul 1;37(Web Server issue):W634-42. Epub 2009 May 29. (2009 IF=7.479)
275. Prosperi MC, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, Bazso F, Sonnerborg A, Schülter E, Struck D, Ulivi G, **Vandamme AM**, Vercauteren J, Zazzi M; EuResist and Virolab study groups. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. *Antivir Ther*. 2009;14(3):433-42. (2009 IF=4.322)
276. Abecasis AB, **Vandamme A-M**, Lemey P. Quantifying differences in the tempo of HIV-1 subtype evolution. *J Virol*. 2009; 83(24):12917-24. Epub 2009 Sep 30. (2009 IF=5.865)

277. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, **Vandamme A-M**, Boucher CA. Transmission of drug-resistant HIV-1 is stabilizing in Europe. *J Infect Dis.* 2009 Nov 15;200(10):1503-8. (2009 IF=5.15)
278. Moens B, López G, Adaui V, González E, Kerremans L, Clark D, Verdonck K, Gotuzzo E, Vanham G, Cassar O, Gessain A, **Vandamme AM**, Van Dooren S. Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination. *J Clin Microbiol.* 2009 Nov;47(11):3682-91. Epub 2009 Sep 9. (2009 IF= 4.162)
279. **Vandamme A-M**, Ait-Khaled M, Albert J, Åsjö B, Bachelier L, Banhegyi D, Bates M, Boucher C, Brun-Vézinet F, Camacho RJ, Clotet B, de Béthune M-P, Dedes N, de Luca A, De Wit S, Doerr H.W., Dressler S, Elston R, Gatell J, Geretti AM, Gerstoft J, Hall WW, Hazuda D, Horban A, Günthard H, Jevtovic D, Kaiser R, Lataillade M, Lundgren JD, Marlowe N, Maroldo L, Miller M, Nielsen C, Palmisano L, Paraskevis D, Perno CF, Petropoulos C, Phillips A, Poljak M, Schapiro J, Schmit J-C, Schuurman R, Simen BB, Soriano V, Stephan C, Suni J, Teofilo E, Tsertsvadze T, Westby M, Yerly S, Youle M, Sönnnerborg A. European HIV Drug Resistance Guidelines 2009 update. The European HIV Drug Resistance Guidelines Panel November 2009. <http://www.rega.kuleuven.be/cev/>
280. **Vandamme A.-M.**, Camacho R. Useful websites for the management of HIV infected patients. In "Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects" 7th Edition (B. Clotet, L. Menéndez-Arias, J. Shapiro, D. Kuritzkes, D. Burger, A. Telenti, F. Brun-Vézinet, A.M. Geretti, C.A. Boucher, D.D. Richman, eds), Ediciones Gráficas Rey, S.L., Barcelona, Spain, 2009.
281. **Vandamme AM.** Bioinformatics tools for the investigation of viral evolution and molecular epidemiology. *Infect Genet Evol.* 2010 Apr;10(3):355. Epub 2009 Oct 12. (IF 2010 = 3.086)
282. de Sousa JD, Müller V, Lemey P, **Vandamme AM.** High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. *PLoS One.* 2010 Apr 1;5(4):e9936 (<http://dx.plos.org/10.1371/journal.pone.0009936>). (IF 2010 = 4.411)
283. Abecasis AB, Wang Y, Libin P, Imbrechts S, de Oliveira T, Camacho RJ, **Vandamme A-M.** Comparative performance of the REGA Subtyping tool version 2 versus

- version 1. *Infections, Genetics and Evolution*. 2010 Apr;10(3):380-5. Epub 2009 Oct 12. (IF 2010 = 3.086)
284. Palma AC, Abecasis AB, Vercauteren J, Carvalho AP, Cabanas J, **Vandamme AM**, Camacho RJ. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. *Infect Genet Evol*. 2010 Apr;10(3):373-9. Epub 2009 Jul 2. (IF 2010 = 3.086)
285. Theys K, Deforche K, Libin P, Camacho RJ, Van Laethem K, **Vandamme AM**. Resistance Pathways of Human Immunodeficiency Virus Type 1 against the Combination of Zidovudine and Lamivudine. *J Gen Virol*. 2010 Aug;91(Pt 8):1898-908. Epub 2010 Apr 21 (IF 2010 = 3.568)
286. Covens K, Megens S, Dekeersmaeker N, Kabeya K, Balzarini J, De Wit S, **Vandamme AM**, Van Laethem K. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. *Antiviral Res*. 2010 Jun;86(3):253-60. Epub 2010 Mar 21. (IF 2010 = 4.439)
287. Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloom PM, Torti C, **Vandamme A-M**, Van Laethem K, Zazzi M, van de Vijver DA. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. *PLoS One*. 2010 Jul 9;5(7):e11505. (IF 2010 = 4.411)
288. Demetriou VL, van de Vijver DA, Kousiappa I, Balotta C, Clotet B, Grossman Z, Jørgensen LB, Lepej SZ, Levy I, Nielsen C, Paraskevis D, Poljak M, Roman F, Ruiz L, Schmidt JC, **Vandamme A-M**, Van Laethem K, Vercauteren J, Kostrikis LG. Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe. *PLoS One*. 2010 Jun 8;5(6):e10976. <http://dx.plos.org/10.1371/journal.pone.0010976>. (IF 2010 = 4.411)
289. Theys K, Deforche K, Beheydt G, Moreau Y, Van Laethem K, Lemey P, Camacho RJ, Rhee SY, Shafer RW, Van Wijngaerden E, **Vandamme A-M**. Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape. *BMC Bioinformatics*. 2010 Aug 3;11(1):409. (IF 2010 = 3.029)
290. Coelmont L, Hanouille X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, **Vandamme A-M**, Bartenschlager R, Gallay P, Lippens G, Neyts J. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. *PLoS One*. 2010 Oct 27;5(10):e13687. (IF 2010 = 4.411)

291. Prosperi MC, Rosen-Zvi M, Altmann A, Zazzi M, Di Giambenedetto S, Kaiser R, Schülter E, Struck D, Sloot P, van de Vijver DA, **Vandamme A-M**, Sönnernborg A; EuResist study group; Virolab study group. Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. *PLoS One*. 2010 Oct 29;5(10):e13753. (IF 2010 = 4.411)
292. **Vandamme A.-M.**, Camacho R. Useful websites for the management of HIV infected patients. In "Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects" 8th Edition (B. Clotet, L. Menénendez-Arias, J. Shapiro, D. Kuritzkes, D. Burger, A. Telenti, F. Brun-Vézinet, A.M. Geretti, C.A. Boucher, D.D. Richman, eds), Ediciones Gráficas Rey, S.L., Barcelona, Spain, 2010.
293. van de Vijver DA, Wensing AM, Åsjö B, Bruckova M, Bruun Jorgensen L, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, Macrae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, **Vandamme AM**, Vercauteren J, Zazzi M, Bachelier L, Lecocq P, Villacian J, Boucher CA. HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. *Acta Dermatovenerol Alp Panonica Adriat*. 2010 Dec;19(4):3-9. (IF 2010 = 0.272)
294. Zazzi M, Kaiser R, Sönnernborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, **Vandamme A-M**, Van Laethem K, Wensing AM, Lengauer T, Incardona F. Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). *HIV Med*. 2011 Apr;12(4):211-218. doi: 10.1111/j.1468-1293.2010.00871.x. Epub 2010 Aug 19. (IF 2011 = 3.006)
295. Abecasis AB, Geretti AM, Albert J, Power L, Weait M, **Vandamme A-M**. Science in court: the myth of HIV fingerprinting. *Lancet Infect Dis*. 2011 Feb;11(2):78-9. (IF 2011 = 17.391)
296. Vandekerckhove L, Wensing A, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti A, Klimkait T, Korn K, Masquelier B, Perno C, Schapiro J, Soriano V, Sönnernborg A, **Vandamme AM**, Verhofstede C, Walter H, Zazzi M, Boucher C; on behalf of the European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. *Lancet Infect Dis*. 2011 May;11(5):394-407. (IF 2011 = 17.391)
297. **Vandamme A.-M.**, Camacho R. Useful websites for the management of HIV infected patients. In "Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis in HIV infected subjects" 8th Edition (B. Clotet, L. Menénendez-Arias, J. Shapiro, D. Kuritzkes, D. Burger, A.

Telenti, F. Brun-Vézinet, A.M. Geretti, C.A. Boucher, D.D. Richman, eds), Ediciones Gráficas Rey, S.L., Barcelona, Spain, 2011.

298. **Vandamme AM**, Camacho RJ, Ceccherini Silberstein F, De Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit J-C, Soriano V, Walter H, Sönnernborg A and the European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update *AIDS Reviews* 2011;13:77-108. (IF 2011 = 3.512)
299. Leitner T on behalf of 8 co-authors (Leitner T, Metzker ML, Zwickl D, Brown JM, Geretti AM, **Vandamme A-M**, Albert J, Hillis DM). Guidelines for HIV in court cases. *Nature*. 2011 May 19;473(7347):284. (IF 2011 = 36.280)
300. Magiorkinis E, Paraskevis D, Detsika MG, Lu L, Magiorkinis G, Lazanas M, Imbrechts S, Van Laethem K, **Vandamme AM**, Pilot-Matias T, Molla A, Camacho RJ, Hatzakis A. Appearance of a single amino acid insertion at position 33 (L33L-L) in HIV-1 protease under a LPV-containing regimen, associated with reduced protease inhibitor susceptibility. *AIDS Res Hum Retroviruses*. 2011 Nov;27(11):1223-9. (IF 2011 = 2.246)
301. Faria NR, Suchard MA, Abecasis A, Sousa JD, Ndembi N, Bonfim I, Camacho RJ, **Vandamme AM**, Lemey P. Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. *Infect Genet Evol*. 2012 Mar;12(2):453-60. (IF 2011 = 3.128)
302. Faria NR, Hodges-Mameletzis I, Silva JC, Rodés B, Erasmus S, Paolucci S, Ruelle J, Pieniazek D, Taveira N, Treviño A, Gonçalves MF, Jallow S, Xu L, Camacho RJ, Soriano V, Goubau P, Sousa JD, **Vandamme AM**, Suchard MA, Lemey P. Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. *J Gen Virol*. 2012 Apr;93(Pt 4):889-99. (IF 2011 = 3.363)
303. Palma AC, Covens K, Snoeck J, **Vandamme AM**, Camacho RJ, Van Laethem K. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G. *J Antimicrob Chemother*. 2012 May;67(5):1075-9. (IF 2011 = 5.068)
304. Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G, Alvarez C, Talledo M, Gotuzzo E, de Almeida Kruschewsky R, Galvão-Castro B, **Vandamme AM**, Van Weyenbergh J. Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN- α in HTLV-1-associated myelopathy. *PLoS Negl Trop Dis*. 2012 Jul;6(7):e1729. (IF 2011 = 4.716)
305. Moens B, Pannecouque C, López G, Talledo M, Gotuzzo E, Khouri R, Bittencourt A, Farré L, Galvão Castro B, **Vandamme AM**, Van Weyenbergh J. Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon

- signaling in HTLV-1-infected CD4+ T cell lines. *Viol J.* 2012 Aug 23;9(1):171. (IF 2011 = 2.343)
306. Kourí V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, Aragonés C, Campos J, Alvarez D, Schrooten Y, Dekeersmaeker N, Imbrechts S, Beheydt G, Vinken L, Pérez D, Alvarez A, Soto Y, **Vandamme AM**, Van Laethem K. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. *J Clin Virol.* 2012 Dec;55(4):348-55. (IF 2011 = 3.97)
 307. Araujo TH, Souza-Brito LI, Libin P, Deforche K, Edwards D, de Albuquerque-Junior AE, **Vandamme AM**, Galvao-Castro B, Alcantara LC. A public HTLV-1 molecular epidemiology database for sequence management and data mining. *PLoS One.* 2012;7(9):e42123. (IF 2011 = 4.09)
 308. Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjo B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kucherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Struck D, van Laethem K, Wensing AM, Boucher CA, **Vandamme AM**. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. *Retrovirology.* 2012 Oct 3;9(1):81. (IF 2012 = 5.657)
 309. Pérez L, Alemán Y, Correa C, Aragonés C, González I, Pérez J, Alvarez A, Pérez L, Kourí V, **Vandamme AM**, Van Laethem K. Antiviral drug resistance in Cuban children infected with HIV-1. *J Int AIDS Soc.* 2012 Nov 11;15(6):18186. (IF 2012 = 3.936)
 310. Pérez L, Alemán Y, Correa C, Fonseca C, Aragonés C, Alvarez A, Kourí V, **Vandamme AM**, Van Laethem K. Antiretroviral drug resistance in HIV-1 therapy-naïve patients in Cuba, 2006-2011. *J Int AIDS Soc.* 2012 Nov 11;15(6):18185. (IF 2012 = 3.936)
 311. Sousa JD, Alvarez C, **Vandamme AM**, Müller V. Enhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1. *Viruses.* 2012 Oct 3;4(10):1950-83. (IF 2011 = 1.5)
 312. Pineda-Peña AC, Bello DC, Sussmann O, **Vandamme AM**, Vercauteren J, van Laethem K, Gómez-López A. HIV-1 Transmitted Drug Resistance in Latin America and the Caribbean: What Do We Know? *AIDS Rev.* 2012 Oct;14(4):256-67. (IF 2012 = 4.075)
 313. Cavaco-Silva J, Aleixo MJ, Van Laethem K, Faria D, Valadas E, Gonçalves MD, Gomes P, **Vandamme AM**, Cunha C, Camacho RJ; on behalf of the Portuguese HIV-2 Resistance Study Group. Mutations selected in HIV-2-infected patients

- failing a regimen including atazanavir. *J Antimicrob Chemother.* 2013 Jan;68(1):190-2. (IF 2012 = 5.338)
314. Vercauteren J, Theys K, Carvalho AP, Valadas E, Duque LM, Teófilo E, Faria T, Faria D, Vera J, Aguas MJ, Peres S, Mansinho K, **Vandamme AM**, Camacho RJ; on behalf of the Portuguese HIV-1 Resistance Study Group. The demise of multidrug-resistant HIV-1: the national time trend in Portugal. *J Antimicrob Chemother.* 2013 Apr;68(4):911-4. (IF 2013 = 5.439)
315. Theys K, Snoeck J, Vercauteren J, Abecasis AB, **Vandamme AM**, Camacho RJ; on behalf of the Portuguese HIV-1 Resistance Study Group. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. *J Antimicrob Chemother.* 2013 Feb;68(2):419-23. (IF 2012 = 5.338)
316. Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho R, Torti C, Schülter E, Clotet B, Sönnernborg A, De Luca A, Grossman Z, Struck D, **Vandamme AM**, Abecasis AB. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. *Antimicrob Agents Chemother.* 2013 Feb;57(2):1053-6. (IF 2013 = 4.451)
317. De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnernborg A, Codoñer Francisco M, Van Laethem K, **Vandamme AM**, Bansi L, Ghisetti V, van de Vijver David AM, Asboe D, Prospero Mattia CF, Di Giambenedetto S; for the Sehere collaboration in Chain. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. *J Infect Dis.* 2013 Apr;207(8):1216-20. (IF 2012 = 5.848)
318. Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA, Albert J, Asjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnernborg A, Stanekova D, Stanojevic M, Struck D, Boucher CA, **Vandamme AM**. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. *Retrovirology.* 2013 Jan 14;10(1):7. (IF 2013 = 4.767)
319. Moshia F, Muchunguzi V, Matee M, Sangeda RZ, Vercauteren J, Nsubuga P, Lyamuya E, **Vandamme AM**. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. *BMC Public Health.* 2013 Jan 15;13(1):38. (IF 2012 = 2.076)

320. Pérez L, Kourí V, Alemán Y, Abrahantes Y, Correa C, Aragonés C, Martínez O, Pérez J, Fonseca C, Campos J, Alvarez D, Schrooten Y, Dekeersmaeker N, Imbrechts S, Beheydt G, Vinken L, Soto Y, Alvarez A, **Vandamme AM**, Van Laethem K. Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba. *Infect Genet Evol.* 2013 Jun;16:144-50. (IF 2012 = 2.768)
321. Theys K, Abecasis AB, **Vandamme AM**. HIV-1 drug resistance: where do polymorphisms fit in? *Future Microbiol.* 2013 Mar;8:303-6. (IF 2013 = 3.819)
322. Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho R, Laethem KV, Pironti A, Zazzi M, Sönnernborg A, Incardona F, Luca AD, Torti C, Ruiz L, Vijver DA, Shafer RW, Bruzzone B, Wijngaerden EV, **Vandamme AM**; Virolab EuResist projects. HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. *Infect Genet Evol.* 2013 Oct;19:349-60. [doi: 10.1016/j.meegid.2013.03.014]. Epub 2013 Mar 21. (IF 2012 = 2.768)
323. Frentz D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Asjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnernborg A, Stanekova D, Stanojevic M, **Vandamme AM**, Boucher CA, Van de Vijver DA; SPREAD Programme. Limited cross-border infections in patients newly diagnosed with HIV in Europe. *Retrovirology.* 2013 Apr 3;10:36. [doi: 10.1186/1742-4690-10-36] (IF 2012 = 5.657)
324. Vercauteren J, Beheydt G, Prosperi M, Libin P, Imbrechts S, Camacho R, Clotet B, De Luca A, Grossman Z, Kaiser R, Sönnernborg A, Torti C, Van Wijngaerden E, Schmit JC, Zazzi M, Geretti AM, **Vandamme AM**, Van Laethem K. Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. *PLoS One.* 2013 Apr 17;8(4):e61436. [doi: 10.1371/journal.pone.0061436] (IF 2012 = 3.730)
325. Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayoub A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloom P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, **Vandamme AM**. RegaDB: community-driven data management and analysis for infectious diseases. *Bioinformatics.* 2013 Jun 1;29(11):1477-80. [doi: 10.1093/bioinformatics/btt162]. Epub 2013 May 2. (IF 2013 = 4.621)

326. Pineda-Peña AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, Gomez-Lopez A, Camacho RJ, de Oliveira T, **Vandamme AM**. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. *Infect Genet Evol.* 2013 Oct;19:337-48. [doi: 10.1016/j.meegid.2013.04.032]. Epub 2013 May 7. (IF 2012 = 2.768)
327. Alteri C, Artese A, Beheydt G, Santoro MM, Costa G, Parrotta L, Bertoli A, Gori C, Orchi N, Girardi E, Antinori A, Alcaro S, d'Arminio Monforte A, Theys K, **Vandamme AM**, Ceccherini-Silberstein F, Svicher V, Perno CF. Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. *J Antimicrob Chemother.* 2013 Oct;68(10):2205-9. doi: 10.1093/jac/dkt173]. Epub 2013 May 17. (IF 2012 = 5.338)
328. Vinken L, Megens S, Schrooten Y, **Vandamme AM**, Van Laethem K. Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences. *J Virol Methods.* 2013 Oct;193(1):135-9. [doi: 10.1016/j.jviromet.2013.05.017]. Epub 2013 Jun 5. (IF 2012 = 1.900)
329. Lemey P, Stanojevic M, **Vandamme AM**. International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology. *Infect Genet Evol.* 2013 Oct;19:335-336. [doi: 10.1016/j.meegid.2013.08.023] (IF 2012 = 2.768)
330. **Vandamme AM**, Pybus OG. Viral phylogeny in court: the unusual case of the Valencian anesthetist. *BMC Biol.* 2013 Jul 19;11:83. [doi: 10.1186/1741-7007-11-83] (IF 2013 = 7.431)
331. Li G, Verheyen J, Rhee SY, Voet A, **Vandamme AM**, Theys K. Functional conservation of HIV-1 gag: implications for rational drug design. *Retrovirology.* 2013 Oct 31;10(1):126. [doi: 10.1186/1742-4690-10-126] (IF 2013 = 4.767)
332. Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnernborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, **Vandamme AM**, Müller V. Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. *BMC Infect Dis.* 2013 Nov 12;13(1):537. [doi: 10.1186/1471-2334-13-537] (IF 2012 = 3.025)
333. Menezes SM, Decanine D, Brassat D, Khouri R, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, **Vandamme AM**, Galvão-Castro B, Liblau R, Weyenbergh JV. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. *J Neuroinflammation.* 2014 Jan 29;11(1):18.

334. Megens S, Vaira D, De Baets G, Dekeersmaecker N, Schrooten Y, Li G, Schymkowitz J, Rousseau F, **Vandamme AM**, Moutschen M, Van Laethem K. Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits. *Virology*. 2014 May;456-457:310-8. doi:10.1016/j.virol.2014.03.023. Epub 2014 Apr 25.
335. Frenzt D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Stanekova D, Stanojevic M, **Vandamme AM**, Boucher C, Programme AW. Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. *PLoS One*. 2014 Apr 10;9(4):e94495. doi:10.1371/journal.pone.0094495.
336. Vrancken B, Rambaut A, Suchard MA, Drummond A, Baele G, Derdelinckx I, Van Wijngaerden E, **Vandamme AM**, Van Laethem K, Lemey P. The genealogical population dynamics of HIV-1 in a large transmission chain: bridging within and among host evolutionary rates. *PLoS Comput Biol*. 2014 Apr 3;10(4):e1003505. doi:10.1371/journal.pcbi.1003505.
337. Li G, **Vandamme A-M**, Ramon J. Learning Ancestral Polytrees. The workshop of Learning Tractable Probabilistic Model co-located with the 31st International Conference on Machine Learning (ICML), Beijing, China, 2014. Conference Proceedings.
338. Pineda-Peña AC, Schrooten Y, Vinken L, Ferreira F, Li G, Trovão NS, Khouri R, Derdelinckx I, De Munter P, Kücherer C, Kostrikis LG, Nielsen C, Littsola K, Wensing A, Stanojevic M, Paredes R, Balotta C, Albert J, Boucher C, Gomez-Lopez A, Van Wijngaerden E, Van Ranst M, Vercauteren J, **Vandamme AM**, Van Laethem K. Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. *PLoS One*. 2014 Jul 8;9(7):e101738. doi: 10.1371/journal.pone.0101738.
339. Mosha F, Ledwaba J, Ndugulile F, Ng'ang'a Z, Nsubuga P, Morris L, Kasubi M, Swai A, Vercauteren J, **Vandamme AM**. Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. *J Infect Dev Ctries*. 2014 Jul 14;8(7):845-52. doi: 10.3855/jidc.3879.
340. Megens S, De Wit S, Bernatchez J, Dekeersmaecker N, Vinken L, Covens K, Theys K, Camacho RJ, **Vandamme AM**, Götte M, Van Laethem K. Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase. *Acta Clin Belg*. 2014 Oct;69(5):348-57. doi: 10.1179/2295333714Y.0000000038. Epub 2014 Aug 7.

341. Cuypers L, Snoeck J, Vrancken B, Kerremans L, Vuagniaux G, Verbeeck J, Nevens F, Camacho RJ, **Vandamme AM**, Van Dooren S. A near-full length genotypic assay for HCV1b. *J Virol Methods*. 2014 Dec; 209:126-35. doi: 10.1016/j.jviromet.2014.09.009. Epub 2014 Sep 22.
342. Li G, Verheyen J, Theys K, Piampongsant S, Van Laethem K, **Vandamme AM**. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. *Retrovirology*. 2014 Sep 25;11(1):79. [Epub ahead of print]
343. Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, Lyamuya EF, Van Wijngaerden E, **Vandamme AM**. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. *BMC Public Health*. 2014 Oct 4;14:1035. doi: 10.1186/1471-2458-14-1035.
344. Turpin J, Journo C, Ko NL, Sinet F, Carpentier A, Galioot A, Edwards D, **Vandamme AM**, Gazzolo L, Dodon MD, Gessain A, Kashanchi F, Balansard I, Lacoste R, Mahieux R. Discovery and characterization of auxiliary proteins encoded by Simian T-cell Lymphotropic Viruses type 3. *J Virol*. 2015 Jan 15;89(2):931-51.
345. Kouri V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, Aragonés C, Campos J, Alvarez D, Schrooten Y, Vinken L, Limia C, Soto Y, **Vandamme AM**, Van Laethem K. High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19754. doi: 10.7448/IAS.17.4.19754.
346. Boons E, Li G, Vanstreels E, Vercruyse T, Pannecouque C, **Vandamme AM**, Daelemans D. A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. *Antiviral Res*. 2014 Dec;112:91-102. doi: 10.1016/j.antiviral.2014.10.007. Epub 2014 Oct 23.
347. Salemi M, **Vandamme AM**. Bioinformatics tools for the investigation of viral evolution and molecular epidemiology. *Infect Genet Evol*. 2014 Dec;28:349-50. doi: 10.1016/j.meegid.2014.11.017.
348. Angelis K, Albert J, Mamais I, Magiorkinis G, Hatzakis A, Hamouda O, Struck D, Vercauteren J, Wensing AM, Alexiev I, Åsjö B, Balotta C, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej S, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnernborg A, Staneková D, Stanojevic M, Boucher CA, Kaplan L, **Vandamme AM**, Paraskevis D. Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. *J Infect Dis*. 2015 Jun 1;211(11):1735-44. doi: 10.1093/infdis/jiu666. Epub 2014 Dec 15.

349. Li G, Theys K, Verheyen J, Pineda-Peña AC, Khouri R, Piampongsant S, Eusébio M, Ramon J, **Vandamme AM**. A new ensemble coevolution system for detecting HIV-1 protein coevolution. *Biol Direct*. 2015 Jan 7;10(1):1. doi: 10.1186/s13062-014-0031-8.
350. Steussy E.E., Eisen J., Imwinkelried E.J. and **Vandamme A.-M**. Microbial Forensics: The Biggest Thing Since DNA? (February 3, 2015). *Criminal Law Bulletin* (Forthcoming); UC Davis Legal Studies Research Paper No. 416. Available at SSRN: <http://ssrn.com/abstract=2560109>.
351. Theys K, Camacho RJ, Gomes P, **Vandamme AM**, Rhee SY; the Portuguese HIV-1 Resistance Study Group. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. *Clin Microbiol Infect*. 2015 Feb 19. pii: S1198-743X(15)00299-2. (IF2013= 5.197)
352. Alemán Y, Vinken L, Kourí V, Pérez L, Álvarez A, Abrahantes Y, Fonseca C, Pérez J, Correa C, Soto Y, Schrooten Y, **Vandamme AM**, Van Laethem K. Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in cuba. *PLoS One*. 2015 Feb 11;10(2):e0117176.
353. Lunar MM, **Vandamme AM**, Tomažič J, Karner P, Vovko TD, Pečavar B, Volčanšek G, Poljak M, Abecasis AB. Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe. *BMC Infect Dis*. 2015 Feb 15;15(1):65. doi: 10.1186/s12879-015-0802-6.
354. Li G, Piampongsant S, Faria NR, Voet A, Pineda-Peña AC, Khouri R, Lemey P, Vandamme AM, Theys K. An integrated map of HIV genome-wide variation from a population perspective. *Retrovirology*. 2015 Feb 15;12:18. doi: 10.1186/s12977-015-0148-6.
355. Kouri V; Khouri R; Alemán Y; Abrahantes Y; Vercauteren J; Pineda-Peña A; Theys K; Megens S; Moutschen M; Pfeifer N; Van Weyenbergh J; Pérez AB; Pérez J; Pérez L; Van Laethem K; **Vandamme A-M**. CRF19_cpx is an evolutionary fit HIV-1 variant strongly associated with rapid progression to AIDS in Cuba. *EBIOM* 2015, March 2015 Volume 2, Issue 3, Pages 244–254 DOI: <http://dx.doi.org/10.1016/j.ebiom.2015.01.015>.
356. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith

- DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, **Vandamme AM**, Shafer RW. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. *PLoS Med.* 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.
357. Vrancken B, Baele G, **Vandamme AM**, Van Laethem K, Suchard MA, Lemey P. Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution. *AIDS.* 2015 Jul 31;29(12):1549-56. doi: 10.1097/QAD.0000000000000731.
358. Cuypers L, Li G, Libin P, Piampongsant S, **Vandamme AM**, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. *Viruses.* 2015 Sep 16;7(9):5018-39. doi: 10.3390/v7092857.
359. Winand R, Theys K, Eusébio M, Aerts J, Camacho RJ, Gomes P, Suchard MA, **Vandamme AM**, Abecasis AB; Portuguese HIV-1 Resistance Study Group. Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals. *AIDS.* 2015 Sep 24;29(15):2045-52. doi: 10.1097/QAD.0000000000000811.
360. Abecasis AB, Faria NR, **Vandamme A-M**. Origin and distribution of HIV-1 subtypes. In "Encyclopedia of AIDS" (Thomas Hope, Douglas D. Richman and Mario Stevenson, eds.), ebooks Springer-Verlag Berlin Heidelberg, Germany, 2015, in press.
361. Van Laethem K, Theys K, **Vandamme AM**. HIV-1 genotypic drug resistance testing: digging deep, reaching wide? *Curr Opin Virol.* 2015 Jun 23;14:16-23. doi: 10.1016/j.coviro.2015.06.001. [Epub ahead of print] Review.

Abstracts for international meetings

1. **Vandamme A.-M.**, Bulens F., Bernar H., Lijnen H.R., Nelles L., & Collen D. Cloning and humanization of a crosslinked human fibrin-specific monoclonal antibody. Xth International congress on fibrinolysis, Indianapolis, Indiana, USA, August 4-8, 1990. *Fibrinolysis* 4, Suppl. 3, 24, 1990. Poster discussion.
2. **Vandamme A.-M.**, Pauwels R., Debyser Z., Desmyter J., & De Clercq E. Inhibition of the formation of HIV-1 DNA by TIBO compounds. VIIth International Conference on AIDS, Florence, Italy, June 16-21, 1991. Poster.

3. **Vandamme A.-M.**, Debyser Z., De Vreese K., Andries K., Janssen P.A.J., Pauwels R., Desmyter J., & De Clercq E. Comparison of RT gene sequences from HIV-1 strains with different sensitivity to TIBO derivatives. Keystone symposium on "Prevention and Treatment of AIDS", Keystone, Colorado, USA March 27-April 3, 1992. Poster.
4. Debyser Z., **Vandamme A.-M.**, Pauwels R., Desmyter J., & De Clercq E. Allosteric inhibition of endogenous HIV-1 reverse transcription by TIBO derivatives. Keystone symposium on "Prevention and Treatment of AIDS", Keystone, Colorado, USA March 27-April 3, 1992.
5. Witvrouw M., **Vandamme A.-M.**, Schols D., Pauwels R., Desmyter J. & De Clercq E. Anti-HIV activity of the TAT inhibitor Ro5-3335 in different cell cultures. Keystone symposium on "Prevention and Treatment of AIDS", Keystone, Colorado, USA March 27-April 3, 1992.
6. **Vandamme A.-M.**, Goubau P., Liu H.-F., & Desmyter J. Molecular analysis of familial HTLV-I associated neuropathies using PCR Vth International Conference on Human Retrovirology : HTLV, Kumamoto, Japan, May 11-13, 1992. Poster.
7. Pauwels R., Andries K., Schols D., Van Daele P., Debyser Z., Janssen M.A.C., **Vandamme A.-M.**, De Vreese K., Desmyter J., De Clercq E., & Janssen P.A.J. Potent and highly selective HIV-1 specific inhibition by a new series of alpha-anilino-phenylacetamide (alpha-APA) derivatives targeted at HIV-1 RT. VIIIth International Conference on AIDS, Amsterdam, the Netherlands, July 19-24, 1992.
8. Balzarini J., Karlsson A., **Vandamme A.-M.**, Vrang L., Öberg B., Pérez-Pérez M.-J., San-Félix A., Velazquez S., Camarasa M.-J., & De Clercq E. Human immunodeficiency virus type 1 (HIV-1) strains resistant against the novel class of HIV-1-specific TSAO nucleoside analogues are sensitive to TIBO and nevirapine and the nucleoside analogues AZT, DDI, and DDC. HIV Drug Resistance Workshop, Noordwijk, The Netherlands, July 17-18, 1992.
9. De Vreese K., **Vandamme A.-M.**, Schols D., Pauwels R., Debyser Z., Desmyter J., De Clercq E., & Anné J. Influence of initial conditions on the development of resistance to TIBO derivatives in cell-culture. HIV Drug Resistance Workshop, Noordwijk, The Netherlands, July 17-18, 1992.
10. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., **Vandamme A.-M.**, Janssen C.G.M., De Vreese K., Woestenborghs R., Anné J., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., & Janssen P.A.J. Potent and highly selective HIV-1 specific inhibition by a new series of alpha-anilino-phenylacetamide (alpha-APA) derivatives targeted at HIV-1 RT. MRC AIDS Directed Programme. First Meeting of the Drug Discovery Working Group, The Royal Marsden Hospital, London, England, June 2, 1992.

11. Goubau P., Kazadi K., Carton H., **Vandamme A.-M.**, Liu H.-F., & Desmyter J. The epidemiology of human T-cell lymphotropic viruses in Zaire. *American Journal of Tropical Medicine and Hygiene* 47, 258. 41st Annual Meeting in Seattle, Washington, USA, November 15-19, 1992.
12. **Vandamme A.-M.**, Debyser Z., Pauwels R., Andries K., Janssen P.A.J., Desmyter J., & De Clercq E. Rapid emergence of HIV-1 resistance to R82913 in a minority of treated patients. HIV Drug Resistance, Second International Workshop, Noordwijk, The Netherlands, June 3-5, 1993.
13. de Béthune M.-P., Pauwels R., Andries K., **Vandamme A.-M.**, Peeters M., Colebunders R., Stoffels P., De Clercq E., & Desmyter J. AZT resistance reversal by the non-nucleoside reverse transcriptase inhibitor alpha-APA R18893 in a symptomatic HIV-infected individual. HIV Drug Resistance, Second International Workshop, Noordwijk, The Netherlands, June 3-5, 1993.
14. **Vandamme A.-M.**, Debyser Z., Pauwels R., De Vreese K., Goubau P., Anné J., Youle M., Gazzard B., Stoffels P.A., Cauwenbergh G.F., Andries K., Janssen P.A.J., Desmyter J., & De Clercq E. Isolation and characterization of clinical HIV-1 strains with different sensitivities to TIBO derivatives. IXth International Conference on AIDS, Berlin, Germany, June 7-11, 1993.
15. de Béthune M.-P., Pauwels R., Peeters M., **Vandamme A.-M.**, Andries K., Colebunders R., Stoffels P., De Clercq E., & Desmyter J. At drug plasma concentrations approximating the 50 % inhibitory concentration, the HIV-1 reverse transcriptase inhibitor alpha-APA R18893 does not select for drug-resistant virus mutants in patients. IXth International Conference on AIDS, Berlin, Germany, June 7-11, 1993.
16. **Vandamme A.-M.**, Van Dooren S., de Béthune M.-P., Pauwels R., Desmyter J., & De Clercq E. Following up on resistance to HIV-1 reverse transcriptase (RT) inhibitors by direct cycle sequencing of the PCR amplified RT gene. First Forum of Young European Researchers, Liège, Belgium, July 18-23, 1993.
17. **Vandamme A.-M.**, Liu H.-F., Goubau P., & Desmyter J. Primate T-lymphotropic virus type I LTR sequence variation and its phylogenetic analysis : compatibility with an African origin of PTLV-I. Sixth International Conference on Human Retrovirology : HTLV, Absecon, New Jersey USA, May 14-19, 1994. *AIDS Research and Human Retroviruses* 10, 501, 1994.
18. Van Brussel M., **Vandamme A.-M.**, Goubau P., & Desmyter J. Analysis of the genomic structure of a new type of primate T-lymphotropic virus : PTLV-L. Sixth International Conference on Human Retrovirology : HTLV, Absecon, New Jersey USA, May 14-19, 1994. *AIDS Research and Human Retroviruses* 10, 443, 1994.

19. Goubau P., Van Brussel M., **Vandamme A.-M.**, Liu H.-F., & Desmyter J. A primate T-lymphotropic virus, PTLV-L, different from HTLV-I and HTLV-II in a wild caught baboon. Sixth International Conference on Human Retrovirology : HTLV, Absecon, New Jersey USA, May 14-19, 1994. *AIDS Research and Human Retroviruses* 10, 443, 1994.
20. Desmyter J., Liu H.-F., de Lange G.G., **Vandamme A.-M.**, & Goubau P. HTLV-II seroprevalence in sub-saharan Africa. Sixth International Conference on Human Retrovirology : HTLV, Absecon, New Jersey USA, May 14-19, 1994. *AIDS Research and Human Retroviruses* 10, 485, 1994.
21. Liu H.-F., **Vandamme A.-M.**, Kazadi K., Carton H., Desmyter J., & Goubau P. Familial transmission and minimal sequence variability of HTLV-I in Zaire. Sixth International Conference on Human Retrovirology : HTLV, Absecon, New Jersey USA, May 14-19, 1994. *AIDS Research and Human Retroviruses* 10, 503, 1994.
22. **Vandamme A.-M.**, Fransen K., Burtonboy G., Debaisieux L., Marissens D., Sprecher S., Vaira D., Verhofstede C., & the Belgian AIDS Reference Laboratories. Belgian multicentre quality control on the performance of selected primer sets for diagnostic HIV-1 PCR. Xth International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
23. **Vandamme A.-M.**, Van Dooren S., Kok W., Goubau P., Fransen K., Kievits T., & Desmyter J. NASBA HIV-1 RNA amplification compared to HIV-1 RNA-PCR on plasma or serum samples : a Belgian field evaluation. Xth International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
24. Esté J.A., Witvrouw M., Tu J., Pauwels R., De Clercq E., & **Vandamme A.-M.** Oncostatin M inhibits HIV-tat mediated transactivation in HeLa-tat cells. Xth International Conference on AIDS, Yokohama, Japan, August 7-12, 1994.
25. Schmit J.C., Peetermans W., Goubau P., Bobbaers H., De Clercq E., Desmyter J., & **Vandamme A.-M.** Direct detection of HIV zidovudine resistance mutation 215 in blood samples by DNA- and RNA-PCR : a pilot study in 40 patients. 11th International round table on nucleosides, nucleotides and their biological applications, Leuven, Belgium, September 7-11, 1994.
26. Schmit J.C., Van Dooren S., Peetermans W., Goubau P., Bobbaers H., Kok W., Kievits T., Desmyter J., De Clercq E. & **Vandamme A.-M.** Follow-up of viral load during anti-HIV treatment using NASBA[®] HIV-1 RNA QT, a quantitative nucleic acid amplification system. Surrogate markers of HIV : Strategies and issues for selection and use, Alexandria, Virginia, USA, October 12-14, 1994.
27. Schmit J.C., Van Dooren S., Peetermans W., Goubau P., Bobbaers H., Kok W., Gobbers E., Desmyter J., De Clercq E. & **Vandamme A.-M.** Quantitative NASBA: a

useful method in assessing the viral load during anti-HIV therapy. Seminars on Applications of PCR: State of the Art. KVCV/Biotechnology, CTL-Gent, October 28, 1994.

28. Van Dooren S., Schmit J.C., Peetermans W., Goubau P., Bobbaers H., Kok W., Kievits T., Desmyter J., De Clercq E. & **Vandamme A.-M.** Evaluation of the NASBA[®] HIV-1 RNA quantification in plasma as a surrogate marker during antiviral treatment. Impact of nucleic acid-based technology: revolution in clinical diagnosis, applications and research, Amsterdam, The Netherlands, November 7-9, 1994.
29. Schmit J.C., Peetermans W., Goubau P., Bobbaers H., Desmyter J., De Clercq E. & **Vandamme A.-M.** PCR detection of the zidovudine resistance mutation 215 in patient blood samples. A first evaluation. Third National Microbiology Meeting of the National Committee of Microbiology (General Microbiology)/NFWO/FNRS. Symposium "Escape Mechanisms for Microorganisms", Leuven, Belgium, November 25, 1994.
30. **Vandamme A.-M.** Phylogenetic analysis of a new PTLV, STLV PP1664, from a pygmy chimpanzee : implications for the origin of HTLVs. Workshop on Molecular Epidemiology of HTLVs, Paris, France, December 10, 1994. Invited speaker.
31. **Vandamme A.-M.**, Schmit J.C., Van Dooren S., Van Laethem K., Gobbers E., Kok W., Albrecht N., Huygen R., Desmyter J., De Clercq E. Quantification of HIV-1 RNA in plasma using the NASBA amplification system compared to an in-house quantitative RNA-PCR and the Amplicor HIV monitor test. Keystone Symposia : HIV pathogenesis, Keystone, Colorado, USA, April 17-23, 1995.
32. **Vandamme A.-M.**, Schmit J.-C., Van Dooren S., Peetermans W., Goubau P., Bobbaers H., Kok W., Gobbers E., Kievits T., Desmyter J., & De Clercq E. Evaluation of the NASBA HIV-1 RNA QT for the follow-up of viral load during anti-HIV treatment. 1st Workshop on Viral Load in HIV-1 infection, a New Marker for Disease Progression and Antiviral Therapy Monitoring, München, Germany, January 21, 1995.
33. Goubau P., **Vandamme A.-M.**, Van Brussel M., Liu H.-F., & Desmyter J. The widening spectrum of primate T-lymphotropic viruses. Meeting of the European Tumor Virus Group, Innsbruck, Germany, March 12, 1995.
34. Beuselinck K., Goubau P., Schmit J.-C., **Vandamme A.-M.**, & Desmyter J. ELISA detection of Digoxigenin labeled PCR products in the diagnosis of hepatitis C virus infection. Progress in Clinical Virology, 1995 Joint Meeting, Prague, Czech Republic, September 10-14, 1995.

35. Salemi M., **Vandamme A.-M.**, Guano F., Gradozzi C., Cattaneo E., Casoli C., & Bertazzoni U. Phylogenetic analysis of the complete sequence of the Italian isolate HTLV-II Gu and its relationship with other isolates. Eighth meeting on research project on AIDS, progress report. Istituto Superiore di Sanità, Rome, Italy, May 29-June 2, 1995.
36. Schmit J.-C., Cogniaux J., Hermans P., Sprecher S., Van Vaeck C., Desmyter J., De Clercq E., & **Vandamme A.-M.** Multiple drug resistance mutations against nucleoside analogues and non-nucleoside specific RT inhibitors in a highly replicating HIV-1 strain. Fourth International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6-9, 1995. *J AIDS Hu Retrovir* 10 (suppl 3), S11-S12, 1995.
37. Salemi M., **Vandamme A.-M.**, Guano F., Gradozzi C., Cattaneo E., Casoli C., & Bertazzoni U. Phylogenetic analysis of the Italian isolate HTLV-II Gu and its relationship with other isolates. Tenth Annual Meeting of the Laboratory of Tumor Cell Biology, NCI, Bethesda, USA, Aug 27-Sept 2, 1995. *AIDS Research and Human Retroviruses* 11 Supplement 1, S145, 1995.
38. Sprecher S., Hermans P., Schmit J.-C., Cogniaux J., Van Vaeck C., De Clercq E., **Vandamme A.-M.**, & Clumeck N. PAN-nucleoside and non-nucleoside resistant strains after sequential therapy with NRTIs and NNRTI. Tenth Annual Meeting of the Laboratory of Tumor Cell Biology, NCI, Bethesda, USA, Aug 27-Sept 2, 1995. *AIDS Research and Human Retroviruses* 11 Supplement 1, S162, 1995.
39. **Vandamme A.-M.**, Liu H.-F., Van Brussel M., Desmyter J., & Goubau P. Phylogenetic analysis of a divergent T-lymphotropic virus from a pygmy chimpanzee supports an African origin for the HTLV/STLV group of viruses. VIIth International Conference in Human Retrovirology : HTLV, Institut Pasteur, Paris, France, October 17-21, 1995. *J AIDS and Human Retrovir* 10, 279, 1995.
40. Van Brussel M., Goubau P., Desmyter J., & **Vandamme A.-M.** The genomic structure of a new primate T-lymphotropic virus, PTLV-L, differs from that of HTLV and STLV types I and II. VIIth International Conference in Human Retrovirology :HTLV, Institiut Pasteur, Paris, France, October 17-21, 1995. *J AIDS and Human Retrovir* 10, 280, 1995.
41. Liu H.-F., Goubau P., Van Laethem K., Desmyter J., & **Vandamme A.-M.** Separate interspecies transmission events gave rise to the three currently known HTLV-I subtypes and the Asian like STLV-I strains from the Sukhumi African baboons. VIIth International Conference in Human Retrovirology : HTLV, Institut Pasteur, Paris, France, October 17-21, 1995. *J AIDS and Human Retrovir* 10, 284, 1995.
42. Goubau P., **Vandamme A.-M.**, Beuselinck K., Van Laethem K., & Desmyter J. HTLV-I & HTLV-II in Efe pygmies of northeastern Zaire. VIIth International Conference in

Human Retrovirology : HTLV, Institut Pasteur, Paris, France, October 17-21, 1995. J AIDS and Human Retrovir 10, 276, 1995.

43. Salemi M., **Vandamme A.-M.**, Guano F., Gradozzi C., Cattaneo E., Casoli C., & Bertazzoni U. Complete sequence of the Italian isolate HTLV-II Gu and its phylogenetic relationship with other isolates. VIIIth International Conference in Human Retrovirology : HTLV, Institut Pasteur, Paris, France, October 17-21, 1995. J AIDS and Human Retrovir 10, 277, 1995.
44. Van Laethem K., Goubau P., Liu H.-F., Van Brussel M., Fleischer C., Desmyter J., & **Vandamme A.-M.** New diagnostic HTLV-PCR assay detecting HTLV-I, STLV-I, HTLV-II and the two new types of STLV could identify potentially new types of HTLV. First European Meeting on Diagnostic PCR, Grand Hotel Krasnapolsky, Amsterdam, The Netherlands, October 12-13, 1995.
45. Beuselinck K., Reynders M., Goubau P., **Vandamme A.-M.**, & Desmyter J. Diagnosis of herpes simplex encephalitis by polymerase chain reaction followed by endonuclease cleavage. First European Meeting on Diagnostic PCR, Grand Hotel Krasnapolsky, Amsterdam, The Netherlands, October 12-13, 1995.
46. Van Brussel M., Goubau P., Desmyter J., & **Vandamme A.-M.** Primate T-lymphotropic viruses use multiple splicing for their gene regulation resulting in a complex genomic structure. Research Conference on Molecular Biology of RNA : Splicing and 3'-end formation of RNA, Mont Ste Odile, France, September 13-17, 1995.
47. **Vandamme A.-M.**, Schmit J.-C., Van Dooren S., Van Laethem K., Goubau P., Peetermans W., De Clercq E. & Desmyter J. Correlation between the NASBA HIV-1 RNA QT and the AMPLICOR HIV MONITOR test for the quantification of HIV-1 RNA in plasma. First European Conference on Experimental AIDS Research, Cannes, March 10-13, 1996.
48. Ellerbrok H., Fleischer C., **Vandamme A.-M.**, Kücherer C., Schneider J., Detmar M., & Pauli G. Molekulare Analyse nach Deutschland importierter HTLV-I Infektionen. Jahrestagung der Gesellschaft für Virologie, Jena, Deutschland, 6-9 März 1996.
49. Schmit J.C., Ruiz L., Clotet B., Van Remoortel B., Witvrouw M., Raventos A., Tor J., Desmyter J., De Clercq E. & **Vandamme A.-M.** Resistance-related multiple mutations in the HIV-1 protease gene of patients treated with the protease inhibitor Ritonavir. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. Antiviral Therapy 1, S1, 20, 1996.
50. Schmit J.C., Martinez-Picado J., Ruiz L., Clotet B., Van Laethem K., Desmyter J., De Clercq E. & **Vandamme A.-M.** Evolution of drug resistance in HIV-1 strains from patients under AZT-ddI or AZT-ddC combination therapy after switching to AZT-

- 3TC or AZT-ddI/ddC-3TC therapy. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. *Antiviral Therapy* 1, S1, 35, 1996.
51. Schmit J.C., Vanderlinden I., Ruiz L., Clotet B., Hermans P., Sprecher S., Arendt V., Peetermans W., Harrer T., Vaira D., Desmyter J., De Clercq E. & **Vandamme A.-M.** Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in patients on ddN combination therapy. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. *Antiviral Therapy* 1, S1, 25, 1996.
 52. **Vandamme A.-M.**, Schmit J.-C., Balzarini J., Van Laethem K., Witvrouw M., Hermans P., Sprecher S., Martinez-Picado J., Clotet B., Peetermans W., Desmyter J., & De Clercq E. Presence of TSAO-resistant virus strains in non-experienced patients. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. *Antiviral Therapy* 1, S1, 30, 1996.
 53. Schmit J.-C., Cogniaux J., Hermans P., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E., & **Vandamme A.-M.** An efficiently replicating HIV strain with multiple resistance to nucleoside analogues including 3TC is able to additionally acquire resistance to non-nucleoside analogues. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. *Antiviral Therapy* 1, S1, 38, 1996.
 54. Este J.A., Van Laethem K., **Vandamme A.-M.**, Desmyter J., & De Clercq E. Resistant phenotype of human immunodeficiency virus type 1 to dextran sulphate is conferred by specific amino acid substitutions in the gp120 molecule. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 3-6, 1996. *Antiviral Therapy* 1, S1, 50, 1996.
 55. Daelemans D., Este J.A., Reymen D., De Clercq E. & **Vandamme A.-M.** S-adenosylmethionine-dependent methylation : a cellular factor involved in HIV-1 transcription activation. EMBL meeting on transcription, Heidelberg, August 24-28, 1996.
 56. Salemi M., **Vandamme A.-M.**, Chiara G., Ferrante P., Cattaneo E., Casoli C., Desmyter J., & Bertazzoni U. Phylogenetic analysis of new HTLV-II Italian isolates: link between NY drug users and the South European epidemics. 1996 Annual Meeting of the Institute of Human Virology, NCI, Baltimore, USA, Sept 7-13, 1996.
 57. Koulikovska M., Liu H.-F., **Vandamme A.-M.** & Murovska M. HTLV-I infection in a patient with myelomonocytic leukemia. 1996 Annual Meeting of the Institute of Human Virology, NCI, Baltimore, USA, Sept 7-13, 1996.
 58. Desmyter J., **Vandamme A.-M.**, Goubau P. HTLV-II infection in Zairean pygmies. 1996 Annual Meeting of the Institute of Human Virology, NCI, Baltimore, USA, Sept 7-13, 1996.

59. Martinez-Picado J., Ruiz L., Tural C., Schmit J.-C., **Vandamme A.-M.**, Cabrera C., Ibanez A., Puig T., Segura A., & Clotet B. A six months follow-up randomized controlled trial of lamivudine (3TC) combined with zidovudine (ZDV) vs. lamivudine plus zidovudine plus zalcitabine (ddC) or didanosine (ddI) in HIV-1 infection and CD4+ cell count between 50-300/ μ l. 36th ICAAC, New Orleans, Louisiana, USA, September 15-18, 1996.
60. **Vandamme A.-M.**, Schmit J.-C., Balzarini J., Witvrouw M., Van Laethem K., Hermans P., Kleim J.-P., Desmyter J., & De Clercq E. In vitro selection of high level quinoxaline (HBY097) resistance using a patient isolate displaying multidrug resistant phenotype. Third International Congress on Drug Therapy in HIV Infection, Birmingham, UK, November 3-7, 1996. AIDS 10, S20, 1996.
61. Ghesquière J., Goubau P., Liu H.-F., **Vandamme A.-M.**, & Desmyter J. Le virus HTLV-II chez les Pygmées Efe de l'Ituri: preuve de sa co-évolution avec l'espèce humaine. 1816e Réunion Scientifique de la Société d'Anthropologie de Paris : Les épidémies, d'hier à aujourd'hui, Marseille, France, Novembre 22-23, 1996.
62. Ellerbrok H., Fleischer C., **Vandamme A.-M.**, Kücherer C., & Pauli G. Molecular Analysis of HTLV-I from patients in Germany. XXIInd Meeting of the European Tumor Virus Group, March 5-9, 1997, Virus Research 47, 120, 1997.
63. Witvrouw M., Arranz M.E., Pannecouque C., Declercq R., Jonckheere H., Schmit J.-C., **Vandamme A.-M.**, Diaz J.A., Desmyter J., Esnouf R., Van Meervelt L, Balzarini J., Vega S. & De Clercq E. New 1,1,3-trioxo-2*H*,4*H*-thieno[3,4-*e*][1,2,4] thiadiazine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. 10th International Conference on Antiviral Research, Atlanta, USA, April 6-11, 1997.
64. Witvrouw M., Pannecouque C., Balzarini J., Jhaumeer-Laulloo S., Pluymers W., Este J.A., Schols D., Cherepanov P., Schmit J.-C., Debyser Z., **Vandamme A.-M.**, Desmyter J., Ramadas S.R. & De Clercq E. Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus. 10th International Conference on Antiviral Research, Atlanta, USA, April 6-11, 1997.
65. Schmit J.C., Clotet B., Hermans P., Arendt V., Leal M., Harrer T., Witvrouw M., De Clercq E. & **Vandamme A.-M.** Multiple dideoxynucleoside (ddN) analogue resistant HIV-1 from European patients. Second European Conference on Experimental AIDS Research, Stockholm, Sweden, May 31 -June03, 1997.
66. Daelemans D., Witvrouw M., Pannecouque C., De Clercq E. & **Vandamme A.-M.** A peptoid inhibitor of Tat/TAR interaction with antiviral activity. Second European Conference on Experimental AIDS Research, Stockholm, Sweden, May 31 -June 03, 1997.

67. Debyser Z., Van Wijngaerden E., McMorow M., De Clercq E., **Vandamme A.-M.** & Desmyter J. The viral load of a divergent clinical HIV-1 strain can presently only be quantified by the branched DNA assay. Second European Conference on Experimental AIDS Research, Stockholm, Sweden, May 31 -June 03, 1997.
68. Salemi M., Gradozzi C., Van Laethem K., Ferrante P., Taylor G., Casoli C., Goubau P., Desmyter J., Bertazzoni U., & **Vandamme A.-M.** Evolutionary rate estimation for the human T-cell lymphotropic virus type II (HTLV-II), using new isolates from European injecting drug users. VIIIth International Conference in Human Retrovirology : HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.
69. Van Brussel M., Liu H.-F., Goubau P., Desmyter J., & **Vandamme A.-M.** The analysis of the genomic structure of STLV-PP provides arguments for its classification as a fourth type of PTLV. VIIIth International Conference in Human Retrovirology : HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.
70. **Vandamme A.-M.**, Van Brussel M., Liu H.-F., Salemi M., Van Laethem K., Van Ranst M., Michels L., Desmyter J., & Goubau P. A new subtype of human T-lymphotropic virus type II, HTLV-II_d, in Zairian Bambuti Efe pygmies and its implications for the origin of HTLV-II. VIIIth International Conference in Human Retrovirology : HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.
71. **Vandamme A.-M.**, Van Laethem K., Liu H.-F., Van Brussel M., Delaporte E., de Castro Costa C.M., Fleischer C., Taylor G., Bertazzoni U., Desmyter J. & Goubau P. Use of a generic PCR assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serologies. VIIIth International Conference in Human Retrovirology : HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.
72. Lewis M.J., Novoa P., Salemi M., **Vandamme A.-M.**, & Hall W.W.. Isolation, cloning, and complete nucleotide sequence of a Brazilian strain of human T-cell lymphotropic virus type II : characterization of a phenotypically and functionally distinct subgroup. VIIIth International Conference in Human Retrovirology : HTLV, Rio de Janeiro, Brazil, June 9-13, 1997.
73. **Vandamme A.-M.** Using AmpliTaq Gold greatly improves the specificity of mutation-selective PCRs for the detection of resistance mutations in HIV-1. Benelux PCR Seminar, Rotterdam, The Netherlands, 15 April 1997. Invited speaker.
74. Debyser Z., Van Wijngaerden E., De Clercq E., McMorow M., **Vandamme A.-M.** & Desmyter J. The branched DNA assay is the only commercial technique that is able to quantify the viral load of a divergent clinical HIV-1 strain. 3rd Annual meeting of the British HIV association, Warwick, UK, 11-13 April 1997.

75. **Vandamme A.-M.**, Liu H.-F., Van Brussel M., Desmyter J., & Goubau P. The three human T-lymphotropic virus type I subtypes arose from three geographically distinct simian reservoirs. International meeting of the European Society for Evolutionary Biology, The Netherlands, August 24-28, 1997.
76. Salemi M., **Vandamme A.-M.**, Chiara G., Ferrante P., Cattaneo E., Casoli C., Desmyter J., & Bertazzoni U. Phylogenetic analysis of new HTLV-II Italian isolates: link between NY drug users and the South European epidemics. International meeting of the European Society for Evolutionary Biology, The Netherlands, August 24-28, 1997.
77. Debyser Z., Van Wijngaerden E., Reynders M., Beuselinck K., Van Laethem K., De Clercq E., Desmyter J. & **Vandamme A.-M.** Comparison of three commercial assays for viral load determination of genetically divergent HIV-1 strains. 3rd Annual European Conference on Nucleic Acid-Based Technologies, Lisbon, Portugal, October 27-28, 1997.
78. **Vandamme A.-M.**, Schmit J.C., Van Laethem K., Van Wijngaerden E., De Clercq E., & Desmyter J. Unexpected high stability of HIV-1 virions in whole blood. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.
79. Schmit J.C., Ruiz L., Stuyver L., Van Laethem K., Vanderlinden I., Martinez-Picado J., Rossau R., Desmyter J., De Clercq E., Clotet B & **Vandamme A.-M.** Comparison of the line probe HIV-1 reverse transcriptase assay, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.
80. **Vandamme A.-M.**, Harrer T., Van Laethem K., De Vroey V., Rascu A., Grünkel M., Löwl P., Kalden J.R., Desmyter J., & De Clercq E. Lack of resistance mutations (including M184V) in treatment-naïve HIV-1 seropositives for up to 7 months after initiation of a 3TC-containing three- or four-drug combination therapy, except for one patient with previous AZT resistance. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.
81. Stuyver L., Rombout A., Wyseur A., Verhelst R., Schoolmeesters A., **Vandamme A.-M.**, Peeters M., Schinazi R., Verhofstede C., & Rossau R. Genetic variability of the HIV-1 RT region, subtype B versus non-B, at drug-resistant codon positions. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.
82. Schmit J.C., Clotet B., Hermans P., Ruiz L., Sprecher S., Arendt V., Leal M., Lissen E., Harrer T., De Clercq E., Witvrouw M., & **Vandamme A.-M.** Multiple

dideoxynucleoside analogue-resistant HIV-1 in Europe. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.

83. Balzarini J., Pelemans H., Esnouf R., Dunkler A., Parniak M.A., **Vandamme A.-M.**, Karlsson A., De Clercq E., & Kleim J.-P. Significance of the 225 Pro-His mutation in HIV-1 reverse transcriptase. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St Petersburg, Florida, USA, June 25-28, 1997.
84. **Vandamme A.-M.**, Van Wijngaerden E., Van Vaerenbergh K., Van Laethem K., De Vroey V., Schmit J.C., Debyser Z., Stuyver L., De Clercq E., & Desmyter J. The use of fast genotypic HIV-1 drug-resistance tests in the decision on chemoprophylaxis after occupational exposure to HIV. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, Oct 11-15, 1997.
85. **Vandamme A.-M.**, Schmit J.C., Witvrouw M., Van Laethem K., Esnouf R., Balzarini J., Kleim J.-P., Desmyter J., & De Clercq E. An HIV-1 strain displayed partial reversal of phenotypic but not genotypic multinucleoside resistance after resistance selection with quinoxaline (HBY 097). Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, Oct 11-15, 1997.
86. Van Vaerenbergh K., Van Laethem K., Van Wijngaerden E., Schmit J.C., Schneider F., Ruiz L., Clotet B., Verhofstede C., Muyldermans G., Stuyver L., Evans C., De Clercq E., Desmyter J. & **Vandamme A.-M.** Predictive value on therapy effectiveness of HIV-1 genotypic resistance at the moment of changing therapy. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, Oct 11-15, 1997.
87. Van Vaerenbergh K., Van Laethem K., Albert J., Albrecht H., Boucher C., Clotet B., Floridia M., Nielsen C., Pedersen C., Perrin L., Ruiz L., Schmit J.C., Schneider F., Schoolmeesters A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerley S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Multinucleoside drug resistance among European HIV-1-infected patients. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, Germany, Oct 11-15, 1997.
88. **Vandamme A.-M.** Molecular analysis of HTLV indeterminate sera using a generic PCR. HERN HTLV-I and -II serology, molecular diagnosis & sero-epidemiology workshop, Bath, UK, October 10-11, 1997. Invited speaker.
89. Van Laethem K., Van Vaerenbergh K., Schmit J.C., De Vroey V., Schuurman R., Sprecher S., Hermans P., De Clercq E., Desmyter J., & **Vandamme A.-M.** Selective PCR for the detection of HIV-1 drug resistance mutations in the follow-up of HIV-1

infected patients. Third European Conference on Experimental AIDS Research, Munchen, Germany, Februari 28 -March 03, 1998.

90. Van Dooren S., Salemi M., Gotuzzo E., Watts D., Audenaert E., Duwe S., Ellerbrok H., Grassmann R., Desmyter J. & **Vandamme A.-M.** Post-Colombian introduction of HTLV-I in Latin-America. Third European Conference on Experimental AIDS Research, Munchen, Germany, Februari 28 -March 03, 1998.
91. Salemi M., Van Dooren S., Audenaert E., Delaporte E., Goubau P., Desmyter J. & **Vandamme A.-M.** Two new HTLV-I subtypes found in seroindeterminates, a Mbuti Efe pygmy and a Gabonese, most probably arisen through interspecies transmission from African monkeys. Third European Conference on Experimental AIDS Research, Munchen, Germany, Februari 28 -March 03, 1998.
92. Van Brussel M., Liu H.-F., Salemi M., Goubau P., Desmyter J., & **Vandamme A.-M.** The genomic organization of the proximal pX regions differs not only between PTLV types but also between subtypes. HERN third pathogenesis workshop, Munchen, Germany, Februari 28, 1998; Virus Research 65, 10, 1999.
93. Van Vaerenbergh K., Harrer T., Schmit J.C., Schmidt B., Walter H., Van Remoortel B. , Van Laethem K., Witvrouw M. , Rascu A., De Vroey V. , Grünke M., Löw P., De Clercq E., Desmyter J. & **Vandamme A.-M.** Breakthrough of resistant virus one year after the initiation of triple or quadruple drugtherapy in naive HIV-1 seropositives. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998.
94. Van Vaerenbergh K., Van Laethem K., Van Wijngaerden E., Schmit JC., Schneider F , Ruiz L., Clotet B., Verhofstede C., Van Wanzele F. , Muyltermans G., Simons P., Stuyver L., Hermans Ph., Evans C., De Clercq E., Desmyter J. & **Vandamme A.-M.** Predictive value on viral load and CD4 counts of HIV-1 genotypic resistance at the moment of changing therapy. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998.
95. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C., Clotet B., Floridia M., Nielsen C., Pedersen C., Perrin L., Pirillo MF., Ruiz L., Schmit JC., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerly S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence of multinucleoside drug resistance among European HIV-1-infected patients receiving various combinations of nucleoside analogues. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998.
96. **Vandamme A.-M.**, Van Laethem K., Schmit J.-C., De Vroey V., Harrer T., Ruiz L., Sprecher S., Hermans P., Clotet B., Desmyter J. and De Clercq E. Patients harbouring both the multinucleoside analogue resistance mutation Q151M and

the AZT resistance mutation T215Y/F carry these two mutations on different HIV-1 quasispecies. 12th World AIDS conference, Genève, Switzerland, June28-July3, 1998.

97. Witvrouw M., Pannecouque C., Erven K., Heens C., Van Remoortel B., **Vandamme A.-M.**, Desmyter J. & De Clercq E. Activity of non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-2 and SIV. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24-27 June 1998.
98. **Vandamme A.-M.** The simian origins of the pathogenic human T-cell lymphotropic virus type I. International meeting on blood borne viral infections, Riga, Latvia, 26-27 May 1998. Invited speaker.
99. **Vandamme A.-M.** Multi nucleoside analogue resistant HIV-1 in Europe. International meeting on blood borne viral infections, Riga, Latvia, 26-27 May 1998. Invited speaker.
100. Murovska M., Koulikovska M., Kozireva S., Nemtseva G., Pavlova O., Lejniece S., Logina I., Yano S., **Vandamme A.-M.** & Blomberg J. HTLV-I/II infection among Latvian inhabitants. International meeting on blood borne viral infections, Riga, Latvia, 26-27 May 1998.
101. Van Dooren S., Salemi M., Gotuzzo E., Watts D., Audenaert E., Duwe S., Ellerbrok H., Grassmann R., Desmyter J. & **Vandamme A.-M.** Evidences for a post-Columbian HTLV-I introduction in Latin-America. 1998 Meeting of the Institute of Human Virology, 23-29 August 1998.
102. **Vandamme A.-M.** Construction and interpretation of phylogenetic trees. Fourth European Workshop on Virus Evolution and Molecular Epidemiology, Leuven, Belgium, 1-4 September 1998. *The Infectious Disease Review* 1, 60, 1999. Invited speaker.
103. **Vandamme A.-M.** Molecular epidemiology of viruses using phylogenetic analysis. Fourth European Workshop on Virus Evolution and Molecular Epidemiology, Leuven, Belgium, 1-4 September 1998. *The Infectious Disease Review* 1, 60-61, 1999. Invited speaker.
104. Santos T.J.T., **Vandamme A.-M.**, Goubau P., Desmyter J., De Castro Costa C.M., Carton H. HTLV prevalence and tropical spastic paraparesis in northeastern Brazil. Fourth European Workshop on Virus Evolution and Molecular Epidemiology, Leuven, Belgium, 1-4 September 1998. *The Infectious Disease Review* 1, 63-64, 1999.
105. **Vandamme A.-M.**, Van Vaerenbergh K., Schmit J.C., Schmidt B., Walter H., Van Remoortel B. , Van Laethem K., Witvrouw M. , Rascu A., De Vroey V. , Grünke M.,

- Löw P., De Clercq E., Desmyter J. & Harrer T. Triple or quadruple drugtherapy in naive HIV-1 seropositives does not prevent the selection of resistant virus in a subset of patients. 4th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 8-12 November 1998. AIDS 12, Suppl 4, S19, 1998.
106. Van Laethem K, Van Vaerenbergh K., Schmit J.C., Sprecher S., Hermans P., De Vroey V., Schuurman R., Harrer T., Witvrouw M., Van Wijngaerden E., De Clercq E., Desmyter J., & **Vandamme A.-M.** Phenotypic assays and sequencing are less sensitive for the detection of resistance in mixed genotypes compared to point mutation assays. 4th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 8-12 November 1998. AIDS 12, Suppl 4, S26, 1998.
 107. Qari S.H., Garcia-Lerma J.G., Reisler R., Van Laethem K, Schmit J.C., Sprecher S., **Vandamme A.-M.** & Heneine W. Rapid phenotypic assay for detection of multidrug resistance in HIV-1 to nucleoside analogues. 6th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, USA, 31 January-4 February 1999.
 108. Van Laethem K, Witvrouw M., Schmit J.C., Sprecher S., Hermans P., Leal M., Harrer T., Clotet B., Ruiz L., Desmyter J., & **Vandamme A.-M.** The multiple nucleoside analogue resistance mutations confer cross-resistance to Abacavir. 6th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, USA, 31 January-4 February 1999.
 109. Leyssen P., **Vandamme A.-M.**, Van Dooren S., De Clercq E., & Neyts J. A unique animal model for the study of the pathogenesis and therapy of flavivirus infection. 12th International Conference on Antiviral Research, Jerusalem, Israel, 21-26 March 1999.
 110. **Vandamme A.-M.**, Salemi M., Van Dooren S., Goubau P., & Desmyter J. Tempo and mode of PTLV evolution. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20, A23, 1999. Invited speaker.
 111. Van Dooren S., Salemi M., Delaporte E., Pourrut X., Verschoor E., Van Goidsenhoven I., Desmyter J. & **Vandamme A.-M.** Analysis of the simian origin of the HTLV-I subtypes. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20, A73, 1999.
 112. Salemi M., Desmyter J., & **Vandamme A.-M.** The evolutionary rate of HTLV-II in injecting drug users is 50 to 200 times faster compared to in endemically infected Amerindian and Pygmy tribes. 9th International Conference on Human

- Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 20, A76, 1999.
113. Salemi M., Desmyter J., & **Vandamme A.-M.** Estimation of the divergence time for the major human and simian T-lymphotropic virus (HTLV/STLV) lineages by analysing full genome sequences. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 20, A73, 1999.
 114. Syrtsev A., Van Dooren S., Senyuta N., de Thé G., Gessain A., **Vandamme A.-M.**, & Gurtsevitch V. Detection of HTLV-I sequences in seronegative individuals from Buryatia. 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 20, A51, 1999.
 115. Syrtsev A., Van Dooren S., Senyuta N., Ruzibakiev R., **Vandamme A.-M.**, Hayami M., & Gurtsevitch V. HTLV-I prevalence among seronegative ethnic Jewish people in Bukhara (Uzbekistan). 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 20, A59, 1999.
 116. Syrtsev A., Van Dooren S., Trofimov D., Kogai B., Senyuta N., Ogorodnikova E., **Vandamme A.-M.**, & Gurtsevitch V. Are seronegative blood donors in Moscow infected with HTLV-I? 9th International Conference on Human Retrovirology: HTLV, Kagoshima, Japan, 5-9 April 1999. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 20, A63, 1999.
 117. Schmit J.C., Witvrouw M., Plessier J.M., Fontaine E., Lambert C., Robert I., Servais J., Arendt V., Schneider F., **Vandamme A.-M.**, De Clercq E., & Hemmer R. HIV-1 patient isolates with a 69-serine-serine insertion in the reverse transcriptase (RT) display resistance to dideoxynucleoside analogues but retain sensitivity to non-nucleoside RT inhibitors (NNRTI) and to acyclic nucleoside phosphonates. The Fourth European Conference On Experimental AIDS Research, Tampere, Finland, 18-21 June 1999.
 118. Goubau P., Desmyter J., Michiels M., **Vandamme A.-M.**, Hulstaert F., Govers L., Zrein M. Validation of the INNO-LIA HTLV-I/II in the confirmation and discrimination of HTLV infections. The Fourth European Conference On Experimental AIDS Research, Tampere, Finland, 18-21 June 1999.
 119. **Vandamme A.-M.**, Van Vaerenbergh K., Debaisieux L., De Cabooter N., Fransen K., Marissens D., Miller K., Muyldermans G., Schoolmeester A., Sprecher S., Stuyver L., Vaira D., Verhofstede C., for the Belgian AIDS Reference Laboratories. Prevalence of HIV-1 drug resistance mutations in naive patients in Belgian hospitals. 3rd

International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA, 23-26 June 1999. *Antiviral Therapy* 4 (Suppl. 1), 103, 1999.

120. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C., Clotet B., Florida M., Gerstoft J., Nielsen C., Perrin L., Pirillo MF., Ruiz L., Schmit JC., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerly S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence of the multidrug resistant 6 bp insert at codon 69 among European HIV-1-infected patients receiving various combinations of nucleoside analogues. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA, 23-26 June 1999. *Antiviral Therapy* 4 (Suppl. 1), 102, 1999.
121. Fontaine E., Plesséria J.M., Lambert C., Staub T., Arendt V., Hemmer R., Schneider F., **Vandamme A.-M.** & Schmit J.C. In vitro selection of HIV-1 strains acquiring a Q151M substitution and other multidrug resistance related mutations. 3rd International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, USA, 23-26 June 1999. *Antiviral Therapy* 4 (Suppl. 1), 26, 1999.
122. Van Dooren S., Salemi M., Desmyter J. & **Vandamme A.-M.** Molecular clock analysis of the different African HTLV-I subtypes. Fifth European Workshop on Virus Evolution and Molecular Epidemiology, Leuven, Belgium, August 30-September 4, 1999. *The Infectious Disease Review* 1, 1999.
123. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C., Clotet B., Florida M., Gerstoft J., Nielsen C., Perrin L., Pirillo MF., Ruiz L., Schmit JC., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerly S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence of nucleoside and multinucleoside drug resistance among European HIV-1-infected patients receiving various combinations of nucleoside analogues. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 26-29 September 1999.
124. Daelemans D., Afonina E., Hudson E.A., Scheel G., Werner G., De Clercq E., **Vandamme A.-M.**, and Pavlakis G.N. Inhibition of nuclear export of HIV-1 Rev protein. European Research Conferences: Molecular Biology of RNA, Processing of Eukaryotic pre-mRNA and Nucleo-Cytoplasmic Transport, Castelvecchio Pascoli, Italy, 11-16 September 1999.
125. Van Laethem K, Witvrouw M., Balzarini J., Pannecouque C., Esnouf R., Schmit J.C., Hermans P., Van Ranst M., Desmyter J., De Clercq E., & **Vandamme A.-M.** In vitro selection of high level resistance towards foscarnet and acyclic nucleoside phosphonates using a patient isolate displaying the multinucleoside resistant pattern. Seventh European Conference on Clinical Aspects and Treatment of HIV-1 Infection, Lisbon, Portugal, 23-27 October, 1999.

126. Riva C., Van Laethem K., Van Vaerenbergh K., Peeters M., Delaporte E., Van Wijngaerden E., De Clercq E., Desmyter J. & **Vandamme A.-M.** HIV-1 drug-resistance testing on A-J subtype strains: evaluation of the PE- Biosystems HIV Genotyping System Kit. Seventh European Conference on Clinical Aspects and Treatment of HIV-1 Infection, Lisbon, Portugal, 23-27 October, 1999.
127. Miller V., Houyez F., Clumeck N., Staszewski S., **Vandamme A.-M.**, Lundgren J., Youle M., Lange J., for the RGI-European Expert Panel. Guidelines for the use of HIV drug resistance testing in clinical management: a European perspective. Seventh European Conference on Clinical Aspects and Treatment of HIV-1 Infection, Lisbon, Portugal, 23-27 October, 1999.
128. **Vandamme A.-M.**, Van Vaerenbergh K., Debaisieux L., De Cabooter N., Fransen K., Marissens D., Miller K., Muyldermans G., Schoolmeester A., Sprecher S., Stuyver L., Vaira D., Verhofstede C., for the Belgian AIDS Reference Laboratories. Prevalence of HIV-1 drug resistance mutations in naive patients in Belgian hospitals. 13de Wetenschappelijke Vergadering van de Belgische Vereniging voor Infectiologie en Klinische Microbiologie, Sint-Niklaas, Belgium, 11 December 1999.
129. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C., Clotet B., Florida M., Gerstoft J., Nielsen C., Perrin L., Pirillo MF., Ruiz L., Schmit JC., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Wijngaerden E., Vella S., Yerly S., De Clercq E., Desmyter J. & **Vandamme A.-M.** Prevalence of the multidrug resistant 6 bp insert at codon 69 among European HIV-1-infected patients receiving various combinations of nucleoside analogues. 13de Wetenschappelijke Vergadering van de Belgische Vereniging voor Infectiologie en Klinische Microbiologie, Sint-Niklaas, Belgium, 11 December 1999.
130. Muyldermans G., Debaisieux L., Fransen K., Marissens D., Miller K., Vaira D., **Vandamme A.-M.**, Vandembroucke A.T., Verhofstede C., Zisis G., Lauwers S. Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories. 13de Wetenschappelijke Vergadering van de Belgische Vereniging voor Infectiologie en Klinische Microbiologie, Sint-Niklaas, Belgium, 11 December 1999.
131. Qari S.H., Garcia-Lerma J.G., Vazquez-Rosales G., Schinazi R.F., Havlir D., Richman D.D., Reisler R., **Vandamme A.-M.**, Schmit J.C., Kavlick M.F., Mitsuya H., Winters M., Merigan T. & Heneine W. A rapid and inexpensive approach for phenotypic analysis of drug resistance to reverse transcriptase (RT) inhibitors by direct analysis of RT activity in plasma. 7th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, USA, 30 January-2 February 2000.
132. **Vandamme A.-M.**, Van Vaerenbergh K., Van Wijngaerden E., Deschamps A., De Graeve V., De Saar V., Maes B., Ceunen H., De Smet K., Stuyver L., De Clercq E.,

- Van Ranst M., Peetermans W., Bobbaers H. & De Geest S. Patients failing HAART are significantly less compliant than patients achieving prolonged undetectable viral load. 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000.
133. Riva C., Fontaine E., Peeters M., Delaporte E., Schmit J.-C., Van Laethem K., Van Vaerenbergh K., Van Wijngaerden E., De Clercq E. & **Vandamme A.-M.** Evaluation of two commercial kits for testing genotypic drug resistance on a panel of HIV-1 clades A-J. 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000.
134. **Vandamme A.-M.**, Houyez F., Bãnhegyí D., Clotet B., De Schrijver G., De Smet K.A.L., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Larder B., Holtzer C., Pillay D., Race E., Schmit J.-C., Schuurman R., Shulse E., Sønnerborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000. Invited speaker.
135. Schmidt B., Walter H., Moschik B., Paatz C., Van Vaerenbergh K., **Vandamme A.-M.**, Schmitt M., Harrer T., Überla K. & Korn K. Simple but reliable algorithm to predict protease inhibitor phenotypic from genotypic data derived from a genotypic/phenotypic database. 2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25-27 February 2000.
136. Fikkert V., Pannecouque C., Cherepanov P., Van Laethem K., **Vandamme A.-M.**, De Clercq E., Witvrouw M. Use of a gp120 recombinant virus assay in the explanation of the molecular mode of action of binding-fusion inhibitors. Keystone Symposia: Novel biological approaches to HIV-1 infection based on new insights into HIV biology, Keystone, USA, 4-10 April 2000.
137. **Vandamme A.-M.**, Strimmer K., Hall W.W., Delaporte E., Mboup S., Peeters M. & Salemi M. Dating the origin of HIV-1 group M and HIV-1 group M/SIVcpz separation. 7th Annual International Discussion Meeting on HIV Dynamics and Evolution, Seattle, USA, 28-30 April 2000. Invited speaker.
138. Salemi M., Strimmer K., Hall W.W., & **Vandamme A.-M.** Uncovering the origin of viral epidemics with a new method to calibrate clock-like phylogenetic trees. 7th Annual International Discussion Meeting on HIV Dynamics and Evolution, Seattle, USA, 28-30 April 2000.
139. Salemi M., Strimmer K., Hall W.W., Delaporte E., Mboup S., Peeters M. & **Vandamme A.-M.** Dating the origin of HIV-1 group M and HIV-1 group M/SIVcpz separation with a new method to calibrate clock-like phylogenetic trees. 8th International Conference on AIDS, Cancer and Related Problems, St-Petersburg, Russia, 19-24 May 2000.

140. Salemi M. & **Vandamme A.-M.** Molecular clock analysis of primate T-cell lymphotropic viruses. Workshop on Endogenous Retroviruses and the Evolution of the Genome, Moscow, Russia, 17-19 May 2000
141. **Vandamme A.-M.** Implementation issues: validation and proficiency. 2nd Spanish Consensus Conference on Drug Resistance Testing in Clinical Practice, Madrid, Spain, 18 March 2000. Invited speaker.
142. Van Dooren S., Salemi M., Liu H.-F., Vancuyck D., Remondegui C., Bouzas M.B., Talarmin A., Desmyter J., Goubau P., & **Vandamme A.-M.** Intrafamilial HTLV-I sequence divergence: a tool for estimating the HTLV-I evolutionary rate? HERN meeting, Potsdam, Germany, 19-21 May, 2000. *Virus Research* 78, 119-120, 2001.
143. **Vandamme A.-M.**, Bertazzoni U. and Salemi M. Evolutionary strategies of Human T-cell lymphotropic virus type II (HTLV-II). Workshop on Microbial Variation and Evolution: historical aspects and perspectives, Ischia, Italy, 7-9 May, 2000.
144. Van Laethem K., Witvrouw M., Pannecouque C., Van Remoortel B., Schmit J.C., Esnouf R., Kleim J.-P., Balzarini J., Desmyter J., De Clercq E. & **Vandamme A.-M.** Mutations in the non-nucleoside binding pocket interfere with the multinucleoside resistance phenotype. Fourth International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain. *Antiviral Therapy* 5, Suppl 3, 22 (Abstract 27).
145. Schmidt B., Korn K., Moschik B., Paatz C., Van Vaerenbergh K., **Vandamme A.-M.**, Schmitt M., Harrer T., Überla K. & Walter H. Comparison of different algorithms for the interpretation of genotypic data for protease inhibitors. Fourth International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain. *Antiviral Therapy* 5, Suppl 3, 61 (Abstract 79).
146. Wensing A.M.J., Holtzer C.D., de Groot T., Albert J., Clotet B., van Lunzen J., Nielsen C., Perrin L., Schneider F., **Vandamme A.-M.**, Boucher C.A.B. & Schuurman R. The prevalence of PI, NRTI and NNRTI resistance-associated mutations in a large ARV-naive, European cross-sectional population. A baseline analysis of the SERVICE project. Fourth International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain. *Antiviral Therapy* 5, Suppl 3, 138 (Abstract 178).
147. Balotta C., Violin M., Van Dooren S., Berlusconi A., Facchi G., Forbici F., Bertoli A., Rezza G., Lo Caputo S., Angarano G., Perno C.F., d'Arminio Monforte A., **Vandamme A.-M.**, Moroni M., for the IcoNA Study Group. Increasing prevalence of non-clade B HIV-1 strains in Italy, as monitored by the analysis of the RT and protease sequences. Fourth International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain. *Antiviral Therapy* 5, Suppl 3, 140 (Abstract 181).

148. Salemi M., Strimmer K., Hall W.W., Duffy M., Delaporte E., Mboup S., Peeters M., & **Vandamme A.-M.** Dating HIV and HCV epidemics with a new method to uncover clock-like molecular evolution: HIV-1 group M originated during the 1930s. XIII International AIDS Conference, 9-14July, 2000, Durban, South Africa.
149. Dileanis J., Kunstman K., Wolinsky S., Palumbo P., Huang D., Brown R.C., Buimer M., Schuurman R., Van Laethem K., **Vandamme A.-M.** Multi-center testing of the PE Biosystems ViroSeq™ HIV-1 Genotyping Kit Version 2. XIII International AIDS Conference, 9-14July, 2000, Durban, South Africa.
150. Balotta C., Violin M., Van Dooren S., Berlusconi A., Facchi G., Forbici F., Bertoli A., Rezza G., Perno C.F., d'Arminio Monforte A., **Vandamme A.-M.**, Moroni M., for the I. CO.N.A. Study Group. RT and protease sequences encompassing RT and protease regions of *pol* gene allow a precise assignment to HIV-1 subtypes. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September, 2000, Toronto Ontario, Canada.
151. Wensing A.M.J., Holtzer C.D., de Groot T., Albert J., Clotet B., van Lunzen J., Nielsen C., Perrin L., Schneider F., **Vandamme A.-M.**, Boucher C.A.B. & Schuurman R. The prevalence of HIV-1 resistance associated mutations in a large ARV-naive European population. A baseline analysis of the SERVICE project. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September, 2000, Toronto Ontario, Canada.
152. Salemi M., Strimmer K., Hall W.W., Duffy M., Delaporte E., Mboup S., Peeters M. & **Vandamme A.-M.** Dating the separation of SIVcpz and HIV-1 group M in the late XVII century and the origin of HIV-1 group M radiation around the 1930s, using a new method to uncover clock-like molecular evolution. 2000 Meeting of the Institute of Human Virology, 10-15 September 2000, Baltimore, USA
153. Van Dooren S., Salemi M., Pourrut X., Delaporte E., Desmyter J. & **Vandamme A.-M.** Analysis of the origin of the African Human T-Cell Lymphotropic Virus Type-I (HTLV-I) subtypes. European Virology 2000 Conference, 17-21 September 2000, Glasgow, Scotland.
154. Salemi M., Van Dooren S., & **Vandamme A.-M.** Molecular clock analysis of the three major lineages of the primate T-cell lymphotropic viruses. Workshop "Call for a network for studies on epidemiology and evolution" at the European Virology 2000 Conference, 17-21 September 2000, Glasgow, Scotland.
155. Van Wijngaerden E., De Saar V., De Graeve V., **Vandamme A.-M.**, Van Vaerenbergh K., Bobbaers H., Deschamps A., Ceunen H. & De Geest S. Non-adherence to HAART: clinically relevant patient categorisation based on electronic event monitoring. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S51-S52 Suppl. 4

156. Van Vaerenbergh K., De Geest S., , Deschamps A., De Graeve V., De Saar V., Maes B., Ceunen H., De Smet K., Peetermans W., Bobbaers H., Van Ranst M., Desmyter J., De Clercq E., Van Wijngaerden E. & **Vandamme A.-M.** Compliance is significantly better in HAART responders compared to non-responders. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S114 Suppl. 4
157. **Vandamme A.-M.**, Van Vaerenbergh K., Schmit J.-C., Schmidt B., Walter H., Fontaine E., Schmitt M., Van Laethem K., Rascu A., De Vroey V., Grünke M., Löw P., Van Ranst M., Desmyter J., De Clercq E. & Harrer T. Initiation of HAART in drug-naïve HIV-1 patients prevents viral breakthrough for up to 43 months in 60% of the patients. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S47 Suppl. 4
158. Fontaine E., Riva C., Peeters M., Schmit J.-C., Delaporte E., Van Laethem K., Van Vaerenbergh K., Van Wijngaerden E., De Clercq E., Van Ranst M. & **Vandamme A.-M.** Evaluation of two commercial kits for the detection of genotypic drug-resistance on a panel of HIV-1 subtypes A-J. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S114 Suppl. 4
159. Van Laethem K., Witvrouw M., Pannecouque C., Van Remoortel B., Esnouf R., Balzarini J., Desmyter J., De Clercq E. & **Vandamme A.-M.** Phenotypic multi-nucleoside resistance linked to the Q151M mutation is enhanced under the selective pressure of acyclic nucleotide analogs but reduced by foscarnet. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S118 Suppl. 4
160. Dileanis J, Marlowe N, Hoo B, Brown RC, Buimer M, Huang D, Palumbo F, Schuurman R, Van Laethem K, **Vandamme AM** & Elbeik T. Performance of the new ViroSeq (TM) HIV-1 genotyping system (version 2) with group M subtype panel and with subtype B clinical samples at test sites. Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK. AIDS 14: S115 Suppl. 4
161. De Graeve V., De Saar V., Van Wijngaerden E. **Vandamme A.-M.**, Van Vaerenbergh K., Deschamps A., Ceunen H., Bobbaers H., & De Geest S. Prevalence, determinants and virological outcome of nonadherence with HAART in HIV/AIDS patients. 5th Low-Lands Mini-Symposium on Drug Exposure. 9 November 2000, Maastricht, The Netherlands.
162. Van Dooren S., Salemi M. & **Vandamme A.-M.** Dating the origin of the African Human T-Cell Lymphotropic Virus type-I (HTLV-I) subtypes. Symposium of Belgian

society for Microbiology, "Emerging and recurrent infectious diseases", Louvain-La-Neuve, Belgium, 8th December 2000.

163. Salemi M. & **Vandamme A.-M.** Evolutionary patterns of simian and human immunodeficiency viruses. Symposium of Belgian society for Microbiology, "Emerging and recurrent infectious diseases", Louvain-La-Neuve, Belgium, 8th December 2000.
164. Balotta C., Facchi G., Violin M., Van Dooren S., Cozzi-Lepri A., Forbici F., Bertoli A., Senese D., Caramello P., Carnevale G., Rizzardinid G., Cremonini L., Mono L., Rezza G., Perno C.F., Ippolito G., d'Arminio Monforte A., **Vandamme A.-M.**, Moroni M., for the I. CO.N.A. Study Group. Increasing Prevalence Of Non-B HIV-1 Clades In Italy Among Heterosexuals And Females Monitored By RT And Protease Sequence Analysis. Eighth Conference on Retroviruses and Opportunistic Infections (CROI), February 4-8, 2001, Chicago, USA
165. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., Pavlakis G.N., De Clercq E. & **Vandamme A.-M.** A novel inhibitor of the CRM1- mediated Rev-export. Eighth Conference on Retroviruses and Opportunistic Infections (CROI), February 4-8, 2001, Chicago, USA
166. Van Craenenbroeck E., Blockeel H., Dehaspe L., Witvrouw M., Pannecouque C., **Vandamme A.-M.** & De Clercq E. Integration of chemical, biological and clinical research data to facilitate HIV research. IBC Chemo*Bio Informatics Conference, February 15-16, 2001, San Diego, CA, USA
167. Lemey P., Salemi M. & **Vandamme A.-M.** Maximum likelihood analysis of clock-like evolution in HIV-1 groupM incorporating non-contemporaneous sequences. 8th Annual International Discussion Meeting on HIV Dynamics and Evolution, Paris, France, 27-29 April 2001.
168. Salemi M. & **Vandamme A.-M.** Investigating Hepatitis C virus evolutionary models through full genome analyses. 8th Annual International Discussion Meeting on HIV Dynamics and Evolution, Paris, France, 27-29 April 2001.
169. Van Dooren S., Gessain A. & **Vandamme A.-M.** Full Genome Analysis of the Current Most Divergent STLV-I Strain Present in a *Macaca arctoides*. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S43.
170. Van Dooren S., Pourrut X., Peeters M., Delaporte E. & **Vandamme A.-M.** A second divergent 'STLV-L'-like strain detected in a *Cercopithecus nictans* from Cameroon. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S44.

171. Salemi M. & **Vandamme A.-M.** Retrovirus evolution and molecular anthropology. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S11.
172. Van Dooren S., Salemi M., Liu H.-F., Goubau P., Prims M., Vancuyck D., Remondegui C., Bouzas M.B., Talarmin A., Gotuzzo E., Gurtsevitch V. & **Vandamme A.-M.** Low HTLV-I evolutionary rate confirmed in cases of vertical intrafamilial HTLV-I transmission. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S44.
173. Switzer W.M., Shanmugam V., Van Dooren S., **Vandamme A.-M.**, Bhullar V., Parekh B. & Heneine W. Identification of a Distinct STLV in an Ethiopian Gelada Baboon (*Theropithecus gelada*). Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S11.
174. **Vandamme A.-M.**, Van Dooren S. & Salemi M. PTLV-I origin and evolution. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S11. Invited speaker.
175. Van Dooren S., Prims M., Verschoor E., Langenhuijzen S., Pourrut X., Peeters M., Delaporte E. & **Vandamme A.-M.** Phylogenetic Characterization of STLV-I Strains from Various Asian and African Monkey Species. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S44.
176. Alcântara L.C.J., Shindo N., Van Dooren S., Kashima S., Costa M.C.R., Andrade T., Andrade-Filho A., Bittencourt A., Dourado I., Covas D.T., **Vandamme A.-M.** & Galvão-Castro B. Molecular Epidemiology of Human T-Cell Lymphotropic Virus Type I (HTLV-I) in Northeast of Brazil. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S33.
177. Shindo N., Alcântara L.C.J., Van Dooren S., Salemi M., Costa M.C.R., Kashima S., Covas D.T., Teva A., Brito I., **Vandamme A.-M.** & Galvão-Castro B. Human Retroviruses (HIV and HTLV) in Brazilian Indians: Seroepidemiological Study and Molecular Epidemiology of HTLV-II Isolates. Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. AIDS Research and Human Retroviruses 17, S41.
178. de Castro Costa C.M., Santos T.J.T., Haddad S.K., Takayanagui O., **Vandamme A.-M.**, Goubau P., & Carton H. Is seronegative TSP a possible HTLV-I/II associated

myelopathy? Tenth International Conference on Human Retrovirology: HTLV and Related Viruses, Dublin, Ireland, 25-29 June 2001. *AIDS Research and Human Retroviruses* 17, S72.

179. Van Vaerenbergh K., Debaisieux L., Derdelinckx I., De Cabooter N., De Smet K., Fransen K., Marissens D., Miller K., Muyldermans G., Sprecher S., Vaira D., Verhofstede C., Zisis G., Van Ranst M., De Clercq E. and **Vandamme A.-M.** A trend for reduced viral load response to the initial therapy in treatment-naïve HIV-1 patients with baseline resistance mutations as measured by LiPA. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 96, 2001.
180. Schapiro J.M., De Luca A., Harrigan R., Hellmann N., McCreedy B., Pillay D., Schuurman R., Shafer R.W., **Vandamme A.-M.**, Miller V. for the EuroGuidelines Group for HIV Resistance. Resistance Assay Interpretation Systems Vary Widely in Method and Approach. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 131, 2001.
181. Derdelinckx I., Van Vaerenbergh K., De Geest S., Deschamps A., De Graeve V., De Saar V. , Maes B., Ceunen H., De Smet K., PeetermansW., Bobbaers H., Van Ranst M, Desmyter J., De Clercq E., Van Wijngaerden E. and **Vandamme A.-M.** Baseline resistance is significantly associated with long-term therapy response, especially in non-adherent patients. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 74, 2001.
182. Snoeck J., Van Laethem K., Schrooten Y., Derdelinckx I., Van Wijngaerden E., De Clercq E., and **Vandamme A.-M.** Difference in the prevalence of resistance-related mutations in HIV-1 subtype B compared to non-B subtypes among treatment-naïve patients. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 92, 2001.
183. Snoeck J., Van Dooren S., Van Laethem K., Derdelinckx I., Van Wijngaerden E., De Clercq E., and **Vandamme A.-M.** Prevalence and origin of HIV-1 group M subtypes among patients attending the Leuven University Hospitals in 1999. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 115, 2001.
184. Van Laethem K., De Luca A., Antinori A., Cingolani A., Perno C.-F. and **Vandamme A.-M.** A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Fifth International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona, USA, 4-8 June 2001. *Antiviral Therapy* 6 (Suppl 1), 132, 2001.

185. De Geest S, De Saar V, De Graeve V, **Vandamme A.-M.**, Van Vaerenbergh K, Bobbaers H, Deschamps A, Ceunen H and Van Wijngaerden E. Non-adherence to HAART: clinically relevant patient categorisation based on electronic event monitoring. Sigma Theta Tau, 12th International Nursing Research Conference, Copenhagen June 8-9th, 2001, Research Congress CD-rom pp. 17.
186. Magiorkinis G., Paraskevis D., Magiorkinis M., **Vandamme A.-M.** and Hatzakis A. Re-analysis of the HIV-1 Circulating Recombinant A/E (CRF01_AE): Evidence of A/E/G Recombination. AIDS Vaccine 2001, 5-8 September 2001, Philadelphia, USA.
187. Van Laethem K., De Luca A., Antinori A., Cingolani A., Perno C.-F. and **Vandamme A.-M.** Rega V5.0: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. 8th European Conference on Clinical Aspects and Treatment of HIV-infection. Athens, Greece, 28-31 October 2001.
188. Deschamps A, De Graeve V, De Saar V, **Vandamme A.-M.**, Van Vaerenbergh K, Ceunen H, Bobbaers H, Van Wijngaerden E., and De Geest S. Prevalence, determinants and clinical consequences of subclinical non-adherence to HAART. 11^o European Conference for Nurses in AIDS care, November 7-11, 2001, Rotterdam
189. **Vandamme A.-M.** The simian origin of HIV-1. 2nd European Society for Emerging Infections (ESEI) Congress. Budapest, Hungary, 21-23 October 2001. Invited speaker.
190. Muyldermans G., Debaisieux L., Fransen K., Marissens D., Miller K., Vaira D., **Vandamme A.-M.**, Vandenbroucke A.T., Verhofstede C., Schmit J.-C., Zissis G., Lauwers S. Use of three HIV quality control programs for the characterization of two proficiency panels. European Meeting on Molecular Diagnostics, Scheveningen, The Netherlands, 11-12 October 2001. Journal of Microbiological Methods 47, 108, 2001.
191. **Vandamme A.-M.** The origins of HIV. Journée de conférences HIV, Luxembourg, Luxembourg, 17 November 2001. Invited speaker.
192. Derdelinckx I., Van Vaerenbergh K., De Geest S., Deschamps A., De Graeve V., De Saar V., Maes B., Ceunen H., De Smet K., Peetermans W., Bobbaers H., Van Ranst M., Desmyter J., De Clercq E., Van Wijngaerden E., **Vandamme A.-M.** Baseline resistance is significantly associated with long-term therapy response, especially in non-adherent patients. Seventeenth Symposium of the BVIKM, Middelheim ziekenhuis, Antwerp, December 15, 2001.
193. Van Laethem K., De Luca A., Antinori A., Cingolani A., Perno C.-F. and **Vandamme A.-M.** Rega V5.0: A genotypic drug resistance interpretation algorithm that

significantly predicts therapy response in HIV-1 infected patients. Seventeenth Symposium of the BVIKM, Middelheim ziekenhuis, Antwerp, Belgium, December 15, 2001.

194. De Graeve V., De Saar V., Van Wijngaerden E. **Vandamme A.-M.**, Van Vaerenbergh K., Deschamps A., Ceunen H., Bobbaers H., & De Geest S. Prevalentie, determinanten en klinische consequenties van therapie-ontrouw aan antiretrovirale therapie bij HIV-positieve patiënten. Vergadering van de Wetenschappelijke vereniging van Verpleegkundigen: "Evidence based practice". Antwerpen, 14 december 2001.
195. Courgnaud V., Salemi M., Pourrut X., Mpoudi-Ngole E., Abela B., Auzel P., Bibollet-Ruche F., Hahn B., **Vandamme A.-M.**, Delaporte E., and Peeters M. Molecular characterization of a novel simian immunodeficiency virus with a *vpu* gene from greater spot-nosed monkeys (*Cercopithecus nictitans*) from Cameroon.. Ninth Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, February 24-28, 2002.
196. Van Dooren S., Switzer W.M., Heneine W., Goubau P., Verschoor E., Parekh B., De Meurichy W., Furley C., Van Ranst M., **Vandamme A.-M.** Lack of evidence for infection with simian immunodeficiency virus in bonobos. 9th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, USA, March 17-20, 2002.
197. Lemey P., Salemi M., Wang B., Saksena N.K., **Vandamme A.-M.** Calculating a time-scale for the SIV/HIV-2 phylogeny using an improved site stripping for clock detection procedure. 9th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, USA, March 17-20, 2002.
198. Robbins K., Lemey P., Pybus O.G., Schable C.A., Saekhou A.M., Brown T.M., Jaffe H.W., **Vandamme A.-M.**, Kalish M.L. Characterization of early U.S. HIV-1 strains, dating of the introduction of HIV into the U.S. and estimation of population history of the U.S. epidemic. 9th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, USA, March 17-20, 2002.
199. de Oliveira T., Salemi M., Bishop K., Tarin M., Engelbert S., **Vandamme A.-M.**, Cassol S. Detecting Adaptive Molecular Evolution in HIV-1 Subtype C Complete Genome. 9th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, USA, March 17-20, 2002.
200. Courgnaud V., Salemi M., Pourrut X., Mpoudi-Ngole E., Abela B., Auzel P., Bibollet-Ruche F., Hahn B., **Vandamme A.-M.**, Delaporte E., Peeters M. Molecular characterization of a novel simian immunodeficiency virus with a *vpu* gene from greater spot-nosed monkeys (*Cercopithecus nictitans*) from Cameroon 9th

International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, USA, March 17-20, 2002.

201. **Vandamme A.-M.** The simian origin of AIDS Third meeting of The FNRS Contact Group "Primateology" and the "Belgian Group for Primateology", Antwerp, Belgium, April 19, 2002. *Primate Tidings* 6, 4-5, 2002. Invited speaker.
202. **Vandamme A.-M.** Entry Inhibitors in Clinical Practice. 2002 Symposium of the Belgian AIDS Reference Laboratories and Centers: 'Treatment and follow-up of HIV infected patients in Belgium', 24 May, Neerijse, Belgium. Invited speaker.
203. Zeitler N., Schmidt B., Korn K., Keulen W., Boucher C.A.B., Beerenwinkel N., Selbig J., **Vandamme A.-M.**, Winslow D.L., Shafer R., Schapiro J.M., Boulmé R., Schmit J.C. & Walter H. Determination of the optimal cut-offs for predicting the phenotype of nine different HIV drug resistance algorithms. XI International HIV Drug Resistance Workshop, Sevilla, Spain, July 2-5, 2002.
204. Derdelinckx I., Van Laethem K., Maes B., Schrooten Y., Dewit S., Florence E., Fransen K., García Ribas S., Marissens D., Moutschen M., Van Wijngaerden E., Vaira D., Zisis G., Van Ranst M. and **Vandamme A.-M.** Drug Resistance among Therapy-naïve HIV-infected Patients Studied by Sequencing and VERSANT™ HIV-1 Resistance Assays (LiPA) Has Limited Impact on Treatment Response. XI International HIV Drug Resistance Workshop, Sevilla, Spain, July 2-5, 2002.
205. Wolf K., Walter H., Schnell T., Keulen W., Beerenwinkel N., Selbig J., **Vandamme A.-M.**, Korn K., and Schmidt B. The Drug Resistance Profile of Tenofovir: a Story of Resistance and Resensitization. XI International HIV Drug Resistance Workshop, Sevilla, Spain, July 2-5, 2002.
206. Kantor R., Katzenstein D., Gonzales M., Sirivichayakul S., Cane P., Pillay C., Snoeck J., Grossman Z., **Vandamme A.-M.**, Morris L., Pillay D., Phanuphak P., Schapiro J.M. and Shafer R.W. Influence of subtype and treatment on genetic profiles of HIV-1 RT and protease: Do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences? XI International HIV Drug Resistance Workshop, Sevilla, Spain, July 2-5, 2002
207. Derdelinckx I., Van Vaerenbergh K., De Geest S., Bobbaers H., Carbonez A., Deschamps A., De Graeve V., De Saar V., Ceunen H., De Smet K., Maes B., Peetermans W., Schrooten Y., Desmyter J., De Clercq E., Van Ranst M, Van Wijngaerden E. and **Vandamme A.-M.** A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002, abstract WePeB5870.

208. Deschamps A, De Saar V, De Graeve V, Van Wijngaerden E. **Vandamme A.-M.**, Van Vaerenbergh K, Ceunen H, Bobbaers H and De Geest S. Diagnostic value of measurement methods of adherence to HAART in HIV-infected persons. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002, abstract ThPpB2136.
209. Wensing A.M.J., Albert J., Balotta C., Camacho R., Clotet B., Fleckenstein B., Hall W., Hatzakis A., Holm-Hansen C., Horban A., Loveday C., Nielsen C., Puchhammer-Stöckl E., Salminen M., Schmit J.C., Schuurman R., **Vandamme A.-M.**, and Boucher C.A.B., on behalf of the SPREAD-representatives. Systematic Surveillance of Transmission of HIV Resistance in Europe. The SPREAD Project. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002, abstract TuPeF5370.
210. Kantor R., Katzenstein D., Cane P.A., Morris L., Snoeck J., **Vandamme A.-M.**, Pillay C., Pillay D., Schapiro J., Shafer R.W. Classical subtype B resistance mutations and novel candidate non-subtype B resistance mutations in treated persons with non-B HIV-1 isolates. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract TuPeB4614.
211. Snoeck J., Riva C., Carr J.K., McCutchan F.E., **Vandamme A.-M.** Preliminary evidence for another HIV-1 circulating recombinant form containing segments from an unknown subtype. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract A10038.
212. Debaisieux L., Van Laethem K., **Vandamme A.-M.**, Schrooten Y., Delforge M. L., Liesnard C. HIV-1 resistance testing using a commercial kit can be performed reliably without prior sequencing experience. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract B10187.
213. Magiorkinis G., Paraskevis D., **Vandamme A.-M.**, Magiorkinis E., Hatzakis A. Determination of the HIV-1 intersubtype recombination hot-spots: Evidence for significant correlation between the intersubtype recombination frequency and sequence similarity. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract TuPeA4413.
214. Fikkert V., Cherepanov P., Van Laethem K., Hantson A., Van Remoortel B., Pannecouque C., De Clercq E., Debyser Z., **Vandamme A.-M.**, Witvrouw M. Chimeric Virus Technology (CVT) for HIV env-genes to evaluate the resistance/susceptibility profile towards HIV entry inhibitors. XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract MoPeB3145.
215. Courgnaud V., Salemi M., Pourrut X., Mpoudi-Ngole E., Abela B., Auzel P., Bibollet-Ruche F., Hahn B., **Vandamme A.-M.**, Delaporte E., Peeters M. Molecular characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (*Cercopithecus nictitans*) from Cameroon XIV

International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract TuPeA4408

216. Peeters M., Liegeois F., Auzel P., Van Dooren S., Mpoudi-Ngole E., Abela B., Loul S., Pourrut X., Butel C., Cournaud V., **Vandamme A.-M.**, Delaporte E. STLV prevalences in wild primate populations in Cameroon: evidence for dual STLV-1 and STLV-3 infection XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. Abstract A10024
217. Celis L., Schmit J.C., Kaye S., De Mendoza C., Verhofstede C., **Vandamme A.-M.**, De Boeck K., De Brauwer A., De Smet K., Louwagie J. and Hulstaert F. External performance analysis of the VERSANT[®] HIV-1 RT Resistance Assay (LiPA). Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 17-21 November 2002.
218. Deschamps A, De Saar V, De Graeve V, Van Wijngaerden E. **Vandamme A.-M.**, Van Vaerenbergh K, Ceunen H, Bobbaers H and De Geest S. Diagnostic value of measurement methods of adherence to HAART in HIV-infected persons. 12th EANAC conference: Facing the future: Sexual Health and HIV Nursing in Europe, Manchester, UK, October 25-27, 2002.
219. **Vandamme A.-M.** The molecular epidemiology of HIV infection in Europe. 3rd Portuguese Workshop on HIV infection, Lisbon, Portugal, November 25-26, 2002. Invited speaker.
220. **Vandamme A.-M.** Clinical implementation of HIV drug resistance testing. 'Moleculaire HIV diagnostiek anno 2002: de stand van zaken. Breda, The Netherlands, December 5, 2002. Invited speaker.
221. **Vandamme A.-M.** Resistance and interpretation systems. 7th AREVIR-meeting. Köln, Germany, 17 January 2003. Invited speaker.
222. Kantor R., Katzenstein D., Gonzales M., Carvalho A.P., Wynhoven B., Soares M.A., Cane P.A., Snoeck J., Sirivichayakul S., Ariyoshi K., Holguin A., Pillay C., Grossman Z., Rodrigues R., Bouzas M.B., Cahn P., Brigido L.F., Morris L., Soriano V., Sugiura W., Phanuphak P., **Vandamme A.-M.**, Pillay D., Tanuri A., Harrigan P.R., Camacho R., Schapiro J., Shafer R.W. Genotypic analyses of RT and protease sequences from persons infected with nonsubtype B HIV-1. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 10-14, 2003.
223. Snoeck J., Van Laethem K., Schrooten Y., Derdelinckx I., Van Wijngaerden E., and **Vandamme A.-M.** Evaluation of Two Interpretation Algorithms for the Prediction of Drug Susceptibility in Non-B Subtype Viruses. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.

224. Zeitler N., Schmidt B., Korn K., Keulen W., Boucher C.A.B., Beerenwinkel N., Selbig J., **Vandamme A.-M.**, D.L. Winslow, Shafer R., Schapiro J.M., Boulmé R., Schmit J.C. and Walter H. About the Translation of Genotypic Resistance Interpretation in Phenotypic Resistance - Or: How Many Fold are Intermediate? First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
225. Derdelinckx I., Van Vaerenbergh K., De Wit S., Zissis G., Van Wanseele F., Verhofstede C., Florence E., Fransen K., Lacor P., Muyldermans G., Moutschen M., Vaira D., Debaisieux L., Van Dooren J.-P., De Boeck K., Louwagie J., Van Wijngaerden E., Van Ranst M. and **Vandamme A.-M.** Evolution of primary resistance in Belgium (1995-2000). First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
226. Wensing A.M.J., Keulen W., van de Vijver D.A.M.C., Been-Tiktak A.M., Buss N. and Boucher C.A.B. on behalf of all GREAT-investigators. Use of HIV-1 genotype interpretation system (RetroGram™) enables prediction of the viral RNA response in HIV-1 infected patients. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
227. Van Laethem K, Witvrouw M., Pannecouque C., Van Remoortel B., Balzarini J., De Clercq E., & **Vandamme A.-M.** Phenotypic resistance to tenofovir of a multinucleoside resistant HIV-1 strain containing Q151M in association with other specific mutations. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
228. Zimmer J.M., Boutonnet N., **Vandamme A.M.**, Schmit J.C. Structural Analysis of 40 HIV-1 Protease-Ligand Complexes. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
229. van de Vijver D.A.M.C., Schuurman R., Nielsen C., Salminen M., Albert J., **Vandamme A.-M.**, Coughlan S., and Boucher C.A.B. on behalf of the SPREAD-network. A statistical model that identifies protease inhibitor treatment associated mutations in therapy naïve patients infected with the Human Immunodeficiency Virus (HIV). First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.
230. Wensing A.M.J., van de Vijver D.A.M.C., Horban A., Stanczak G., Schmit J.C., Soriano V., de Mendoza C., Nielsen C., Schuurman R., de Wolf F., van Sighem A. and Boucher C.A.B. on behalf of the SPREAD-Network. Combined Analysis of resistance Transmission over time of Chronically and acute infected HIV patients in

Europe. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003.

231. **Vandamme A.-M.** on behalf of the European HIV Drug Resistance Guidelines Panel. HIV Drug Resistance Guidelines. European Issues. First European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Luxembourg, Luxembourg, March 6-8, 2003. Invited speaker.
232. Lemey P., Salemi M., Wang B., Saksena N.K., **Vandamme A.-M.** A molecular clock scan for the HIV-1 genome. 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
233. Salemi M., de Oliveira T., Soares M., Pybus O., **Vandamme A.-M.**, Cassol S., and Fitch W. M.. The recently introduced HIV-1 subtype C in Brazil appears to be two times more infectious than HIV-1 B subtype. 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
234. Paraskevis D., Lemey P., Salemi M., Suchard M., Ray S., Van de Peer Y., **Vandamme A.-M.** Analysis of the evolutionary relationships of the HIV-1 and the SIVcpz sequences using bayesian inference: Implications for the origin of HIV-1. 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
235. Lemey P., Pybus O. G., Salemi M., Wang B., Saksena N.K., Salemi M., **Vandamme A.-M.** Population dynamics of HIV-2 subtype A in rural Guinea-Bisseau. 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
236. Salemi M., De Oliveira T., Courgnaud V., Moulton V., Holland B., Cassol S., Switzer W.M., and **Vandamme A.-M.** The six major primate lentivirus (PLV) lineages have mosaic genomes. 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
237. de Oliveira T., Salemi M., Gordon M., **Vandamme A.-M.**, and Cassol S. Evolutionary evidence that HIV-1 Tat and Rev are targets of strong positive selection: new insights for designing an AIDS vaccine? 10th International Workshop on HIV Dynamics and Evolution, Lake Arrowhead, CA, USA, 13-16 April 2003.
238. Paraskevis D., Lemey P., Salemi M., Suchard M., Van de Peer Y., **Vandamme A.-M.**, Analysis of the evolutionary relationships of HIV-1 and SIVcpz sequences using Bayesian inference: implications for the origin of HIV-1. Belgian Bioinformatics Conference 2003, Leuven, Belgium, May 13, 2003.
239. Zlateva K., Lemey P., **Vandamme A.-M.**, and Van Ranst M. Circulation patterns and molecular evolution and epidemiology of human respiratory syncytial virus

subgroup A: positively selected sites in the attachment glycoprotein. Twelfth International Conference on Negative Strand Viruses in Pisa June 14th-19th, 2003.

240. Zlateva K.T., Lemey P., **Vandamme A.M.**, and Van Ranst M. Phylogeny and Rate of Evolution of Subgroup A Human Respiratory Syncytial Viruses. 9th International Workshop on virus Evolution and Molecular Epidemiology, Stanford, California, USA, 13-23, 2003.
241. Balzarini J., Van Laethem K., Hatse S., Vermeire K., De Clercq E., Peumans W., Van Damme E., **Vandamme A.-M.**, Schols D. Resistance development of human immunodeficiency virus by plant lectins from the Amaryllidaceae family. Glycovirology Meeting, Göteborg, Sweden, June 15-19, 2003.
242. Van Dooren S., P. Lemey and A-M. Vandamme. Scanning the PTLV Genome for a Molecular Clock, Evolutionary Rates and Selective Pressures. The eleventh International Conference on Human Retrovirology: HTLV and Related Viruses. June 9 - 12, 2003 San Francisco, USA.
243. Alcantara L.C., S. Van Dooren, M. Gonçalves, S. Kashima, M.C. Costa, F.L. Santos, A.L. Bittencourt, I. Dourado, A.A. Filho, D.T. Covas, A-M. Vandamme and B. Galvão-Castro. Globin Haplotypes of Human T-Cell Lymphotropic Virus Type I (HTLV-I) Infected Individuals in Salvador, Bahia, Brazil suggest a Postcolumbian African Origin of this Virus. The eleventh International Conference on Human Retrovirology: HTLV and Related Viruses. June 9 - 12, 2003 San Francisco, USA
244. Van Laethem K., Schrooten Y., Hatse S., Vermeire K., De Clercq E., Peumans W., Van Damme E., Schols D., **Vandamme A.-M.** and Balzarini J. *In vitro* resistance development of human immunodeficiency virus type 1 towards mannose-specific plant lectins. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo des Sol, Los Cabos, Mexico, 10-14 June 2003. Antiviral Therapy 2003 8:S29.
245. Kantor R., Carvalho AP., Wynhoven B., Soares MA., Cane P., Clarke J., Snoeck J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas MB., Cahn P., Brigido LF., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., **Vandamme A.-M.**, Weber J., Pillay D., Tanuri A., Harrigan PR., Camacho R., Schapiro JM., Shafer RW. & Katzenstein D. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo des Sol, Los Cabos, Mexico, 10-14 June 2003. Antiviral Therapy 2003 8:S58.
246. Snoeck J., Kantor R., Shafer RW., Derdelinckx I., Carvalho AP., Wynhoven B., Soares MA., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas MB., Van Laethem K., Brun-Vézinet F., Reid C., Cahn P.,

- Brigido LF., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan PR., Camacho R., Schapiro JM., Katzenstein D. & **Vandamme A.-M.** Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo des Sol, Los Cabos, Mexico, 10-14 June 2003. *Antiviral Therapy* 2003 8:S111.
247. Wensing AMJ., van de Vijver DAMC., Asjo B., Balotta C., Camacho R., de Mendoza C., Deroo S., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hoepelman A., Horban A., Korn K., Kuecherer C., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer E., Roman F., Salminen M., Schmit JCC., Soriano V., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Van Laethem K., Violin M., Yerly S., Zazzi M. & Boucher CAB. On behalf of the SPREAD Programme. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo des Sol, Los Cabos, Mexico, 10-14 June 2003. *Antiviral Therapy* 2003 8:S131
248. Abecasis A., Gomes P., Derdelinckx I., Carvalho AP., Diogo I., Gonçalves F., Cabanas J., Lobo MC., **Vandamme A.-M.** & Camacho R. L89I/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo des Sol, Los Cabos, Mexico, 10-14 June 2003. *Antiviral Therapy* 2003 8:S140. Poster
249. Van de Vijver DAMC., Schuurman R., Nielsen C., Salminen M., Albert J., **Vandamme A.-M.**, Coughlan S., Shafer R. & Boucher CAB. On behalf of the SPREAD-network. A systematic approach that identifies 11 new mutations as indicators of transmission of resistance. XII International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, Cabo del Sol, Los Cabos, Mexico, 10-14 June 2003. *Antiviral Therapy* 2003 8:S146.
250. Wensing AMJ., van de Vijver DAMC., Asjo B., Balotta C., Camacho R., de Luca A., de Mendoza C., Deroo S., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hoepelman A., Horban A., Korn K., Kuecherer C., Leitner T., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer E., Roman F., Ruiz L., Salminen M., Schmit JCC., Soriano V., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Van Laethem K., Violin M., Yerly S., Zazzi M. & Boucher CAB., on behalf of the SPREAD Programme. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH-Study. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July, 2003. Abstract LB01

251. Courgnaud V., Liegeois F., de Vos S., Butel C., Van Dooren S., Loul S., Abela B., Mpoudi-Ngole E., **Vandamme A.-M.**, Delaporte E., Peeters M.. STLV infection in wild primate populations in Cameroon: evidence for dual STLV-1 and STLV-3 infection in *Cercocebus agilis*. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July, 2003, Abstract 290. Antiviral Therapy 8, S256, 2003.
252. Paraskevis D., Magiorkinis E., Magiorkinis G., Lemey P., **Vandamme A.-M.**, Kiosses V.G., Theodoridou M., Papanicolaou V., Stavrianeas N. & Hatzakis A. Phylogenetic analysis of a transmission chain of the HIV-1 CRF04_CPX initially designated as "Subtype I" in Greece. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 13-16 July, 2003.
253. Derdelinckx I., Van Laethem K., Walter H., Di Giambenedetto S., Perno C. F., Antinori A., De Luca A., **Vandamme A.-M.** Evaluation of HIV Drug Resistance Interpretation Rules for Boosted Protease Inhibitors (PI) 43rd Annual ICAAC, Chicago, September 14-17, 2003. H-913
254. Zimmer J.M., Boutonnet N., Lasters I., De Maeyer M., **Vandamme A.M.**, Schmit J.C. In silico approach to support prediction of HIV-1 protease drug resistance positions 9th European AIDS Conferences (EACS) Warsaw, Poland, October 25-29, 2003.
255. Wensing A., van de Vijver D., Angarano G., Asjo B., Balotta C., Boeri E., Camacho R., De Luca A., de Mendoza C., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., Macrae E., Maljkovic I., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer E., Ruiz L., Salminen M., Schmit J., Schneider F., Schuurmann R., Soriano V., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., Boucher C. Drug susceptibility patterns in 195 european patients de novo infected with drug resistant virus: implications for post-exposure prophylaxis. 9th European AIDS Conferences (EACS) Warsaw, Poland, October 25-29, 2003.
256. **Vandamme A.-M.** Genotypic HIV-1 drug resistance interpretation systems. 9th European AIDS Conferences (EACS) Warsaw, Poland, October 25-29, 2003. Invited speaker.
257. **Vandamme A.-M.** Recommendations for the use and interpretation of HIV drug resistance testing. 4th Portuguese Workshop on HIV infection, Lisbon, Portugal, November 24-25, 2003. Invited speaker.
258. **Vandamme A.-M.** Communication of resistance results and Euroguidelines. HIV symposium om resistens, Copenhagen, Denmark, December 2, 2003. Invited speaker.

259. Kantor R, Shafer R W, Efron B, Camacho R, Harrigan P R, Tanuri A, Pillay D, Weber J, **Vandamme A-M**, Phanuphak P, Sugiura W, Soriano V, Morris L, Schapiro J M, Katzenstein D, and The International Non-subtype B Working Group. HIV-1 Subtype-related Differences in Genotypic Evolution: Analysis of Subtypes B and C Reverse Transcriptase and Protease Sequences. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 10-14, 2003.
260. Zlateva K.T., Lemey P., Vandamme A.M., and Van Ranst M. Genetic variability among subgroup B human respiratory syncytial viruses with a 60 nucleotide duplication in the G-gene ectodomain, International Congress on Infectious Diseases, Cancun, Mexico, March 4-7, 2004.
261. Deforche K., Van Laethem K., Abecasis A., Snoek J., Carvalho A.P., Derdelinckx I., Gomes P., Cabanas J., Soares M.A., Brindeiro R.M., Tanuri A., Camacho R., **Vandamme A.-M.**. Bayesian Network reveals linkage for mutations at position 89 of HIV-1 protease to other protease codons and to antiviral therapy with protease inhibitors. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 53, 2004. Abstract 92. Poster
262. Van Laethem K. Schrooten Y., Van Ranst M., **Vandamme A.-M.** A genotypic assay for the detection of drug resistance in the HIV-1 envelope gene. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 59, 2004. Abstract 102.
263. Derdelinckx I., Van Laethem K., De Roo A., De Wit S., Fransen K., Kabamba B., Lacor P., Moutschen M., Muyldermans G., Vaira D., Vandercam B., Van Der Gucht B., Van Ranst M., Van Wijngaerden E., Verhofstede C., Clumeck N., Sasse A. and **Vandamme A.-M.** Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2003. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 6, 2004. Abstract 10.
264. Maes B., Y. Schrooten, J. Snoeck, I. Derdelinckx, M. Van Ranst, **A-M. Vandamme** and K. Van Laethem. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 60, 2004. Abstract 104.
265. Stanojevic M., Jevtovic D., Salemovic D., Van Laethem K., Schrooten Y., Jovanovic T. and **Vandamme A.-M.** Prevalence of mutations associated with antiretroviral drug resistance among newly diagnosed patients in Serbia and Montenegro. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical

- Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 7, 2004. Abstract 12.
266. Van de Vijver D.A.M.C., A.M.J. Wensing, E. Op de Coul, G. Angarano, B. Åsjö, C. Balotta, E. Boeri, R. Camacho, M-L. Chaix, D. Costagliola, A. de Luca, I. Maljkovic, C. de Mendoza, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, I.M. Hoepelman, R. Hemmer, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. MacRae, C. Nielsen, V. Ormaasen, L. Perrin, D. Paraskevis, E. Puchhammer-Stöckl, L. Ruiz, M. Salminen, J.C.C. Schmit, F. Schneider, R. Schuurman, V. Soriano, G. Stanczak, M. Stanojevic, **A-M. Vandamme**, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi and C.A.B. Boucher on behalf of the SPREAD Programme. Increasing prevalence of HIV-1 non-B subtypes across Europe from 1996-1999 to 2000-2002; results from the CATCH-study. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 2, 2004. Abstract 3.
267. Van de Vijver D, B. Brenner, D. Turner, P. Sandstorm, D. Dunn, H. Green, D. Bennet, W. Heneine, R. Shafer, T. Leitner, D. Costagliola, **A-M. Vandamme**, M. Wainberg, C. Boucher and R. Schuurman. A systematic approach to identify mutations that can be used in epidemiological studies on transmission of drug resistant HIV. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 10, 2004. Abstract 16.
268. Vergne L, J. Snoeck, A. Aghokeng, C. Mulanga, E. Mpoudi-Ngole, C. Toure-Kane, D. Valéa, G. Malonga-Mouellet, L. Zekeng, S. Mboup, **A-M. Vandamme**, E. Delaporte, M. Peeters and K. Van Laethem. Comparison of 3 interpretation algorithms for the prediction of drug resistance to NRTIs, NNRTIs and PLs in treatment naïve non-B HIV-1 strains. Second European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Rome, Italy, March 11-13, 2004. HIV Medicine 5, 48, 2004. Abstract 82.
269. Lemey P., I. Derdelinckx, E. Van Wijngaerden, **A-M. Vandamme**. Evolution under drug selective pressure can disturb phylogenetic inferences for HIV transmission chains. Eleventh International Workshop: HIV Dynamics & Evolution. Stockholm, April 29- May 2, 2004.
270. Abecasis A., D. Paraskevis, J. Vera, A.P. Carvalho, P. Gomes, **A-M. Vandamme**, R. Camacho. Analysis of BF recombinant sequences: Identification of a new recombination pattern in Portuguese intravenous drug users. Eleventh International Workshop: HIV Dynamics & Evolution. Stockholm, April 29- May 2, 2004. Poster
271. Paraskevis D, Deforche K, Lemey P, Abecasis A, Magiorkinis G, Hatzakis A, Camacho R, **Vandamme A-M**. Development of SlidingBayes for exploring

recombination using a sliding window approach based on Bayesian phylogenetic inference: Application on the analysis of complex SIV and HIV recombinants. Eleventh International Workshop: HIV Dynamics & Evolution. Stockholm, April 29-May 2, 2004. Oral

272. Kantor R, D Katzenstein, S Y Rhee, A P Carvalho, B Wynhoven, M A Soares, P Cane, J Clarke, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, H Rudich, R Rodrigues, M B Bouzas, P Cahn, L Brigido, Z Grossman, L Morris, V Soriano, W Sugiura, P Phanuphak, **A M Vandamme**, J Weber, D Pillay, A Tanuri, P R Harrigan, R Camacho, J M Schapiro, R W Shafer. HIV-1 protease and RT mutations according to subtype and antiretroviral therapy: A watch list for epidemiologic studies using a web-based application. XV International AIDS Conference, Bangkok, 2004. Abstract no. MoPeC3446. MedGenMed. 2004 Jul 11;6(3):MoPeC3446 [eJIAS. 2004 Jul 11;1(1):MoPeC3446]
273. Salemi M, T de Oliveira, M A Soares, O G Pybus, A T Dumans, A Tanuri, **A M Vandamme**, S Cassol, W M Fitch. HIV-1 C subtype in Southern Brazil seems to be two times more infectious than HIV-1 B. XV International AIDS Conference, Bangkok, 2004. Abstract no. TuPeA4370. MedGenMed. 2004 Jul 11;6(3):TuPeA4370 [eJIAS. 2004 Jul 11;1(1):TuPeA4370]
274. de Oliveira T, M Salminen, S Cassol, R Camacho, K Deforche, D Pavareskevis, C Seebregts, J Snoeck, **A M Vandamme**. An automated HIV-1 subtyping tool. XV International AIDS Conference, Bangkok, 2004. Abstract no. TuPeA4377. MedGenMed. 2004 Jul 11;6(3):TuPeA4377 [eJIAS. 2004 Jul 11;1(1):TuPeA4377]
275. Lemey P., Pybus O., Rambaut A., Drummond A.J., Robertson D.L., Roques P., Worobey M., & **Vandamme A.M.** Inferring the epidemic history of HIV-1 group O. 7th international meeting on molecular epidemiology and evolutionary genetics of infectious diseases, Valencia, Spain, July 18-22, 2004.
276. Gordon M., Graham N., Bland R., Rollins N., De Oliveira T., Monosi B., Van Laethem K., **Vandamme A.-M.** and Cassol S. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. XIII International HIV Drug Resistance workshop: basic principles & clinical implications, Tenerife, Spain, June 8-12, 2004.
277. van de Vijver D., Brenner B., Turner D., Sandstrom P., Dunn D., Green H., Bennett D., Heneine W., Shafer R., Leitner T., Costagliola D., **Vandamme A.-M.**, Wainberg M., Boucher C. and Schuurman R. Validation of molecular indicators of resistance transmission (MIRTs) for epidemiological studies of drug resistance transmission in HIV. XIII International HIV Drug Resistance workshop: basic principles & clinical implications, Tenerife, Spain, June 8-12, 2004.

278. van de Vijver D.A.M.C., Wensing A.M.J., Agarano G., Asjö B., Balotta C., Boeri E., Camacho R., Chaix M.-L., Costagliola D., Op de Coul E., de Luca A., Maljkovic I., de Mendoza C., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hoepelman I.M., Hemmer R., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Meyer L., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Van Laethem K., violin M., Wilbe K., Yerly S., Zazzi M. and Boucher C.A.B. on behalf of the SPREAD Programme. The calculated genetic barrier for drug resistance mutations in six different non-B subtypes and two CRFs in a large European dataset is largely similar to subtype B. XIII International HIV Drug Resistance workshop: basic principles & clinical implications, Tenerife, Spain, June 8-12, 2004.
279. Camacho R., Deforche K., Valadas M.E., Van Laethem K., Aguas M.J., Vera J., Rosado L., Batista T., Bezerra V., Soares I., Branco T., Mouzinho A., Teófilo E., Faria T., Abecasis A., Gomes P., Carvalho A.P. and **Vandamme A.-M.** Nelfinavir resistance in HIV-1 subtype B and G infected patients: evidence for different pathways and novel mutations associated with failure of nelfinavir based regimens. XIII International HIV Drug Resistance workshop: basic principles & clinical implications, Tenerife, Spain, June 8-12, 2004. Poster
280. Snoeck J., Kantor R., Shafer R.W., Van Laethem K., Deforche K., Carvalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Reid C., Cahn P., Brigido L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan P.R., Camacho R., Schapiro J.M., Katzenstein D. and **Vandamme A.-M.** Discordance between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent. XIII International HIV Drug Resistance workshop: basic principles & clinical implications, Tenerife, Spain, June 8-12, 2004.
281. Zlateva K.T., Lemey P., **Vandamme A.M.**, and Van Ranst M. Molecular epidemiology and evolution of subgroup B HRSV. 2nd European Congress of Virology, Madrid, Spain, September 5-9, 2004.
282. **Vandamme A.-M.** Simian to human transmission of retroviruses - holistic view. Second Brazilian workshop on virus evolution and molecular epidemiology, Salvador, Bahia, Brazil, November 8-13, 2004. Invited speaker.
283. Mikhail M, Wang B, Lemey P, Beckholdt B, **Vandamme A M**, Gill M, and Saksena N. Can Epidemiologic Linkage in Chronically HIV-1-infected Cohorts Be Established? 12th Conference on Retroviruses and Opportunistic Infections February 22–25, 2005, Boston, MA, USA, Abstract 364.

284. van de Vijver D.A.M.C., Wensing A.M.J., Asjo B., Bruckova M., Bruun Jorgensen L., Horban A., Linka M., Lazanas M., Loveday C., MacRai E., Nielsen C., Paraskevis D., Poljak M., Puchhammer-Stöckl E., Ruiz L., Schmit J.C.C., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Vercauteren J. and Boucher C.A.B on behalf of the SPREAD programme. Frequency of antiretroviral drug resistance associated mutations in sequences from treated individuals across Europe: the CAPTURE study. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.
285. Deforche K., Camacho R., Grossman Z., Soares M.A., Shafer R.W., Van Laethem K., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Cahn P., Brigido L.F., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan P.R., Schapiro J.M., Katzenstein D., Kantor R. and **Vandamme A.-M.** Applying Bayesian networks to study nelfinavir resistance pathways in subtypes A, B, C, F and G. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.
286. Vercauteren J., Derdelinckx I., Deforche K., Deroo A., De Wit S., Farber M., Fransen K., Kabamba B., Lacor P., Liesnard C., Moutschen M., Muyldermans G., Schrooten Y., Vaira D., Vandercam B., Van Der Gucht B., Van Laethem K., Van Ranst M., Van Wijngaerden E., Verhofstede C., Clumeck N., Sasse A. and **Vandamme A.-M.** Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2004. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.
287. Stanojevic M., Jevtovic D.J., Salemovic D., Van Laethem K., Schrooten Y., Jovanovic T. and **Vandamme A.-M.** Persistence of transmitted drug-resistant virus containing Q151M mutation. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.
288. van de Vijver D.A.M.C., Wensing A.M.J., Angarano G., Asjo B., Balotta C., Boeri E., Camacho R., Chaix M.-L., Costagliola D., Op de Coul E.L.M., de Luca A., Maljkovic I., de Mendoza C., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hoepelman I.M., Hemmer R., Horban A., Korn K., Kücherer C., Leitner T., Loveday C., MacRae E., Meyer L., Nielsen C., Ormaasen V., Perrin L., Paraskevis D., Puchhammer-Stöckl E., Ruiz L., Salminen M., Schmit J.C.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M. and Boucher C.A.B. on behalf of the SPREAD Programme. Potential impact of differences in frequency of minor substitutions between HIV-1 subtypes on the genetic barrier for resistance to protease inhibitors. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.

289. Abecasis A.B., Deforche K., Bachelier L.T., McKenna P., **Vandamme A.-M.** and Camacho R. Lack of reduced susceptibility to PIs in wild-type non-B subtypes and detection of hypersusceptibility to nelfinavir in HIV-1 patients infected with CRFO2_AG. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005. Oral
290. Grossman Z., Maayan S., Averbuch D., Istomin V., Rudich H., Ram D., Mendelson E., Deforche K., **Vandamme A.-M.** and Schapiro J.M. Differential impact of polymorphic substitutions at position 89 of the protease gene on resistance to protease inhibitors in subtype C-patients. Third European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications. Athens, Greece, March 30-April 1, 2005.
291. Vermeire K, Van Laethem K, **Vandamme A.-M.**, Bell Th, De Clercq E & Schols D. Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor. 18th International Conference on Antiviral Research, Barcelona, Spain, April 11-14, 2005
292. Abecasis A, Lemey P, Paraskevis D, Carvalho AP, Palma AC, Hatzakis A, Gomes P, Vera J, Camacho R, **Vandamme AM.** Estimating the date of the most recent common ancestor (MRCA) of sub-subtype F1. 12th International Workshop of HIV Dynamics and Evolution. April 23-26 2005, Cleveland, Ohio, USA. Oral
293. Gonzalez LMF, Van Laethem K, Abecasis AB, Soares EAJM, Deforche K, **Vandamme AM**, Camacho R and Soares MA. Role of HIV-1 protease residues 71 and 89 in protease inhibitor resistance of subtype G viruses. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 102. Antiviral Therapy 2005; 10:S112 . Poster
294. Z Grossman, S Maayan, D Averbuch, V Istomin, Rudich H, Ram D, Mendelson E, Deforche K, **Vandamme AM** and Schapiro JM. Substitution of methionine at position 89 of the protease gene by other amino-acids occurs differentially during selection of particular resistance pathways in subtype C-patients. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 105. Antiviral Therapy 2005; 10:S115
295. van de Vijver DAMC, Wensing AMJ, Åsjö B, Bruckova M, Bruun Jorgensen L, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JCC, Stanczak G, Stanojevic M, **Vandamme A-M**, Vercauteren J and Boucher CAB on behalf of the SPREAD Programme Selective transmission of drug resistance mutations. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 113. Antiviral Therapy 2005; 10:S126

296. Deforche K, Camacho R, Grossman Z, Silander T, Soares MA, Shafer RW, Van Laethem K, Carvalho AP, Wynhoven B, Cane P, Clarke J, Snoeck J, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Cahn P, Brigido LF, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan PR, Schapiro JM, Katzenstein D, Kantor R and **Vandamme AM**. Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 119. *Antiviral Therapy* 2005; 10:S132
297. Deforche K, R Camacho, Z Grossman, T Silander, MA Soares, RW Shafer, K Van Laethem, Carvalho AP, Wynhoven B, Cane P, Clarke J, Snoeck J, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Cahn P, Brigido LF, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan PR, Schapiro JM, Katzenstein D, Kantor R and **Vandamme A-M**. Interactions between nevirapine resistance mutations and NRTI resistance mutations. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 131 .*Antiviral Therapy* 2005; 10:S144
298. van de Vijver DAMC, Wensing AMJ, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, Op de Coul ELM, de Luca A, Maljkovic I, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman IM, Hemmer R, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Meyer L, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JCC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, **Vandamme A-M**, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M and Boucher CAB on behalf of the SPREAD Programme. Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 132. *Antiviral Therapy* 2005; 10:S145
299. Kantor R, DeLong A, Shafer RW, Carvalho AP, Wynhoven B, Cane P, Sirivichayakul S, Soares MA, Snoeck J, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, **Vandamme AM**, Tanuri A, Phanuphak P, Weber J, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Hogan J and Katzenstein DA.. Selection of resistance following first-line antiretroviral regimens among HIV-1 subtypes. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 133 . *Antiviral Therapy* 2005; 10:S146

300. Camacho R, Godinho AR, Gomes P, Abecasis A, **Vandamme A-M**, Palma C, Carvalho AP, Cabanas J and Gonçalves J. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutation. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 138. *Antiviral Therapy* 2005; 10:S151. Poster
301. **Vandamme A-M**, Deforche K, Van Laethem K and Camacho R. HIV-1 subtype A1, C, F and G strains have a higher tipranavir mutation score than subtype B strains. XIV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 7-11 June 2005, Quebec, Canada, abstract 139. *Antiviral Therapy* 2005; 10:S152
302. Gotuzzo E., Moody J., Verdonck K., Cabada M., Gonzalez E., Cairampoma R., **Vandamme A.-M.**, Terashima A. & Vermund S.H. HTLV-1 mother-to-child transmission among peruvian women with Tsp/Ham or stronglyloides stercoralis. 12nd international conference on human retrovirology, Montego Bay, Jamaica June 22-25, 2005.
303. Van Dooren S., Lemey P., Pybus O.G. & **Vandamme A.** Comparison of human T-cell lymphotropic virus introductions and evolutionary rates using Bayesian methods. 12nd international conference on human retrovirology, Montego Bay, Jamaica June 22-25, 2005.
304. Wensing A.M.J., van de Vijver D.A.M.C., Vercauteren J., Albert J., Bratt G., Clumeck N., Coughlan S., Grossman Z., Hatzakis A., Horban A., Jevtovic D., Bruun Jørgensen L., Kuecherer C., Lange J., Nielsen C., Paraskevis D., Poggensee G., Puchhammer-Stöckl E., Schmit J.-C., Stanczak G., Stanojevic M., **Vandamme A.-M.**, Boucher C.A.B. Comparative disease progression observed in newly diagnosed patients infected with drug resistant and susceptible HIV-1: no signs for increased virulence. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil 24-27 July 2005, abstract WeOaLB0101.
305. Arrais TC, Thiers V, Rimlinger F, Brechot C, **Vandamme A-M**, Van Dooren S, Perez R, Ferraz MLG. A phylogenetic analysis to evaluate the outcome of chronic hepatitis C in hemodialysis patients after interferon monotherapy. 11th International Workshop on virus evolution and molecular epidemiology, 5 September – 9 September, 2005, Petrópolis, Brazil.
306. **Vandamme A-M**. HTLV and HIV molecular epidemiology: dating their zoonotic origin. BioSapiens-viRgil Workshop on Bioinformatics for Viral Infections . Bonn, 21-23 Sept, 2005. Invited speaker.
307. **Vandamme A.-M.** HTLV and HIV molecular epidemiology: dating their zoonotic origin. Origins, transmission resistance and susceptibility to AIDS and related

viruses: The evolution, cross-species transmission and pathogenesis of lentiviruses. Meeting organised by the Clinical Immunology & Allergy Section, The Royal Society of Medicine, London November 7, 2005. Invited speaker.

308. **Vandamme A.-M.**, HIV-1 subtypes and drug resistance. Minisymposium HIV fitness and drug resistance, University of Antwerp, Belgium, Dec. 7, 2005. Invited speaker.
309. Van Laethem K, Y Schrooten, P Lemey, K Deforche, M Van Ranst, E Van Wijngaerden, and **A-M Vandamme**. Consecutive Transmission of Dual-class Resistant HIV-1 in Untreated Patients. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, USA, Febr 5-8, 2006. Poster 643.
310. Paraskevis D, A Rambaut, G Magiorkinis, A Hatzakis, A M Wensing, D Van De Vijver, C Boucher, and **A-M Vandamme**. Estimation of HIV-1 Subtype B Migration within Europe and between Europe and the United States Based on Phylogenetic Analyses of 1101 Sequences. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, USA, Febr 5-8, 2006. Poster 315.
311. Abecasis A, Lemey P, de Oliveira T, Rambaut A and **Vandamme A.-M.** Re-analysis of HIV-1 pure subtypes: evidence of a recombinant origin of subtype G and the consequences for HIV-1 classification. 13th International Workshop on HIV Dynamics and Evolution, Woods Hole, USA, April 5-8, 2006. Oral
312. **Vandamme A.-M.**, Cassol S. Antiviral drug resistance and therapy response in HIV infected patients. RSA-Flanders. 10 Years Celebration for Science & Technology Cooperation. 13-15 March 2006, Cape Town. South-Africa. Invited speaker
313. **Vandamme A.-M.** Clinical update on CCR5 inhibitors. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco. Invited speaker.
314. **Vandamme A.-M.**, European Resistance Guidelines. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco. Invited speaker.
315. van de Vijver D.A.M.C., A.M.J. Wensing, B. Åsjö, M. Bruckova, F. Brun-Vézinet, L. Bruun Jorgensen, R. Camacho, A. Horban, M. Linka, M. Lazanas, C. Loveday, E. MacRae, C. Nielsen, D. Paraskevis, M. Poljak, E. Puchhammer-Stöckl, L. Ruiz, J.C.C. Schmit, G. Stanczak, M. Stanojevic, **A.-M. Vandamme**, J. Vercauteren, M. Zazzi, and C.A.B. Boucher on behalf of the SPREAD Programme. Substantial concordance for predicting susceptibility to antiretroviral drugs in 2000 isolates using three European HIV drug resistance interpretation systems. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 4. Reviews in Antiviral Therapy 2006; 2: 19-20.

316. van de Vijver D.A.M.C., A.M.J. Wensing, B. Åsjö, M. Bruckova, L. Bruun Jorgensen, R. Camacho A. Horban, M. Linka, M. Lazanas, C. Loveday, E. MacRae, C. Nielsen, D. Paraskevis, M. Poljak, E. Puchhammer-Stöckl, L. Ruiz, J.C.C. Schmit, G. Stanczak, M. Stanojevic, **A.-M. Vandamme**, J. Vercauteren, M. Zazzi, and C.A.B. Boucher on behalf of the SPREAD Programme. Patterns of predicted drug susceptibility and its change over time among 2000 isolates across Europe: the CAPTURE study. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 13. *Reviews in Antiviral Therapy* 2006, 2: 25.
317. van de Vijver D.A.M.C., P. Sloot A. Hoekstra, B. Ó Nualláin, A. Tirado-Ramos, S. Wesner, A. De Luca, L. Ruiz, C. Torti, **A.-M Vandamme**, V. Müller, P. Plaszczak, M. Bubak, P. Coveney, W. Keulen, C.A.B. Boucher on behalf of the ViroLab project. ViroLab – A virtual laboratory for decision support in viral diseases treatment. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco , abstract 71. *Reviews in Antiviral Therapy* 2006, 2: 57.
318. Paraskevis D., A. Rambaut, G. Magiorkinis, A. Hatzakis, A.M.J. Wensing, D.A. van de Vijver, G. Angarano, B. Åsjö, C. Balotta, E. Boeri, R. Camacho, M.-L. Chaix, D. Costagliola, A. De Luca, C. deMendoza, Derdelinckx, Z. Grossman, O. Hamouda, R. Hemmer, A. Hoepelman, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. MacRae, I. Maljkovic, L. Meyer, C. Nielsen, E.L.M. Op de Coul, V. Ormaasen, L. Perrin, E. Puchhammer-Stöckl, L. Ruiz, M. Salminen, J.-C. Schmit, F. Roman, R. Schuurman, V. Soriano, G. Stanczak, M. Stanojevic, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi, C.A. Boucher and **A.-M. Vandamme**, for the CATCH Programme. Estimation of HIV-1 subtype B Migration within Europe based on phylogenetic analyses of 1001 sequences. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, , abstract 2. *Reviews in Antiviral Therapy* 2006, 2: 18.
319. Vercauteren J., K. Van Laethem, K. Deforche, M. Bogaert, H. Ceunen, S. De Wit, F. Echahidi, CM. Farber, K. Fransen, JC. Goffard, E. Goudeseune, A. Henry, P. Lacor, C. Liesnard, M. Moutschen, D. Pierard, R. Rens, Y. Schrooten, D. Vaira, B. Vandercam, A. Van den Heuvel, B. Van Der Gucht, M. Van Ranst, E. Van Wijngaerden, C. Verhofstede, N. Clumeck, A. Sasse and **A.-M. Vandamme**. Prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium prospectively collected from 2003 to 2005 is significantly higher than 5%. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, , abstract 16. *Reviews in Antiviral Therapy* 2006, 2: 26. Poster.
320. Deforche K, R Camacho, K Theys, K Van Laethem, and **AM Vandamme**. Variation in estimated rate for developing resistance mutations in treatment naive HIV isolates. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 99. *Reviews in Antiviral Therapy* 2006, 2: 70. Poster.

321. Covens K, J Weber, W Meersseman, P Lemey, K Lagrou, M Van Ranst, E Van Wijngaerden, M Quiñones-Mateu, **A-M Vandamme** and K Van Laethem. Fatal brain necrosis in primary HIV-1 infection despite treatment: Viral characterization. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 68. *Reviews in Antiviral Therapy* 2006, 2: 55. Poster.
322. Van Laethem K, Y Schrooten, P Lemey, K Covens, M Van Ranst, E Van Wijngaerden, **A-M Vandamme**. Consecutive transmission of dual-class resistant HIV-1 with the development of a secondary protease mutation in untreated patients. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 9. *Reviews in Antiviral Therapy* 2006, 2: 22. Poster.
323. Wensing AMJ, J Vercauteren, DA van de Vijver, J Albert, G Poggensee, JC Schmit, D Struck, **AM Vandamme**, B Asjo, C Balotta, R Camacho, S Coughlan, Z Grossman, A Horban, K Korn, C Nielsen, D Paraskevis, E Puchhammer-Stockl, C Riva, L Ruiz, R Schuurman, M Salminen, A Sonnerborg, M Stanojevic and CAB Boucher on behalf of the SPREAD-programme. First representative prospective surveillance data on HIV baseline drug resistance from 17 countries in Europe; the SPREAD-programme. 4th European HIV Drug Resistance Workshop, 29 - 31 March 2006, Monaco, abstract 1. *Reviews in Antiviral Therapy* 2006, 2: 18. Oral.
324. Deforche K, Camacho R, Van Laethem K, Lemey P, Moreau Y, **Vandamme A-M**. Predicting in vivo evolution of HIV under treatment based on mutation, fitness and epistasis as first principles. Workshop on Quantitative Methods for Research on Antiviral Resistance, Boston, MA May 11-12, 2006. Oral.
325. Wensing AMJ, J Vercauteren, DA van de Vijver, J Albert, G Poggensee, JC Schmit, D Struck, **AM Vandamme**, B Asjo, C Balotta, R Camacho, S Coughlan, Z Grossman, A Horban, K Korn, C Nielsen, D Paraskevis, E Puchhammer-Stockl, C Riva, L Ruiz, R Schuurman, M Salminen, A Sonnerborg, M Stanojevic and CAB Boucher on behalf of the SPREAD-program. Transmission of drug-resistance in Europe is characterized by single mutations and revertants. XV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 13-17 June 2006, Sitges, Spain, abstract 98. *Antiviral Therapy* 2006; 11:S111. Poster.
326. Camacho R, K Theys, A Abecasis, K Deforche, AP Carvalho, J Cabanas, P Gomes and **A-M Vandamme**. Rise and fall of the RT K65R incidence in the Portuguese resistance database. XV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 13-17 June 2006, Sitges, Spain, abstract 121. *Antiviral Therapy* 2006; 11:S134. Poster.
327. Camacho R, K Theys, A Abecasis, K Deforche, AP Carvalho, J Cabanas, P Gomes and **A-M Vandamme**. The in vivo selection of mutations L74I/V is linked to combined nucleoside reverse transcriptase and non-nucleoside reverse transcriptase inhibitor exposure. XV International HIV Drug Resistance Workshop: Basic

- Principles & Clinical Implications, 13-17 June 2006, Sitges, Spain, abstract 148. Antiviral Therapy 2006; 11:S164. Poster.
328. Deforche K, R Camacho, K Van Laethem, P Lemey, Y Moreau, **A-M Vandamme**. Predicting ordered accumulation of mutations of HIV under treatment using an estimate of the HIV in vivo fitness function during treatment. XV International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications, 13-17 June 2006, Sitges, Spain, abstract 168. Antiviral Therapy 2006; 11:S188. Poster.
329. **Vandamme AM**. European HIV Drug Resistance Guidelines - 2006 update. 2006 Annual meeting of the Belgian AIDS Reference Laboratories and AIDS Reference Centers, 19 June 2006; Brussels, Belgium. Invited speaker.
330. Paraskevis D., Beloukas A., Magiorkinis E., Magiorkinis G., **Vandamme A.-M.**, Albert J., Hatzakis A. Assessment of phylogenetic accuracy for reconstructing HIV-1 epidemiological relationships. XVI International AIDS Conference, Toronto, Canada, 13-16 August 2006. Abstract no. WEPE0026. Poster.
331. Wensing A.M., Vercauteren J., Vijver D.A., Albert J., Poggensee G., Schmit J.-C., Struck D., **Vandamme A.M.**, Åsjö B., Balotta C., Camacho R., Coughlan S., Grossman Z., Horban A., Kücherer C., Nielsen C., Paraskevis D., Puchhammer-Stöckl E., Riva C., Ruiz L., Salminen M., Schuurman R., Sonnerborg A., Stanojevic M., Boucher C.A., on behalf of the SPREAD-programme. Transmission of HIV drug resistance in Europe. XVI International AIDS Conference, Toronto, Canada, 13-16 August 2006. Abstract no. TUAB0101. Oral.
332. Paraskevis D., A. Abecasis, J. Vercauteren, A.M.J. Wensing, D.A. van de Vijver, J. Albert, B. Åsjö, C. Balotta, R. Camacho, S.Coughlan, Z. Grossman, A. Hatzakis, A. Horban, K. Korn, C. Nielsen, D. Pillay, G. Poggensee, E. Puchhammer-Stockl, C. Riva, L. Ruiz, J.-C. Schmit, R. Schuurman, M. Salminen, A. Sonnerborg, M. Stanojevic, D. Struck, **A.-M. Vandamme** and C. AB Boucher on behalf of the SPREAD-programme. Prevalence of HIV-1 subtypes among newly HIV-1 diagnosed individuals during 2002-2003 in Europe: Evidence for a continuous introduction of non-B subtypes. 1st International Workshop on HIV Transmission - Principles of Intervention, Toronto, Canada, 11 and 12 August 2006. Oral.
333. Resik S, Lemey Ph, Ping L-H, Kouri V, Joanes J, Perez J, **Vandamme A.-M.**, Swanstrom R. Limitations to contact tracing and phylogenetic analysis in establishing HIV transmission networks in Cuba. 12th International Bioinformatics Workshop on virus evolution and molecular epidemiology, Athens, Greece, Sept. 11-15, 2006. Poster.
334. Salichos L, Abecasis A, Deforche K, Camacho R & **Vandamme A.-M.** Classification of Portuguese HIV-1 strains using the automated REGA HIV-1 Subtyping Tool V1.0 and further phylogenetic analysis 12th International Bioinformatics Workshop on

- virus evolution and molecular epidemiology, Athens, Greece, Sept. 11-15, 2006. Poster.
335. **Vandamme A.-M.** Genetic diversity of HIV-1 Clinical implications. 2006 Workshop Roche PCR, Amadora, Portugal, 27 October, 2006. Invited speaker.
 336. Deschamps A E., De Geest S, **Vandamme A-M**, Van Wijngaerden E. Diagnostic value of the 2-item Swiss HIV Cohort Study Adherence Questionnaire. Eighth International Congress on Drug Therapy in HIV Infection, Glasgow,UK, 12-16 Nov 2006 Poster nummer: 950176.
 337. Vercauteren J, K Theys, M Debruyne, AP Carvalho, **AM Vandamme**, R Camacho. Declining incidence of multidrug-resistant HIV-1 over time (2001-2006): which new drugs do we really need? Eighth International Congress on Drug Therapy in HIV Infection, Glasgow,UK, 12-16 Nov 2006. Oral.
 338. Deforche K, Camacho R, Van Laethem K, Lemey Ph, Rambaut A, Moureau Y & **Vandamme A.-M.** Estimating the *in vivo* HIV-1 fitness landscape to predict evolution during antiviral drug treatment. BioScope-IT Annual Meeting, Gent, Belgium, Nov. 24, 2006. Poster.
 339. Shwen Ho Y., A Abecasis, B Wang, K Theys, K. Deforche, **A.M. Vandamme** and N Saksena. Evidence for distinct patterns of HIV-1 N-linked glycosylation in *env* GP120 in diverse blood leukocytes populations and plasma *in vivo*. 14th Conference on Retroviruses and Opportunistic Infections (CROI), 25-28 February, 2007, Los Angeles, USA. Abstract 173. Poster
 340. Deforche K, P Lemey, R Camacho, K Van Laethem, B Shapiro, Y Moreau, A Rambaut and **A.M. Vandamme**. Understanding the adenine richness of the HIV genome through the estimation of misincorporation rates *in vivo*. 14th Conference on Retroviruses and Opportunistic Infections (CROI), 25-28 February, 2007, Los Angeles, USA. Abstract 212 Poster
 341. Theys K, K Deforche, R Camacho, K Van Laethem, P Lemey, Y Moreau and **A.M. Vandamme**. Estimating an *in vivo* fitness landscape during protease and reverse transcriptase treatment from observed genetic evolution to predict accumulation of mutations under selective pressure. 14th Conference on Retroviruses and Opportunistic Infections (CROI), 25-28 February, 2007, Los Angeles, USA. Abstract 635. Poster
 342. Wensing A.M., Vercauteren J., Vijver D.A., Albert J., Poggensee G., Schmit J.-C., Struck D., **Vandamme A.M.**, Åsjö B., Balotta C., Camacho R., Coughlan S., Grossman Z., Horban A., Kücherer C., Nielsen C., Paraskevis D., Puchhammer-Stöckl E., Riva C., Ruiz L., Salminen M., Schuurman R., Sonnerborg A., Stanojevic M., Boucher C.A., on behalf of the SPREAD-programme. Transmission of HIV drug

resistance in Europe. 11th International Workshop on HIV Observational Databases - Monte Carlo 2007. abstract 10C816. Poster.

343. Deschamps AE, Keymeulen J, **Vandamme A-M**, Van Wijngaerden E. Appointment non adherent patients are 6 times more at risk for virological failure.. 2nd International Conference on HIV Treatment Adherence. March 28-30, 2007. Jersey City, New Jersey. O-128. Oral
344. Deschamps AE, Denhaerynck K, **Vandamme A-M**, De Geest S, Van Wijngaerden E. Clinically Validated Electronic Monitoring Algorithm to Detect Non Adherence Based on it's Intervention Effect. 2nd International Conference on HIV Treatment Adherence. March 28-30, 2007. Jersey City, New Jersey. P-129. Journal of the International Association of Physicians in AIDS Care 6 (3): 161, 2007. Poster
345. Vercauteren J, K Theys, M Debruyne, K Deforche, JL Duque, S Peres, A P Carvalho, K Mansinho, **A.M. Vandamme** and R Camacho. The incidence of multidrug and class resistance in HIV-1 infected patients is decreasing over time (2001-2006). Fifth European HIV Drug resistance workshop, 28-30 maart 2007, Cascais – Portugal. Abstract 1. Reviews in Antiviral Therapy 2:38, 2007. Oral
346. Van Laethem K, P Gomes, K Deforche, A.M. Geretti, R Camacho and **A.M. Vandamme**. Rega V7.0: an upgraded genotypic drug resistance interpretation system for HIV-1 and HIV-2 infected patients. Fifth European HIV Drug resistance workshop, 28-30 maart 2007, Cascais – Portugal. Abstract 68. Reviews in Antiviral Therapy 2:75, 2007. Poster
347. Libin P, K Deforche, K Van Laethem, R Camacho and **A.M. Vandamme**. RegaDB: An open source, community-driven HIV data and analysis management environmet. Fifth European HIV Drug resistance workshop, 28-30 maart 2007, Cascais – Portugal. Abstract 81. Reviews in Antiviral Therapy 2:82-83, 2007. Poster
348. Deforche K, R Camacho, K Van Laethem, P Lemey, Y Moreau and **A.M. Vandamme**. Predicting clinical relevant resistance to nelfinavir from the baseline genotype by modelling the individual genetic barrier to nelfinavir resistance. Fifth European HIV Drug resistance workshop, 28-30 maart 2007, Cascais – Portugal. Abstract 115. Reviews in Antiviral Therapy 2:101, 2007. Poster
349. Magiorkinis E, D Paraskevis, G Magiorkinis, M Lazanas, **A-M Vandamme**, A Hatzakis and R Camacho. Identification of a single amino acid insertion in HIV-1 protease associated with reduced susceptibility to Lopinavir/r. Fifth European HIV Drug Resistance Workshop. From basic science to clinical implications. Cascais Portugal, 28-30 March 2007. Abstract 116. Reviews in Antiviral Therapy 2:101, 2007. Poster.

350. Zimmer J.M., .F Roman, J.M. Plesséria, C Lambert, J Y Servais, K Covens, K Van Laethem, J Weber, J C Schmit, **A M Vandamme**, M Quinones-Mateu and M De Maeyer. Impact of a protease G48E substitution on HIV-1 replicative capacity in vitro. Fifth European HIV Drug resistance workshop, 28-30 maart 2007, Cascais – Portugal. Abstract 118. *Reviews in Antiviral Therapy* 2:102-103, 2007. Poster
351. Theys K, Deforche K, **Vandamme A-M**. Using ancestral state reconstruction as an alternative to correct for different epidemiologies when comparing naïve versus treated sequence datasets. *Statistical and Epidemiologic Methods in HIV/AIDS Research* April 11-13, 2007. Poster.
352. Shapiro B., Lemey P., Schuster S., Van Laethem K., **Vandamme A.-M.** & Rambaut A. Population genomic analysis of within-host HIV diversity. Abstract selected for oral presentation at the 14th International Discussion Meeting on HIV Dynamics and Evolution, Segovia, Spain, April 17-20, 2007. Oral.
353. **Vandamme AM**. From the bench to the courtroom: interpretation of virological evidence of HIV transmission. 13th Annual Conference of the British HIV Association (BHIVA). Edinburgh, UK, 25-28 April, 2007. Invited speaker
354. Van Dooren S, G López; D Clark, K Verdonck, E Gotuzzo, G Vanham, O Cassar, A Gessain and **A-M Vandamme** Multiplex real-time PCR for simultaneous detection, genotyping and proviral load determination of human T-lymphotropic virus types 1 to 3. 13th International Conference on Human Retrovirology HTLV and Related Viruses May 21-25, 2007, Hakone, Japan. Abstract 70 – Oral
355. Farre L, HM S Barbosa, C S Requiao, A S C da Silva, **A-M Vandamme**, J Van Weyenberg and A L Bittencourt. An exceptional pediatric case of ATL with a monoclonal CD4+CD8+ phenotype and an indolent course. 13th International Conference on Human Retrovirology: HTLV, 22-25 May 2007, Hakone Japan. Abstract 321 – Poster.
356. Khouri R, D Decanine, L Farre, **A-M Vandamme**, A L Bittencourt and J Van Weyenbergh. In vitro response to IFN correlates with survival in ATL patients. 13th International Conference on Human Retrovirology: HTLV, 22-25 May 2007, Hakone Japan. Abstract 337– Poster.
357. Alcantara L, S Van Dooren, K Deforche, A Rambaut, S Cassol, B Galvao-Castro, **A-M Vandamme** and T de Oliveira. The LASP HTLV-1 automated subtyping tool (<http://lasp.cpqgm.fiocruz.br/virus-genotype/html/subtypinghtlv.html>). 13th International Conference on Human Retrovirology: HTLV, 22-25 May 2007, Hakone Japan. Abstract 277 – Poster.
358. Cavaco Silva J, J Cabanas, MF Gonçalves, K Van Laethem, **AM Vandamme**, P Gomes and RJ Camacho Mutations in HIV-2 protease selected by protease

inhibitor therapy XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Barbados, 12–16 June 2007. ABSTRACT 78. Antiviral Therapy 2007; 12:S87. Poster.

359. Rhee SY, WJ Fessel, NM Marlowe, CM Rowland, **A-M Vandamme**, K Van Laethem, F Brun-Vezinet, V Calvez and RW Shafer. Current genotypic interpretation systems are comparable in their predictive ability and highly dependent on identifying the most active protease inhibitor. XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Barbados, 12–16 June 2007. Abstract 82. Antiviral Therapy 2007; 12:S91. Poster.
360. Van Laethem K, C Pannecouque, B Scarth, M Götte and **A-M Vandamme** . Foscarnet selects for a D113V mutation within the Q151M cluster that suppresses zidovudine resistance XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Barbados, 12–16 June 2007. Abstract 115. Antiviral Therapy 2007; 12: S128. Poster.
361. Deforche K, A Cozzi-Lepri, K Theys, B Clotet, R Camacho, J Kjaer, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren and **A-M Vandamme** for the EuroSIDA Study Group. Proof-of-principle evaluation of predictive performance for therapy outcome of baseline estimated fitness and genetic barrier towards resistance in a clinical cohort of HIV-1-treated patients XVI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Barbados, 12–16 June 2007. Abstract 157. Antiviral Therapy 2007; 12: S172. Poster.
362. Ho YS, Abecasis AB, Potter SJ, Charleston M, **Vandamme A-M**, Saksena K. Evidence for critical differences in HIV-1 env gp120 N-linked glycosylation patterns in plasma and diverse blood leukocyte compartments in vivo. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 22-25 2007. Sydney, Australia. (Abstract number MOAA202). Oral
363. Van Laethem K, Y Schrooten, P Lemey, K Covens, N Dekeersmaeker, M Van Ranst, E Van Wijngaerden, **A-M Vandamme**. Transmission Cluster of Dual-Class Resistant HIV-1 in Untreated Patients. 13th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 9-14 September 2007, Lisbon, Portugal. Abstract 9. Poster.
364. Theys K., R. Camacho, **A-M Vandamme**. Prevalence of the nucleoside analogue drug resistance mutation K65R differs among different HIV-1 subtypes in a Portuguese HIV-1 Drug Resistance Database. 13th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 9-14 September 2007, Lisbon, Portugal. Abstract 20. Poster.
365. Snoeck J., Palma C., Mosha F., Camacho R., **A-M Vandamme**. Characterization of HIV-1 BG recombinants from Portugal. 13th International Bioinformatics Workshop

on Virus Evolution and Molecular Epidemiology, 9-14 September 2007, Lisbon, Portugal. Abstract 5. Poster.

366. Sangeda R Z, K Deforche, K Theys, R Camacho, Van Laethem K, **A-M Vandamme**. Estimating the Human Immunodeficiency Virus (HIV) fitness landscape under treatment pressure using observed evolution in longitudinal sequence data under salvage treatment. 13th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 9-14 September 2007, Lisbon, Portugal. Abstract 21. Poster.
367. Khouri Ricardo, D Decanine, L Farre, **A-M Vandamme**, AL Bittencourt, J Van Weyenbergh. In vitro response to IFN correlates with survival in ATL patients. 13th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 9-14 September 2007, Lisbon, Portugal. Abstract 29. Poster.
368. Sousa JD., Lemey P, **Vandamme A-M**. Promiscuous Sex and Genital Ulcer Diseases Explain the Pandemic Emergence of HIV. 11th European AIDS Conference / EACS, October 24-27, 2007, Madrid. P17.5/01. Poster.
369. **Vandamme AM**. Update on epidemiology of HIV-2 and HIV-1 subtypes and CRF around the world. "Infezione da HIV-2 e Sottotipi Non-B: Nuovi Approcci Diagnostici e Terapeutici" Brescia, Italy, 30 novembre 2007. Invited speaker.
370. Covens K, K Kabeya, Y Schrooten, N Dekeersmaeker, J Weber, ME Quiñones-Mateu, **A-M Vandamme**, S De Wit, K Van Laethem. Characterization of *in vivo* mutational patterns within HIV-1 group M viruses developed during long-term enfuvirtide therapy and after discontinuation of enfuvirtide Third International Workshop Targeting HIV Entry December 7-8, 2007. Washington DC, USA. Reviews in Antiviral Therapy, 1: 71, 2008 Oral.
371. Van Dooren S, B Hendrickx, L Kerremans, J-M Dumont, R Crabbe, J Liz, G Vuagniaux and **A-M Vandamme**. Development of a near full-genome HCV1b resistance test 2nd International Workshop on Hepatitis C, Resistance and New Compounds 30 October - 1 November 2007, Boston MA. Oral.
372. Snoeck J, L Kerremans, G Vuagniaux, J Liz, R Crabbe, J Verbeeck J, M Van Ranst M, **Vandamme A-M** and Van Dooren S. A near-full genome sequencing strategy for HCV1b EASL-AASLD-ADASL-ALEH-IASL Conference Hepatitis B & C Virus Resistance to Antiviral Therapies – Paris, France, February 14-16, 2008. Abstract 49. Poster.
373. Gifford R, T de Oliveira, A Rambaut, O Pybus, D Dunn, **A M Vandamme**, P Kellam, D Pillay, and UK Collaborative Group on HIV Drug Resistance. Phylogenetic Surveillance of Viral Genetic Diversity and the Evolving Molecular Epidemiology of HIV-1. 15th Conference on Retroviruses and Opportunistic Infections (CROI), February 3-6, 2008, Boston, USA. Poster.

374. Vercauteren J, AMJ Wensing, D Van de Vijver, J Albert, C Balotta, O Hamouda, C Kücherer, D Struck, B Asjo, M Bruckova, R Camacho, S Coughlan, Z Grossman, A Horban, K Kom, L Kostrikis, C Nielsen, D Paraskevis, M Poljak, E Puchhammer-Stockl, C Riva, L Ruiz, M Salminen, J Schmit, R Schuurman, A Sonnerberg, D Stanekova, M Stanojevic, **A-M Vandamme**, C AB Boucher, on behalf of the Spread-programme. Trends in transmitted drug resistant HIV-1 in Europe (Sept 2002-Dec 2005). Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 5. Reviews in Antiviral Therapy, 2: 51-52, 2008 Oral.
375. Libin P, M Assel, A Loehden, K Theys, K Van Laethem, E Van Wijngaerden, G Lapadula, C Torti, A De Luca, L Ruiz, B Clotet, S Wesner, P Sloot and **A-M Vandamme**. Applying the RegaDB platform for data integration in the ViroLab project. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 10. Reviews in Antiviral Therapy, 2: 55, 2008 Poster.
376. Abecasis A B, AMJ Wensing, D Paraskevis, J Vercauteren, D A Van de Vijver, J Albert, B Asjo, C Balotta, M Bruckova, R J Camacho, S Coughlan, Z Grossman, O Hamouda, A Hatzakis, A Horban, K Kom, L Kostrikis, C Kuecherer, C Nielsen, M Poljak, E Puchhammer-Stockl, C Riva, L Ruiz, M Salminen, J Schmit, R Schuurman, A Sonnerborg, D Stanekova, M Stanojevic, D Struck, C AB Boucher, **A-M Vandamme** on behalf of the Spread-programme. Demographic determinants of HIV-1 subtype distribution in Europe. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 31. Reviews in Antiviral Therapy, 2: 67-68, 2008 Oral.
377. Theys K, K Deforche, AMJ Wensing, D A Van de Vijver, J Albert, B Asjo, C Balotta, R Camacho, S Coughlan, Z Grossman, A Horban, K Kom C Nielsen, D Paraskevis, C Kuecherer, O Hamouda, E Puchhammer-Stockl, C Riva, L Ruiz, J Schmit, R Schuurman, A. Sonnerborg, M Stanojevic, D Stuck, C AB Boucher, **A-M Vandamme**, on behalf of the Spread-programme. Correlation between estimated fitness under protease inhibitor selective pressure and VL, CD4 in recently diagnosed treatment-naïve patients. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 56. Reviews in Antiviral Therapy, 2: 82-83, 2008 Poster.
378. Van Laethem K, Y Schrooten, K Covens, N Dekeersmaeker, P De Munter, E Van Wijngaerden, M Van Ranst and **A-M Vandamme**. A genotypic assay for the amplification and sequencing of integrase from diverse human immunodeficiency virus type 1 group M subtypes. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 78. Reviews in Antiviral Therapy, 2: 95-96, 2008 Oral.

379. Covens K, Dekeersmaecker N, Schrooten Y, **A-M Vandamme** and Van Laethem K. A novel recombinant virus assay for measuring drug susceptibility to PI, RTI, INI and EI in HIV-1 group M subtypes. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Abstract 80. *Reviews in Antiviral Therapy*, 2: 96-97, 2008 Oral.
380. **Vandamme A-M**. Guidelines for the use of HIV molecular epidemiology for HIV transmission investigation in forensic context. "Round table discussion on Resistance genotyping and HIV transmission investigation: Ethical and Legal Implications". Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Chair and Invited speaker.
381. **Vandamme A-M**. Where are we with tropism testing? Thoughts from the European HIV Drug Resistance Guidelines Panel. Sixth European HIV Drug Resistance Workshop. From basic science to clinical implications. Budapest Hungary, 26-28 March 2008. Invited speaker.
382. Van Weyenbergh J, R Khouri, D Decanine, AC da Silva, L Farre, **A-M Vandamme**, AL Bittencourt. FAS promoter polymorphism determines IFN-induced apoptosis in vitro and survival in ATL patients. 2009 meeting of the HTLV European Research Network 2008. June 1-3, 2008, Brugge, Belgium. Abstract p12, Oral.
383. Khouri R, D Decanine, L Farre, AL Bittencourt, **A-M Vandamme**, J Van Weyenbergh. Differential response to IFN-alpha/beta in vitro might predict survival in ATL patients. 2009 meeting of the HTLV European Research Network 2008. June 1-3, 2008, Brugge, Belgium. Abstract p35, Oral.
384. Moens B, G López, V Adai, D Clark, K Verdonck, E Gotuzzo, G Vanham, O Cassar, A Gessain, **A-M Vandamme**, S Van Dooren. Development, optimization and comparative analysis of a multiplex real-time PCR for HTLV-1, 2 and 3. 2009 meeting of the HTLV European Research Network 2008. June 1-3, 2008, Brugge, Belgium. Abstract p43, Oral.
385. Grossman Z., K. Theys, AP Carvalho, D. Ram, K. Deforche, H. Rudich, J. Vercauteren, F. Milleguir, P. Libin, E. Mendelson, RJ Camacho, I. Levy and **AM Vandamme**. Prevalence of K65R in different HIV-1 subtypes and its association with TAMs and NNRTI related mutations. 17th International HIV drug resistance workshop, June 10-14, 2008, Sitges, Spain. Abstract 51. *Antiviral Therapy* 2008, 13 Suppl 3: A56 Poster.
386. Sangeda RZ, K. Deforche, K. Theys, P. Libin, J. Vercauteren, RJ Camacho, K. Van Laethem and **AM Vandamme**. Modelling the HIV Fitness Landscape under Indinavir treatment pressure using observed evolution in longitudinal sequence

- data. 17th International HIV drug resistance workshop, June 10-14, 2008, Sitges, Spain. Abstract 84. *Antiviral Therapy* 2008, 13 Suppl 3: A91. Poster.
387. Cavaco Silva J, AC Miranda, J Cabanas, A Mercés, E Valadas, MJ Aleixo, T Branco, J Vera, I Germano, K Mansinho, K Van Laethem, **AM Vandamme**, P gomes and RJ Camacho. Mutations selected by therapy in HIV-2 reverse transcriptase. 17th International HIV drug resistance workshop, June 10-14, 2008, Sitges, Spain. Abstract 49. *Antiviral Therapy* 2008, 13 Suppl 3: A54. Poster.
388. **Vandamme A-M**. Drug Resistance Interpretation Tools. First South-African workshop on 'HIV Drug Resistance in Clinical Practice', University of the Western Cape, Cape Town, South Africa, 5 Sept 2008. Invited speaker.
389. **Vandamme A-M**. The simian origin of human retroviruses. First Symposium on Evolution of host-pathogen interactions, a view from the host and the pathogen side. 19 November 2008, Leuven, Belgium. Invited speaker.
390. **Vandamme A-M**. Overview on epidemiology of HIV-1 subtypes and CRFs. Symposium HIV: Resistances And New Therapeutical Perspectives. 9 December 2008, Milan, Italy. Invited speaker.
391. Clement J, J Vercauteren, WW. Verstraeten, G Ducoffre, **A-M Vandamme**, P Maes and M Van Ranst. Global Warming and rising Hantavirus Incidence in Belgium: of Mast, Mice and Men. 2009 Meeting of the European Society for Clinical Virology (ESCV), Amsterdam, the Netherlands, January 7-10, 2009. *J Clin Virol* 2009; 44 (Suppl. 1) S 10. Oral.
392. Moens B, K Dée, K Covens, R Khouri, S Van Dooren, C Pannecoque, **A-M Vandamme**, J Van Weyenbergh. Establishment of an *in vitro* multi-parametric drug screening assay for adult T-cell leukaemia/lymphoma. Oncoforum, Leuven Kankerinstituut, 4 februari 2009, Leuven, Belgium. Abstract 8. Oral.
393. Khouri R, K Theys, D Decanine, K Deforche, A Clara Silva, L Farre, A Bittencourt, **A-M Vandamme**, J Van Weyenbergh. *In silico* modeling of *in vitro* pro-apoptotic, antiproliferative and antiviral activity of IFN-alpha might predict *in vivo* response and survival in Adult T-cell Leukemia. Oncoforum, Leuven Kankerinstituut, 4 februari 2009, Leuven, Belgium. Abstract 9. Oral.
394. Sousa J, Lemey P, Müller V, and **Vandamme A-M**. The Origins of Epidemic HIV Date to a Unique Window of Opportunity for the Initial Spread of SIV Infections Transmitted to Human Populations. 16th Conference on Retroviruses and Opportunistic Infections (CROI), February 8-11, 2009, Montréal, Canada. Poster.
395. Bennett D, D Pillay, V Miller, R Kantor, J Schapiro, D Van Der Vijver, **A-M Vandamme**, R Camacho, M Jordan, R Shafer, and WHO Surveillance Mutations List

Working Group. The WHO Updated List of Mutations for Surveillance of Transmitted Drug-resistant HIV. 16th Conference on Retroviruses and Opportunistic Infections (CROI), February 8-11, 2009, Montréal, Canada. Poster.

396. Cavaco Silva J, A Miranda, J Cabanas, M Gonçalves, E Valadas, K Mansinho, K Van Laethem, **A-M Vandamme**, P Gomes, and RJ Camacho. Amino Acid Substitutions Selected by Therapy in HIV-2 Protease and Reverse Transcriptase. 16th Conference on Retroviruses and Opportunistic Infections (CROI), February 8-11, 2009, Montréal, Canada. Poster
397. Cavaco Silva J, A C Miranda, M F Gonçalves, E Valadas, K Mansinho, K Van Laethem, **A-M. Vandamme**, P Gomes, R J Camacho. Emergence of K65R in HIV-2 infected patients under therapy. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 60. *Reviews in Antiviral Therapy* 2009, 1:66. Oral
398. Frenzt D, D A M C Van de Vijver, A Altmann, M Assel, A De Luca, P Libin, V Müller, B Ó Nualláin, M Prosperi, L Ruiz, P Sloot, E Schülter, C Torti, **A-M. Vandamme**, C A B Boucher. Predicting virological response by different systems interpreting genotypic HIV-1 drug resistance in a large European cohort. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 91. *Reviews in Antiviral Therapy* 2009, 1:97. Oral
399. Frenzt D, C A B Boucher, M Assel, M Bubak, A De Luca, F Incardona, P Libin, L Ruiz, P Sloot, C Torti, **A-M. Vandamme**, M Zazzi, D A M C Van de Vijver. Predicting virological response using genotypic approaches for tenofovir. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 95. *Reviews in Antiviral Therapy* 2009, 1:101-102. Poster
400. Imbrechts S, P Libin, K Deforche, J Silva, M Cartier, J Ruelle, J Snoeck, L Kerremans, R J Camacho, **A-M Vandamme**. Extending the RegaDB data and analysis management software environment towards HIV-1, HIV-2 and HCV. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 99. *Reviews in Antiviral Therapy* 2009, 1:104-105. Poster
401. Beheydt G, K Theys, P Libin, S Imbrechts, K Deforche, **A-M Vandamme**. Automating the workflow for estimating HIV genetic fitness landscapes under drug selective pressure. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 101. *Reviews in Antiviral Therapy* 2009, 1:106-107. Poster
402. Vandekerckhove L, AMJ Wensing, R Kaiser, F Brun-Vézinet, B. Clotet, A De Luca, S Dressler, F Garcia, A Geretti, T Klimkait, K Korn, B Masquelier, C Perno, JM Schapiro, A Sönnernborg, **A-M Vandamme**, H Walter, M Zazzi, C Boucher. Clinical management of HIV-1 tropism testing: development of European guidelines. 7th

European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 104. Reviews in Antiviral Therapy 2009, 1:109-110. Oral

403. Sangeda R Z, K Deforche, J Vercauteren, P Libin, S Imbrechts, K Theys, Z Grossman, R Camacho, K Van Laethem, A Altmann, M Zazzi, A Sönnernborg, R Kaiser, A De Luca, C Torti, L Ruiz, DA van de Vijver, RW Shafer, E Van Wijngaerden, **A-M Vandamme**, for the Virolab and EuResist projects. Evaluation of longitudinal fitness landscapes in prediction of treatment outcome in clinical datasets of HIV-1 infected patients. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Abstract 105. Reviews in Antiviral Therapy 2009, 1:113-114. Oral
404. **Vandamme A-M** on behalf of the writing committee. 2009 update of the European HIV Drug Resistance Guidelines. 7th European HIV Drug Resistance Workshop. 25-27 March 2009; Stockholm, Sweden. Invited speaker.
405. Abecasis AB, **Vandamme A-M**, Lemey P. The Evolutionary Rate of HIV-1 Subtypes. 16th HIV Dynamics and Evolution Workshop. April 4-7 2009, Oxford, UK. Abstract 41. Oral.
406. Yunpeng Wang, A Abecasis, RJ. Camacho and **A-M Vandamme**. Comparative performance of REGA Subtyping tool version 2 versus version 1. 16th HIV Dynamics and Evolution Workshop. April 4-7 2009. Oxford, UK. Abstract 103. Poster.
407. **Vandamme A-M**. The dynamics of retroviruses' evolution. ICAR - Italian Conference on AIDS and Retroviruses, Milan, May, 24th-26th 2009. Invited speaker.
408. Snoeck J, I Kerremans, G Vuagniaux, JS Liz, R Crabbé, J Verbeeck, M Van Ranst, R Camacho, S Vandooren and **A-M Vandamme**. A near full-length genotyping strategy for hepatitis C virus genotypes 1a and 1b. 18th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. June 9-13, 2009, Fort Myers, Florida. Abstract 65. Antiviral Therapy 2009; 14 Suppl 1:A73. Poster
409. Silva JC, AC Miranda, MF Gonçalves, E Valadas, K Mansinho, K Van Laethem, **A-M Vandamme**, P Gomes and RJ Camacho on behalf of the Portuguese HIV-2 Study Group. Therapy-selected mutations at RT position 215 counteract selection of K65R in HIV-2-infected patients. 18th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. June 9-13, 2009, Fort Myers, Florida. Abstract 88. Antiviral Therapy 2009; 14 Suppl 1:A105. Poster
410. Snoeck J, L Kerremans, L Coelmont, G Vuagniaux, JS Liz, R Crabbé, J Neyts, **A-M Vandamme**. Analysis of the HCV genome in search for amino acid changes potentially involved in resistance against the cyclophilin inhibitor Debio 025. 4th

International Workshop on Hepatitis C, Resistance and New Compounds, 25 and 26 June 2009, Boston. Oral

411. Assel M, D van de Vijver, P Libin, K Theys, D Harezlak, B Ó Nualláin, P Nowakowski, M Bubak, **A-M Vandamme**, S Imbrechts, R Sangeda, T Jiang, D Frentz and P Sloot. A Collaborative Environment Allowing Clinical Investigations on Integrated Biomedical Databases. HealthGRID Conference 28 June - 1 July 2009, Berlin, Germany, 2009. Oral.
412. **Vandamme A-M**. Origen y epidemiología de infecciones por HTLV-1 y VIH. Primera Conferencia Nacional 'HTLV-1 en el Peru', June 27-28, 2009, Miraflores-Lima, Peru. Invited speaker.
413. **Vandamme A-M**. Origin of HIV. 8th SIMPAIDS – Brazilian AIDS Research Conference. June 28-July 1, 2009, Rio de Janeiro, Brazil. Invited speaker.
414. Khouri R, A Bittencourt, **A-M Vandamme**, B Galvão-Castro, B Moens, D Decanine, J Van Weyenbergh, K Dee, L Farre. SOD1 ex vivo levels discriminate between asymptomatic infection, HAM/TSP and ATL: a potential therapeutic target in HTLV-1 associated pathologies. 14th International Conference on Human Retrovirology: HTLV and related retroviruses. July 1-4, 2009, Salvador-Bahia, Brazil. Abstract OP-23. Oral
415. Van Weyenbergh J, A Bittencourt, AC Silva, **A-M Vandamme**, B Galvão-Castro, D Decanine, K Deforche, K Theys, L Farre, R Khouri. Mechanisms of action of IFN-Alpha in ATL and HAM/TSP patients: in vitro pro-apoptotic and antiproliferative but not antiviral activity predict in vivo outcome. 14th International Conference on Human Retrovirology: HTLV and related retroviruses. July 1-4, 2009, Salvador-Bahia, Brazil. Abstract OP-39. Oral
416. Moens B, **A-M Vandamme**, C Pannecouque, J Van Weyenbergh, K Dee, K Covens, R Khouri, S Van Dooren. A rapid in vitro multi-parametric drug screening assay for adult T-cell leukaemia/lymphoma. 14th International Conference on Human Retrovirology: HTLV and related retroviruses. July 1-4, 2009, Salvador-Bahia, Brazil. Abstract OP-55. Oral
417. Alcantara LC Jr, S Cassol, P Libin, K Deforche, O Pybus, M Van Ranst, B Galvão-Castro, **A-M Vandamme**, T de Oliveira. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. 14th International Conference on Human Retrovirology: HTLV and related retroviruses. July 1-4, 2009, Salvador-Bahia, Brazil. Abstract OP-62. Oral
418. Santos A.F., A.B. Abecasis, **A.-M. Vandamme**, R.J. Camacho, M.A. Soares. Discordant genotypic interpretation and phenotypic role of protease mutations in

HIV-1 subtypes B and G. 5th IAS Conference on HIV Pathogenesis and Treatment, Cape Town, South Africa 19-22 July 2009, CDA079. Poster

419. Müller V, de Sousa JD, Lemey P, **Vandamme A-M**. Simulating the origin of HIV-1 group M in Kinshasa: why did the epidemic emerge when it did? 2nd Central European Forum for Microbiology, 7-9 October 2009, Keszthely, Lake Balaton, Hungary. Oral.
420. Van Weyenbergh, J., Khouri, R., Decanine, D., Theys, K., Deforche, K., Silva, A.C., Farre, L., Bittencourt, A., **Vandamme, A.-M.** IFN-Beta Pro-Apoptotic and Antiproliferative Activity is Superior to IFN-Alpha in Adult T-Cell Leukemia: Ex Vivo Response Predicts Survival. Cellular and Cytokine Interactions in Health and Disease, Tri-Society Annual Conference, Lisbon, Portugal; 17-21 October 2009. Poster
421. **Vandamme A-M**. Basic Concept of Molecular Evolution and Principles of Multiple Sequence Alignments. 1st Bioinformatics Training & Mentoring Course MRC/UVRI, Entebbe, Uganda, 28-30 October, 2009. Invited speaker.
422. **Vandamme A-M**. Phylogenetic Evidence in Court (HIV Transmission). 1st Bioinformatics Training & Mentoring Course MRC/UVRI, Entebbe, Uganda, 28-30 October, 2009. Invited speaker.
423. Faria N.R., I. Hodges-Mameletzis, R.J. Camacho, B. Rodés, J. Ruelle, S. Paolucci, J. Cavaco-Silva, M.F. Gonçalves, S. Jallow, P. Goubau, V. Soriano, J.D. de Sousa, M. Suchard, **A.-M. Vandamme**, P. Lemey. Uncovering HIV-2 diffusion patterns using Bayesian phylogeographic analysis. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. HIV Medicine 10, 2, 2009. Abstract PE1.1/2. Poster.
424. Vandekerckhove L., A.M.J. Wensing, R. Kaiser, F. Brun-Vézinet, B. Clotet, A. De Luca, S. Dressler, F. García, A.M. Geretti, T. Klimkait, K. Korn, B. Masquelier, C.F. Perno, J.M. Schapiro, A. Sönnernborg, V. Soriano, **A.-M. Vandamme**, H. Walter, M. Zazzi, C.A.B. Boucher, on behalf of the European Consensus Group on clinical management of tropism testing. European consensus on clinical use and interpretation of HIV-1 tropism testing. 12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. HIV Medicine 10, 2, 2009. Abstract LBPE1.2/ 9. Poster.
425. Theys K., R.Z. Sangeda, R. Camacho, B. Clotet, K. Van Laethem, M. Zazzi, A. Sönnernborg, R. Kaiser, A. De Luca, C. Torti, A.M.J. Wensing, G. Stanczak, M. Linka, M. Poljak, S.Z. Lepej, E. Van Wijngaerden, C. Verhofstede, S.-Y. Rhee, **A.-M. Vandamme**, for the EHR, Virolab, EuResist and BREACH Projects. Untangling pathways to tipranavir resistance in patients infected with various HIV-1 subtypes.

12th European AIDS Conference/EACS, 11-14 November 2009, Cologne, Germany. HIV Medicine 10, 2, 2009. Abstract PE7.4/9. Poster.

426. de Sousa JD, Müller V, Lemey P, **Vandamme A-M**. The origin of epidemic HIVs by GUD facilitated heterosexual transmission. *Epidemics*², 2nd International Conference on Infectious Disease Dynamics, 2-4 December 2009, Athens, Greece. Poster.
427. Imbrechts S, Libin P, Beheydt G, Theys K, Sangeda R, Camacho R, Clotet B, Van Laethem K, Zazzi M, Sönnernborg A, Kaiser R, De Luca A, Torti C, Wensing A.M.J., Stanczak G, Linka M, Poljak M, Lepej SZ, Van Wijngaerden E, Verhofstede C, Rhee S-Y, **Vandamme A-M**, for the EHR, Virolab, EuResist and BREACH projects. Comparing the prevalence of tipranavir resistance mutations in naïve, PI experienced and tipranavir experienced patients. 15th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 7-11 September 2009, Rotterdam, The Netherlands. Abstract 24. Poster.
428. Sangeda R, Theys K, Camacho R, Clotet B, Van Laethem K, Zazzi M, Sönnernborg A, Kaiser R, De Luca A, Torti C, Wensing A.M.J., Stanczak G, Linka M, Poljak M, Lepej SZ, Van Wijngaerden E, Verhofstede C, Rhee S-Y, **Vandamme A-M**, for the EHR, Virolab, EuResist and BREACH projects. Untangling Pathways to Tipranavir Resistance in HIV-1 Treatment Experienced Patients from Various Subtypes. 15th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 7-11 September 2009, Rotterdam, The Netherlands. Abstract 25. Poster.
429. Cavaco-Silva J., M.F. Gonçalves, Aleixo MJ, Branco T, Germano I, Mansinho K, Van Laethem K, **A.-M. Vandamme**, Gomes P, R.J. Camacho. Mutations selected by indinavir therapy in HIV-2. 15th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 7-11 September 2009, Rotterdam, The Netherlands. Abstract 28. Poster.
430. Moens B, K Dée, K Covens, R Khouri, C Pannecouque, **A-M Vandamme**, J Van Weyenbergh. An *in vitro* model closely mimicking patient response to combination therapy of AZT and IFN- α for adult T-cell leukaemia/lymphoma. BACR Annual meeting 2010, Saturday, January 30, 2010. *Belg J Med Oncol* 2010 ; 4 : 83-102. Poster.
431. Khouri R, D Decanine, L Farre, A Bittencourt, **A-M Vandamme**, J Van Weyenbergh. Gene expression profiling of *ex vivo* IFN-alpha response in primary cells from Adult T-cell Leukemia patients. BACR Annual meeting 2010, Saturday, January 30, 2010. *Belg J Med Oncol* 2010 ; 4 : 83-102. Poster.
432. Di Giambenedetto S, L Bansi, A Sönnernborg, R Camacho, C Torti, I Fanti, **A-M Vandamme**, V Borghi, D Asboe, Andrea De Luca, and the Virolab, Euresist and

- Chain Consortia. Opposite Trends in Multiclass HIV-1 Drug Resistance and Exhaustion of Drug Options in Treatment-experienced Patients Undergoing Resistance Testing in 7 Western European Countries from 1997 to 2008. 17th Conference on Retroviruses and Opportunistic Infections (CROI), February 16-19, 2010, San Francisco, US. Abstract 586. Poster.
433. Van Laethem K, Dekeersmaeker N, Covens K, and **A-M Vandamme**. Differential Impact of Amino Acids Arg, Ser, and Thr at HIV-1 Reverse Transcriptase Position 70 on Susceptibility towards NRTI and Foscarnet. 17th Conference on Retroviruses and Opportunistic Infections (CROI), February 16-19, 2010, San Francisco, US. Abstract 550. Poster.
434. Cavaco Silva J, K Theys, A C Miranda, M D Gonçalves, M J Aleixo, K Mansinho, K Van Laethem, **A-M Vandamme**, P Gomes, R J Camacho, and HIV-2 Resistance Study Group. Bayesian Network Analysis of Resistance Pathways in HIV-2 Protease. 17th Conference on Retroviruses and Opportunistic Infections (CROI), February 16-19, 2010, San Francisco, US. Abstract 560. Poster.
435. Van Laethem K, K Covens, N Dekeersmaeker, K Kabeya, J Balzarini, S De Wit, **A-M. Vandamme**. HIV-1 gp41 mutations 43T and 50V elevate resistance levels of common enfuvirtide mutants while all mutants remained highly susceptible to sifuvirtide. 8th European HIV Drug Resistance Workshop, 17-19 March 2010, Sorrento, Italy. Abstract 24. Reviews in Antiviral Therapy 2010, 1:24. Poster
436. Zazzi M, R Kaiser, A Sonnerborg, D Struck, A Altmann, M Prosperi, M Rosen-Zvi, A Petroczi, Y Peres, E Schuler, C Boucher, F Brun-Vezinet, P Harrigan, L Morris, M Obermeier, C Perno, P Phanuphak, D Pillay, R Shafer, **A-M Vandamme**, K Van Laethem, A Wensing, T Lengauer, F Incardona. Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). 8th European HIV Drug Resistance Workshop, 17-19 March 2010, Sorrento, Italy. Abstract 45. Reviews in Antiviral Therapy 2010, 1:43. Oral
437. Cavaco Silva J, K Theys, MF Gonçalves, I Neves, J Vera, A Dinis, P Fonseca, L Tavares, N Faria, K Van Laethem, **A-M Vandamme**, P Gomes, K Mansinho, RJ Camacho. Bayesian network analysis of resistance pathways in HIV-2 reverse transcriptase. 8th European HIV Drug Resistance Workshop, 17-19 March 2010, Sorrento, Italy. Abstract 46. Reviews in Antiviral Therapy 2010, 1:44-45. Oral
438. Beheydt G, J Vercauteren, P Libin, S Imbrechts, RJ Camacho, B Clotet, A De Luca, Z Grossman, R Kaiser, A Sonnerborg, C Torti, E Van Wijngaerden, M Zazzi, AM Geretti, **A-M Vandamme**, M Prosperi. Rega 8: An improved genotypic interpretation system that significantly predicts HIV-therapy response for B and non-B subtypes. 8th European HIV Drug Resistance Workshop, 17-19 March 2010, Sorrento, Italy. Abstract 50. Reviews in Antiviral Therapy 2010, 1:48-49. Poster

439. Theys K, G Beheydt, P Libin, T Goedeweck, RJ Camacho, K Deforche and **A-M Vandamme**. Individualized Genetic Barrier to Resistance using Zidovudine plus Lamivudine Fitness Landscape. 14th International Workshop on HIV Observational Databases, 25-27 March 2010, Sitges, Spain. Abstract 124. Poster
440. Theys K, T Goedeweck, G Beheydt, K Van Laethem, K Deforche, A Altmann, RJ Camacho, B Clotet, A De Luca, R Kaiser, Z Grossman, C Torti, T Lengauer and **A-M Vandamme**. Treatment Selective Pressure at Population Level Increases the Fitness of Wild Type HIV-1 over Time. 14th International Workshop on HIV Observational Databases, 25-27 March 2010, Sitges, Spain. Abstract 125. Poster
441. Van Laethem K., Covens K., Dekeersmaecker N., Kabeya K., Balzarini J., De Wit S., **Vandamme A.-M.** HIV-1 gp41 mutations 43T and 50V elevate resistance levels of common enfuvirtide mutants while all mutants remained highly susceptible to sifuvirtide. 4th European Congress of Virology, Cernobbio, Italy, 7-11 April 2010. Oral.
442. **Vandamme A.-M.** Guidelines for the use of HIV molecular epidemiology for HIV transmission investigation in forensic context. 20th European Congress of Clinical Microbiology and Infectious Diseases, 10-13 April 2010, Vienna, Austria. Invited speaker.
443. Theys, K., Deforche, K., Vercauteren, J., Libin, P., van de Vijver, D.A.M., Albert, J., Asjö, B., Balotta, C., Bruckova, M., Camacho, R.J., Clotet, B., Coughlan, S., Grossman, Z., Hamouda, O., Horban, A., Korn, K., Kostrikis, L., Kücherer, C., Nielsen, C., Paraskevis, D., Poljak, M., Puchhammer-Stockl, E., Riva, C., Ruiz, L., Liitsola, K., Schmit, J.-C., Schuurman, R., Sönnnerborg, A., Stanekova, D., Stanojevic, M., Struck, D., Van Laethem, K., Wensing, A.M.J., Boucher, C.A.B., **Vandamme, A.-M.** Treatment-associated polymorphisms in protease but not in reverse transcriptase are significantly associated with higher viremia and lower CD4 cell count in recently diagnosed treatment-naïve patients. 17th International HIV Dynamics & Evolution Workshop, April 25-28, 2010, Monterey, CA, U.S. Oral.
444. Faria, N.R., Hodges-Mameletzis, I., Silva, J., Gonçalves, M.F., Jallow, S., Rodés, B., Paolucci, S., Ruelle, J., Xu, L., Smit, E., Goubau, P., Soriano, V., Camacho, R.J., de Sousa, J., **Vandamme, A.-M.**, Suchard, M., Lemey, P. Bayesian spatiotemporal reconstruction of the HIV-2 epidemic history. 17th International HIV Dynamics & Evolution Workshop, April 25-28, 2010, Monterey, CA, U.S. Oral.
445. Van Weyenbergh J, R Khouri, D Decanine, B Moens, K Theys, L Farré, A Bittencourt, **A-M Vandamme**. Adult T-cell leukemia: a critical role for IFN/STAT1/FAS signaling in cell fate? HERN Meeting, 28-30 May 2010, Lyon, France. Oral
446. Beheydt G, J Vercauteren, I Levy, H Rudich, D Ram, AP Carvalho, K Van Laethem, **A-M Vandamme**, R Camacho, Z Grossman. Expected HIV-1 etravirine resistance

- after treatment failure with efavirenz and/or nevirapine. International HIV & Hepatitis Virus Drug Resistance Workshop & Curative Strategies, June 8-12, 2010, Dubrovnik, Croatia. Antiviral Therapy 2010, Vol. 15, Suppl. 2: A65 (Abstract 54). Poster
447. Beheydt G, M Zazzi, AP Carvalho, I Diogo, D Ram, H Rudich, R Camacho, Z Grossman, K Van Laethem, **A-M Vandamme**. Study of the regimen-specific HIV-1 genotypic susceptibility score after treatment failure. International HIV & Hepatitis Virus Drug Resistance Workshop & Curative Strategies, June 8-12, 2010, Dubrovnik, Croatia. Antiviral Therapy 2010, Vol. 15, Suppl. 2: A99 (Abstract 82). Poster
448. Cavaco-Silva J, MF Gonçalves, K Van Laethem, **A-M Vandamme**, P Gomes, J Machado, R Abreu, N Janeiro, C Cunha, RJ Camacho on behalf of the HIV-2 Resistance Study Group. Transmission of drug resistance in HIV-2 infected patients. International HIV & Hepatitis Virus Drug Resistance Workshop & Curative Strategies, June 8-12, 2010, Dubrovnik, Croatia. Antiviral Therapy 2010, Vol. 15, Suppl. 2: A182 (Abstract 144). Oral
449. Bartha I., M. Assel, P. Sloom, M. Zazzi, C. Torti, E. Schülter, A. De Luca, A. Sönnernborg, A.B. Abecasis, **A.-M. Vandamme**, R. Paredes, D. Van De Vijver, V. Müller. Estimating the frequency of superinfection in a large European collaborative HIV database. XVIII International AIDS Conference, Vienna, Austria, July 18-23 2010. Abstract FRAA0102. Oral
450. Beheydt G, M Zazzi, AP Carvalho, I Diogo, D Ram, H Rudich, RJ Camacho, Z Grossman, **A-M Vandamme** and K Van Laethem. The genotypic susceptibility score of Rega v8.0.2 after treatment failure. 16th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology. August 29 - September 3 2010, Rockville, MD, USA. Abstract 12. Poster
451. Kerremans L, **Vandamme A-M**, Snoeck J. Using HCV genotypic sequence information for epidemiological and viral evolution studies. 16th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology. August 29 - September 3 2010, Rockville, MD, USA. Abstract 38. Poster
452. Li G, Beheydt G, Bielza C, Larrañaga P, Camacho RJ, Grossman Z, Torti C, Zazzi M, Prospero M, Kaiser R, Van Laethem K, De Maeyer M, Jansen M, **Vandamme A-M**. Learning ancestral polytrees for HIV-1 mutation pathways against protease inhibitor Nelfinavir. 9th European Conference on Computational Biology, Ghent, Belgium, September 26-29 2010. Abstract 64. Poster
453. de Sousa B., A. Abecasis, R. Camacho, P. Gomes, C.Nunes, M.R. Oliveira Martins, **A-M. Vandamme**. BioSI: Collaborative Research in Biostatistics and Bioinformatics.

Poster presented at the World Statistics Day. 20th October 2010. Faculdade de Ciências da Universidade de Lisboa. Lisbon, Portugal. Poster

454. Li G., Beheydt, G., Camacho, R.J., **Vandamme, A.-M.**, Theys, K. Analysis of HIV-1 resistance pathways using multi-polytree: implications of multiple HIV- 1 mutation pathways. 10th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases. Amsterdam, the Netherlands, 3-5 November 2010. Abstract O103. Oral
455. Faria N.R., Ndembi N., Abecasis A., Suchard M., **Vandamme A.M.**, Peeters M., Lemey, P. A spatiotemporal reconstruction of HIV-1 CRF02_AG epidemic history in Cameroon. 10th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases. Amsterdam, the Netherlands, 3-5 November 2010. Abstract O102. Oral
456. Khouri, R., Decanine, D., Moens, B., Theys, K., Farré, L., Bittencourt, A., **Vandamme, A.M.**, Van Weyenbergh, J. Type I IFN as a key player in both pathogenesis and therapy of HTLV-1 associated leukemia and neurodegenerative disease. SBI International Immunology Meeting, Porto Alegre, Brazil 3-6 November 2010. Poster.
457. Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnnerborg AM, **Vandamme AM**, Verhofstede C, Walter H , Zazzi M and Boucher CAB on behalf of the European Consensus Group on clinical management of tropism testing. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing vs 1.0. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010. Abstract O121. Oral.
458. Pironti A, Sönnnerborg A, Zazzi M, Kaiser R, Struck D, Clotet B, **Vandamme A-M**, Incardona F, Lengauer T, Rosen-Zvi M and Prospero M. The EuResist Expert Model for Customised HAART Optimisation: 2010 Update and Extension to Newest Compounds. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 7-11 November 2010. Abstract O6. Oral
459. **Vandamme A-M**. European HIV Drug Resistance Guidelines – update. CHAIN Workshop in Ljubljana, Slovenia, 11-12 Dec 2010. Invited speaker.
460. **Vandamme AM**. Understanding and predicting evolutionary pathways of HIV-1 to antiretroviral resistance. HIV-STOP: new strategies to combat HIV, Gent, Belgium, 10 Dec, 2010. Invited speaker.
461. Abecasis AB., Wensing AM.J., Vercauteren J, Paraskevis D, van de Vijver D, Theys K, Albert J, Schmit J-C, Kücherer C, Hamouda O, Struck D, Åsjö B, Balotta C, Bruun

- Jørgensen L, Camacho R, Coughlan S, Grossman Z, Horban A, Kostrikis L, Liitsola K, Linka M, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnnerborg A, Stanekova D, Stanojevic M, Boucher C & **A-M Vandamme** on behalf of the SPREAD Programme, of the European Society for Antiviral Resistance and of the EuropeHIVResistance Network. Genetic diversity of HIV-1 in Europe and its demographic determinants (2002-2005). 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March 2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:13-14, 2011. Abstract O11. Oral
462. Snoeck J, Kerremans L, Vuagniaux G, Vandooren S, **Vandamme AM**. Genotyping full length HCV 1b viruses : comparison of a capillary sequencing and a deepsequencing approach. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March 2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:16-17, 2011. Abstract O14. Oral
463. Rosen-Zvi M, Zazzi M, Incardona F, Aaroni E, Kaiser R, Lengauer T, Camacho R, Clotet B, **Vandamme AM**, Schmit JC , Sönnnerborg A - for the EuResist Network: Declining differences in treatment outcome among different patient categories in Europe, 1992-2010. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March 2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:32, 2011. Abstract O29. Oral
464. Feng Y, J Vercauteren, AP Carvalho, I Diogo, P Gomes, **AM Vandamme**, RJ Camacho. The prevalence of multidrug and full class resistance is decreasing during the last decade in HIV-1 infected patients in Portugal. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March 2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:61-62, 2011. Abstract P26. Poster
465. Vandekerckhove L, A.M.J. Wensing, R. Kaiser, F. Brun-Vezinet, B. Clotet, A. De Luca, S. Dressler, F. Garcia, A.M.Geretti, T. Klimkait, K. Korn, B. Masquelier, C.F. Perno, J.Schapiro, V. Soriano, A. Sonnerborg, **A.M. Vandamme**, C. Verhofstede, H. Walter, M. Zazzi, C.A. Boucher. European guidelines on the clinical management of HIV-1 tropism testing; Consensus statement version 1.0. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March 2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:85-86, 2011. Abstract P52. Poster
466. Beheydt G, Schülter E, Imbrechts S, Abecasis A, Codoñer FM, Paraskevis D, Sönnnerborg A, **Vandamme AM**, Kjaer J. A system to query distributed heterogeneous viral databases. 9th European Workshop on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 23-25 March

2011. *Reviews in Antiviral Therapy & Infectious Diseases* 2:86-87, 2011. Abstract P26. Poster
467. Kjær J., P. Libin, G. Beheydt, S. Imbrechts, M. Rickenbach, I. Fanti, F. Incardona and **A.-M. Vandamme**. Simplifying and automating cohort study feasibility, quality assurance and data management – a distributed approach to data management. 15th International Workshop on HIV Observational Databases, Prague, Czech Republic, 24-26 March 2011, Abstract 57. Poster
468. **Vandamme, A-M**. Predictive value of drug resistance and tropism interpretation systems. Advanced Course on the Clinical Interpretation of HIV Drug Resistance Testing Results. April 21-22, 2011, Havana, Cuba. Invited speaker
469. **Vandamme, A-M**. Clinical Relevance of resistance test results. How to use interpretation systems. Advanced Course on the Clinical Interpretation of HIV Drug Resistance Testing Results. April 21-22, 2011, Havana, Cuba. Invited speaker
470. Faria, NR, Ndembi N, Abecasis A, Suchard MA, **Vandamme AM**, Lemey P. Phylodynamics of the CRF02_AG clade in Cameroon. 18th HIV Dynamics and Evolution, Galway, Ireland. May 1-4, 2011. Oral.
471. **Vandamme, A-M**. Viral resistance testing – where are we? 21st ECCMID (European Congress of Clinical Microbiology and Infectious Diseases). May 7-10, 2011, Milan, Italy. Invited speaker.
472. Sangeda RZ, F Moshia, S Aboud, A Kamuhabwa, E Lyamuya, **A-M Vandamme**. Adherence to anti-retroviral drugs among people living with HIV and AIDS at Amana District Hospital in Dar-es-salaam. 5th International workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource Limited Settings, INTEREST. May 10-13, 2011, Dar-es-salaam, Tanzania. Poster P_23. Poster.
473. Moens B, Decanine D, Khouri R, Lopez G, Talledo M, Gotuzzo E, Bex F, Castro BG, **Vandamme A-M**, Van Weyenbergh J. Ascorbic acid has superior antiviral and antiproliferative effects over IFN-alpha in HAM/TSP PBMC ex vivo. 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses. June 4-8, 2011, Leuven, Belgium. Oral.
474. **Khouri R**, Soares G, Silva-Santos G, Santana G, Thepen T, Farre L, Bittencourt A, Lopez G, Talledo M, Gotuzzo E, **Vandamme A-M**, Galvao-Castro B, Van Weyenbergh J. CD64 as a biomarker and therapeutic target in HAM/TSP and HTLV-1-associated Infective Dermatitis. 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses. June 4-8, 2011, Leuven, Belgium. Poster.

475. Menezes SM, D Decanine, R Khouri, **A-M Vandamme**, B Galvão-Castro, J Van Weyenbergh. B cell costimulatory molecules: potential biomarkers in HAM/TSP. 15th International Conference on Human Retrovirology: HTLV and Related Retroviruses. June 4-8, 2011, Leuven, Belgium. Poster.
476. Kjær J, Kristensen DK, Beheydt G, Imbrechts S, Rickenbach M, Fanti I, Incardona F, **Vandamme A-M**. Development of a cross-European virtual sample repository and HIV resistance database. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. June 7-11, 2011, Los Cabos, Mexico. Abstract 85. *Antiretroviral Therapy 2011*; 16 Suppl 1: A106. Poster.
477. Choilai T, C T Jones, Y Tang, J Snoeck, **A-M Vandamme**, L Coelmont, J Neyts, G Vuagniaux, R Crabbe, N Naoumov, B Li, K Lin. Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals. 6th International Workshop on Hepatitis C, Resistance and New Compounds. June 23-24, 2011, Cambridge, USA. Oral.
478. Kourí V, L Pérez, Y Alemán, C Correa, J Pérez, C Fonseca, C Aragonés, J Campos, D Pérez, A Álvarez, PA Martínez, Y Soto, **A-M Vandamme**, K Van Laethem. Antiretroviral resistance of HIV-1 in individuals presenting therapeutic failure and subtypes distribution in Cuba. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. July 17-20, 2011, Rome, Italy. Abstract CDB093. Poster.
479. **Vandamme A-M**. Predictive value and clinical use of drug resistance interpretation systems. 9th SIMPAIDS – Brazilian AIDS Research Conference. August 31-Sept 3, 2011, Salvador, Brazil. Invited speaker.
480. **Vandamme A-M**. Utilização de ferramentas de interpretação de resistência do HIV-1 às drogas antiretrovirais. Segundo workshop brasileiro em banco de dados de sequências do HTLV-1 e HIV-1 para o estudo de retrovírus humanas e suporte de vacinas, Salvador, Brazil, 5-7 Sept 2011. Invited speaker.
481. **Vandamme A-M**. Fundamentals of Molecular Evolution. 2011 Amazon Bioinformatics Workshop, Belém, Brazil, 8-12 Sept 2011. Invited speaker.
482. **Vandamme A-M**. Alignment algorithms. 2011 Amazon Bioinformatics Workshop, Belém, Brazil, 8-12 Sept 2011. Invited speaker.
483. Snoeck J, C Casado, S Colombo, A Rauch, S García, R Martinez, K Theys, R Khouri, HF Günthard, A Telenti, C López-Galíndez, **A-M Vandamme**. A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression *Frontiers of Retrovirology*. October 3-5, 2011, Amsterdam, The Netherlands. Poster.

484. Frenzt D, D van de Vijver, A Abecasis, J. Albert, L Bruun Jørgensen, O Hamouda, C Kücherer, J-C Schmit, D Struck, **A-M Vandamme**, J Vercauteren, B Åsjö, C Balotta, D Beshkov, R Camacho, A Griskevicius, A Horban, T Kolupajeva, K Korn, L Kostrikis, K Liitsola, M Linka, D Otelea, D Paraskevis, R Paredes, M Poljak, E Puchhammer-Stöckl, R Schuurman, A Sönnnerborg, D Staneková, M Stanojevic, S Zidovec Lepej, A Wensing, C Boucher on behalf of the SPREAD programme. Transmission of HIV resistant to non-nucleoside RT inhibitors is rising in MSM in Europe. 13th European AIDS Conference / EACS, October 12-15. 2011, Belgrade, Serbia. Abstract PS1/5. Oral.
485. Li B, J Snoeck, Y Tang, CT Jones, C Tiongyip, W Bao, J Yu, **A-M Vandamme**, G Vuagniaux, R Crabbe, C Avila, N Naumov, K Lin. Alisporivir, a host-targeting antiviral, provides low viral breakthrough rate and high barrier to resistance in HCV genotype 1 treatment-naïve patients in the phase 2b (ESSENTIAL) study. The Liver Meeting. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases, November 4-8, 2011, San Francisco, USA. Oral
486. **Vandamme A-M**. Viral pathogen phylogenomics and disease dynamics: HIV as example. ECDC Expert consultation: Breakthroughs in molecular epidemiology of human pathogens: how to translate into public health practice 22-23 November, 2011, Stockholm, Sweden. Invited speaker.
487. **Vandamme A-M**. Current controversies on the origin and adaptation of epidemic HIVs. Cologne Spring Meeting 2012: Molecular Ecology and Evolution. Feb 22-24, 2012. Cologne, Germany. Satellite Meeting Feb 24 - 25. Viral Evolution: Linking Genetics to Epidemics. Invited speaker.
488. Beheydt G, Theys K, Clotet B, Schülter E, Schmit JC, Sonnerborg A, Zazzi M, Van Laethem K, Camacho RJ, **Vandamme AM**. Bayesian network analysis of mutational pathways to DRV resistance. CROI 2012 – Seattle 5-8 March, 2012. Poster
489. Li B, J Snoeck, Y Tang, CT Jones, W Bao, J Yu, Y Li, **A-M Vandamme**, G Vuagniaux, K Lin. Alisporivir, a Host-targeting Antiviral, in Combination with Peg-IFN α 2a and Ribavirin Results in Superior SVR and No Viral Breakthrough in HCV Genotype 1 Treatment-naïve Patients of IL28B CC Genotype: Results from the Phase IIb ESSENTIAL Study. 22nd Conference of the Asian Pacific Association for the Study of the Liver. February 16-19, 2012, Taipei, Taiwan. Poster
490. Mosha F, Ledwaba J, Ndugulile F, Ng'ang'a Z, Mwangi C, Nsubuga P, Nkengasong J, Kasubi M, Swai A, Morris L, **Vandamme A-M**, Njenga K. High prevalence of HIV antiretroviral drug resistance among treated patients in Tanzania, both in clinical responders and non-responders. 10th European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance. Barcelona, Spain. 28-30 March, 2012. Poster

491. Theys K., J. Vercauteren, J. Snoeck, Z. Grossman, B. Clotet, A. De Luca, R. Kaiser, A. Sonnerborg, C. Torti, J.-C. Schmit, M. Zazzi, R. Camacho, **A.-M. Vandamme** and A. Abecasis, in collaboration with the EuResist consortium A large scale analysis of a subtype-dependent impact of K65R selection in HIV-1 patients treated with cART including TDF. 10th European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance. Barcelona, Spain. 28-30 March, 2012. Poster
492. Megens S, D Vaira, N Dekeersmaeker, Y Schrooten, **A-M Vandamme**, M Moutschen, K Van Laethem. Cellular sequence insertion in HIV reverse transcriptase confers resistance to RTIs and partly compensates for replication deficits of RTI mutations. 10th European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance. Barcelona, Spain. 28-30 March, 2012. Poster
493. **Vandamme A-M**. Origins of human retroviruses. 22nd Annual meeting of the Society for Virology. Essen, Germany, 14-17 March 2012. Invited speaker
494. Vercauteren J, Y Feng, AP Carvalho, I Diogo, P Gomes, **AM Vandamme**, RJ Camacho. The prevalence of multidrug resistant HIV-1 decreased during the last decade in Portugal: a mixed model accounting for multiple measures per patient. Leuven Statistics Days 2012. Leuven, Belgium, June 7-8, 2012. Poster
495. Avi R., Huik K., Pauskar M., Lutsar I., **Vandamme A.-M.**, Abecasis A. The population dynamics of the HIV-1 epidemic in Estonia through virus genetic analysis and national case recording. 17th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 27 - 31 August 2012, Belgrade, Serbia. Poster
496. Vinken L., Megens S., Schrooten Y., **Vandamme A.-M.**, Van Laethem K. Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences. 17th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 27 - 31 August 2012, Belgrade, Serbia. Poster
497. Pineda-Peña A.C., Rodrigues-Faria N., Imbrechts S., Libin P., Deforche K., Abecasis A.B., Gomez A., Camacho R.J., de Oliveira T., **Vandamme A.-M**. Performance of the subtyping tools in the surveillance of hiv-1 epidemic: comparison between rega version 3 and six other automated tools to identify pure subtypes and circulating recombinant forms. 17th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 27 - 31 August 2012, Belgrade, Serbia. Poster
498. Vercauteren J, Theys K, Carvalho AP, Valadas E, Duque LM, Teofilo E, Faria T, Faria D, Vera J, Aguas MJ, Peres S, Mansinho K, **Vandamme AM**, Camacho R (Portuguese HIV-1 Resistance Group). The demise of multidrug resistant HIV-1. BREACH meeting, Brussels, September 28, 2012. Poster

499. Megens S, Vaira D, Dekeersmaeker N, Schrooten Y, **Vandamme AM**, Moutschen M, Van Laethem K. Cellular sequence insertion in HIV reverse transcriptase confers resistance to RTIs and partly compensates for replication deficits of RTI mutations. BREACH meeting, Brussels, September 28, 2012. Poster
500. Pineda-Peña AC, Rodrigues-Faria N, Imbrechts S, Libin P, Deforche K, Abecasis AB, Gomez A, Camacho RJ, de Oliveira T, **Vandamme AM**. Performance of the subtyping tools in the surveillance of hiv-1 epidemic: comparison between rega version 3 and six other automated tools to identify pure subtypes and circulating recombinant forms. BREACH meeting, Brussels, September 28, 2012. Poster
501. Snoeck J, Casado C, Colombo S, Rauch A, García S, Martinez R, Theys K, Khouri R, Günthard HF, Telenti A, López-Galíndez C, **Vandamme AM**. A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. BREACH meeting, Brussels, September 28, 2012. Poster
502. Pérez L., Alemán Y., Correa C., Pérez J., Aragonés C., Gonzalez I., Álvarez A., Pérez J.E., **Vandamme A-M.**, Kourí V., Van Laethem K. Antiviral drug resistance in Cuban children infected with HIV-1. Eleventh International Congress on Drug Therapy in HIV Infection, 11-15 November 2012 Glasgow, UK. Poster
503. Vrancken B, Rambaut A, Baele G, **Vandamme A-M**, Van Laethem K, Van Wijngaerden E, Drummond A, Suchard M and Lemey P. Reconstruction of an HIV Transmission History in a Bayesian Coalescent Framework. 11th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases, October 30 – November 2, 2012, New Orleans, USA. Oral
504. **Vandamme AM**, Camacho RJ. HIV drug resistance algorithms and interpretation systems for clinicians. 7th South African HIV Drug Resistance and Treatment Monitoring Workshop. 28 November 2012, Cape Town, Sout Africa. Invited speakers.
505. Vrancken, B., Rambaut, A., Baele, G., **Vandamme, A.-M.**, Van Laethem, K., Van Wijngaerden, E., Drummond, A., Suchard, M., Lemey, P. Reconstruction of an HIV transmission chain in a Bayesian coalescent framework. International Work-Conference on Bioinformatics and Biomedical Engineering 2013, March 18-20, 2013 Granada, Spain. Oral.
506. Vercauteren J, Beheydt G, Prosperi M, Libin P, Imbrechts S, Camacho R, Clotet B, De Luca A, Grossman Z, Kaiser R, Sönnnerborg A, Torti C, Van Wijngaerden E, Schmit JC, Zazzi M, Geretti AM, **Vandamme A-M**, Van Laethem K. Clinical evaluation of Rega 8: An updated genotypic interpretation system that significantly predicts HIV-therapy response. 11th European Meeting on HIV & Hepatitis – Treatment Strategies & Antiviral Drug Resistance. Rome, Italy, March 20-22, 2013. Poster

507. Albini L., BM. Cesana, K. Theys, M. Zazzi, C. Boucher, R. Paredes, A. Sonnerborg, AM. Geretti, **A-M. Vandamme**, C. Torti. Transmitted Drug-Resistance Associated Mutations (TDRAMs) in HIV-1 Protease are Correlated with a Faster Pre-Therapy Decline in CD4+ T-Cell Count. 17th International Workshop on HIV Observational Databases. Cavtat, Croatia, 11-13 April 2013. Poster
508. **Vandamme A-M**. Connecting trees to maps: phylodynamics of HIV infection. 2e Congresso Nacional de Medicina Tropical. Lisbon, Portugal. 19-22 April 2013. Invited speaker
509. **Vandamme, A-M**. Connecting trees to maps: redrawing the populations history for viral pathogens. 23rd ECCMID (European Congress of Clinical Microbiology and Infectious Diseases). 27-30 April 2013, Berlin, Germany. Invited speaker.
510. Bartha I, M Assel, P Sloom, M Zazzi, C Torti, E Schülter, A de Luca, A Sönnerborg, AB. Abecasis, K Van Laethem, A Rosi, J Svärd, R Paredes, DAMC van de Vijver, **A-M Vandamme** and V Müller. HIV superinfection does not contribute to transmitted drug resistance. 20th International HIV Dynamics and Evolution Meeting. 8-11 May 2013, Utrecht, The Netherlands. Poster
511. Pineda-Peña A-C, NR Faria, F-J Diaz, P Olaya, C Møller Frederiksen, L Guangdi, A Gomez-Lopez, P Lemey, **A-M Vandamme**. The Colombian Epidemic Is Dominated By HIV-1 Subtype B Over Time: A Molecular Epidemiology And Phylodynamics Study. 20th International HIV Dynamics and Evolution Meeting. 8-11 May 2013, Utrecht, The Netherlands. Poster
512. Vrancken B, A Rambaut, A Drummond, G Baele, M Suchard, E Van Wijngaerden, **A-M Vandamme**, K Van Laethem, and P Lemey. Reconciling host and pathogen trees for a large HIV transmission chain. 20th International HIV Dynamics and Evolution Meeting. 8-11 May 2013, Utrecht, The Netherlands. Poster
513. Menezes SM, D Decanine, R Khouri, SV Schnitman, RA Kruschewsky, **A-M Vandamme**, B Galvão-Castro, J Van Weyenbergh. A selective defect in Fas-mediated apoptosis in HAM/TSP: An ex vivo, in vitro and in silico study. 16th International Conference on Human Retrovirology HTLV and Related Viruses. Montréal Québec Canada. June 26- 30, 2013. Poster.
514. Khouri R, G Silva-Santos, L Farre, A Bittencourt, **A-M Vandamme**, J Van Weyenbergh. Superior antiviral and antiproliferative activity of IFN-beta vs. IFN-alpha in primary ATL cells occurs downstream of STAT1 signaling. 16th International Conference on Human Retrovirology HTLV and Related Viruses. Montréal Québec Canada. June 26- 30, 2013. Poster.
515. Alvarez C, K Verdonck, M Tipismana, M Talledo, J Rosado, D Clark, J Van Weyenbergh, **A-M Vandamme**, E Gotuzzo. HAM/TSP in relatives of HAM/TSP

- cases and in relatives of asymptomatic HTLV-1 carriers. 16th International Conference on Human Retrovirology HTLV and Related Viruses. Montréal Québec Canada. June 26- 30, 2013. Poster.
516. **Vandamme AM**. Interpretação de resistência do HIV-1. 3rd Congresso Brasileiro sobre HIV-AIDS e Vírus Relacionados. Bahia, Brazil, 25-27 July 2013. Invited speaker.
517. Winand R, Eusébio M, Camacho RJ, **Vandamme A-M**, Abecasis AB. Development Of A Phylogenetic Framework For The Detection Of HIV-1 Drug Resistance Transmission Chains. 18th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Gainesville, FL, US. 26-30 August 2013. Poster.
518. Stanojevic M, AMJ Wensing, D Paraskevis, J Vercauteren, K Theys, DAMC Van de Vijver, J Albert, B Asjö, C Balotta, D Beshkov, RJ Camacho, B Clotet, C De Gascun, A Griskevicius, Z Grossman, O Hamouda, A Horban, T Kolupajeva, K Korn, LG Kostrikis, C Kücherer, K Liitsola, M Linka, C Nielsen, D Otelea, R Paredes, M Poljak, E Puchhammer-Stöckl, J-C Schmit, A Sönnernborg, D Stanekova, D Struck, CAB Boucher, **A-M Vandamme** and AB Abecasis. Estimation of selective pressure exerted on HIV sequences from drug naïve patients. 18th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Gainesville, FL, US. 26-30 August 2013. Poster
519. Eusébio M, Winand R, Camacho R, **Vandamme A-M**, Abecasis AB. HIV-1 drug resistance transmission chains in subtype B in Portugal. TasP summit 2013 - Controlling the HIV Epidemic with Antiretrovirals: From Consensus to Implementation. London, UK. 22-24 September 2013. Poster
520. **Vandamme A-M**. Phylogenomics of HIV. International Meeting on Microbial Epidemiological Markers (IMMEM-10). Paris, France. 2-5 October 2013. Invited speaker.
521. Li G, Verheyen G, Ramon J, Eusebio M, Theys K, **Vandamme A-M**. The HIV-1 gag and protease coevolution networks. 14th European AIDS Conference, Brussels, Belgium. Oct 16-19, 2013. Poster.
522. Li G, Verheyen G, Rhee SY, Voet A, Eusebio M, **Vandamme A-M**, Theys K. Functional conservation of HIV-1 gag: implications for rational drug design. 14th European AIDS Conference, Brussels, Belgium. Oct 16-19, 2013. Poster.
523. Eusebio M, Winand R, Pineda-Pena A, Li G, Camacho RJ, **Vandamme AM**, Abecasis AB. TDR levels and mutation patterns in Portugal differ significantly in HIV-1 subtype G compared to subtype B. 14th European AIDS Conference, Brussels, Belgium. Oct 16-19, 2013. Poster.

524. Li G, Piamponsant S, Lemey P, **Vandamme AM**, Theys K. HIV genome-wide diversity and interactions: implications for vaccine and drug design. Infectious Disease Genomics and Global Health, Hinxton, Cambridge, UK. 16-18 October 2013. Oral
525. Boons E, Vanstreels E, Vercruyssen T, Li G, Pannecouque C, Vandamme A-M, Daelemans D. Broad-spectrum anti-HIV activity of a llama single domain intrabody targeting Rev multimerization. BELVIR 2013: First meeting of the Belgian Society for Virology, Brussels, Belgium. 8 Nov 2013. Poster.
526. Pineda-Peña Andrea-Clemencia, Yoeri Schrooten, Lore Vinken, Fossie Ferreira, Guangdi Li, Nidia Sequeira Trovão, Ricardo Khouri, Inge Derdelinckx, Paul De Munter, Claudia Kücherer, Leondios G. Kostrikis, Claus Nielsen, Kirsi Littsola, Annemarie Wensing, Maja Stanojevic, Roger Paredes, Claudia Balotta, Jan Albert, Charles Boucher, Arley Gomez-Lopez, Eric Van Wijngaerden, Marc Van Ranst, Jurgen Vercauteren, Kristel Van Laethem, **Anne-Mieke Vandamme**. Predictors of HIV-1 transmitted drug resistance and transmission networks in the Leuven cohort. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 32, 2014. Poster.
527. Eusébio M., Winand R., Pineda-Peña A.-C., Li G., Gomes P., Camacho R.J., **Vandamme A.-M.**, Abecasis A.B. Transmission clusters of drug resistance in subtype B in Portugal. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 35, 2014. Poster.
528. Cuypers L., J. Snoeck, B. Vrancken, L. Kerremans, G. Vuagniaux, F. Nevens, **A.M. Vandamme**. Analysis of NGS data from heterogeneous HCV1b populations. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 52, 2014. Poster.
529. Lunar M.M., Abecasis A.B., **Vandamme A.M.**, Tomažič J, Vidmar L, Karner P, Vovko T.D., Pečavar B, Poljak M. The characteristics of the HIV-1 subtype B epidemic in Slovenia. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 19, 2014. Poster.
530. Abecasis AB, Bártolo I, **Vandamme AM**, Azevedo-Pereira JM and Taveira N. HIV-1 transmission chains in a court case: use of clonal sequences to test direction and timing of transmission. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 4, 2014. Oral.

531. Hofstra M., N. Sauvageot, J. Albert, I. Alexiev, F. Garcia, D. Struck, D. Van de Vijver, B. Asjo, C. Balotta, D. Beshkov, R. Camacho, S. Coughlan, A. Griskevicius, O. Hamouda, A. Horban, T. Kolupajeva, L. Kostrikis, C. Kücherer, K. Liitsola, M. Linka, O. Mor, C. Nielsen, D. Otelea, D. Paraskevis, R. Paredes, G. Parruti, M. Poljak, E. Puchhammer-Stöckl, A. Sönnernborg, D. Staneková, M. Stanojevic, **A.-M. Vandamme**, S. Zidovec Lepej, C.A.B. Boucher, J.C. Schmit, A.M.J. Wensing, on behalf of the SPREAD program. Prevalence of resistance mutations associated with decreased susceptibility to rilpivirine in antiretroviral naïve patients from Europe. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 6, 2014. Oral.
532. Casadellà M., P. Ham, A. van Kessel, M. Noguera-Julian, C. Pou, F. Garcia, D. Struck, I. Alexiev, B. Åsjö, L. Kostrikis, C. Kücherer, K. Liitsola, M. Linka, C. Nielsen, D. Otelea, D. Paraskevis, M. Poljak, E. Puchhammer-Stöckl, D. Staneková, M. Stanojevic, **A.-M. Vandamme**, S. Zidovec Lepej, B. Clotet, C. Boucher, R. Paredes, A. Wensing on behalf of the SPREAD programme. Primary Resistance to Integrase Strand-Transfer Inhibitors in Europe. 12th European Meeting on HIV & Hepatitis: Treatment Strategies and Antiviral Drug Resistance. Barcelona, Spain. March 26-28, 2014. Reviews in Antiviral Therapy & Infectious Diseases – Volume 2: page 46, 2014. Poster.
533. Sousa João Dinis de, **Vandamme Anne-Mieke** and Müller Viktor. Syphilis and chancroid as novel factors potentially driving HIV emergence. From emerging to pandemic viruses: Interplay between host ecology and viral evolution – Conférences Jacques Monod –Centre National de la RechercheScientifique–April 2-6, 2014, Roscoff, France. Poster.
534. Menezes SM, George Soares, Ricardo Khouri, Daniele Decanine, Gilvaneia Silva Santos, Saul Velloso Schnitman, Ramon Kruschewsky, Giovanni López, Carolina Alvarez, Michael Talledo, Eduardo Gotuzzo, David Brassat, Roland Liblau, **A-M Vandamme**, Bernardo Galvão-Castro, Johan Van Weyenbergh. Monocyte expression of CD86 and CD95 correlates to disease progression in HAM/TSP despite a decrease in total monocytes. Hern in Rome. A Translational Approach. Rome, Italy. June 2-4, 2014. Oral
535. Dierckx T, Ricardo Khouri, Soraya Maria Menezes, Bram Vrancken, Christophe Pannecouque, Achiléa Bittencourt, Lourdes Farré, Bernardo Galvão-Castro, **A-M Vandamme**, Johan Van Weyenbergh. Differentiating between host transcriptomic response to type I IFNS in HTLV-1-infected cell lines. Hern in Rome. A Translational Approach. Rome, Italy. June 2-4, 2014. Oral
536. I. Mamais, J. Albert, K. Angelis, G. Magiorkinis, A. Hatzakis, O. Hamouda, D. Struck, J. Vercauteren, A.M.J. Wensing, I. Alexiev, B. Åsjö, C. Balotta, R.J. Camacho, S. Coughlan, A. Griskevicius, Z. Grossman, A. Horban, L.G. Kostrikis, S.J. Lepej, K.

- Liitsola, M. Linka, C. Nielsen, D. Otelea, R. Paredes, M. Poljak, E. Puchhammer-Stöckl, J.C. Schmit, A. Sönnernborg, D. Staneková, M. Stanojevic, C.A.B. Boucher, **A.-M. Vandamme**, D. Paraskevis. The global spread of HIV-1 CRF01_AE epidemic: a phylogeographic analysis. 20th International AIDS Conference. Melbourne, Australia. July 22-25, 2014. Poster
537. **Vandamme A.-M.** Molecular epidemiology as a forensic technique for HIV and HCV transmission investigation. 19th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Rome, Italy. September 7-12, 2014. Invited speaker
538. Winand R., Eusébio M., Li G., Gomes P., Camacho R.J., Aerts J., **Vandamme A.-M.**, Abecasis A.B. Transmissibility of HIV-1 subtype B Drug Resistance Mutations: A Phylogenetic Framework. 19th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Rome, Italy. September 7-12, 2014. Poster.
539. Cuypers L., Snoeck J., Vrancken B., Kerremans L., Vuagniaux G., Nevens F., **Vandamme A.-M.**. Evaluation of software to map NGS reads from heterogeneous HCV1b populations. 19th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Rome, Italy. September 7-12, 2014. Poster.
540. Libin P., **Vandamme A.-M.** PhyloGeoTool: a tool to visualize large phylogenies in their geospatial context. 19th International Bioinformatics Workshop On Virus Evolution And Molecular Epidemiology. Rome, Italy. September 7-12, 2014. Poster.
541. Kouri V; Yoan Alemán; Lissette Pérez; Jorge Pérez; Carlos Fonseca; Consuelo Correa; Carlos Aragonés; Jorge Campos; Delmis Álvarez; Yoeri Schrooten; Lore Vinken; Celia Limia; Yudira Soto; **Anne-Mieke Vandamme** and Kristel Van Laethem. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. International Congress of Drug Therapy in HIV Infection 2–6 November 2014, Glasgow, UK. Poster.
542. **Vandamme A.-M.** HIV transmission chain investigation, a multidisciplinary approach. 3rd BREACH Symposium. Brussels, Belgium. November 21-22, 2014. Invited speaker.
543. Pineda-Peña Andrea-Clemencia, Yoeri Schrooten, Lore Vinken, Fossie Ferreira, Guangdi Li , Nídia Sequeira Trovão, Ricardo Khouri, Inge Derdelinckx, Paul De Munter, Claudia Kücherer, Leondios G. Kostrikis, Claus Nielsen, Kirsi Liitsola, Annemarie Wensing, Maja Stanojevic, Roger Paredes, Claudia Balotta, Jan Albert, Charles Boucher, Arley Gomez-Lopez, Eric Van Wijngaerden, Marc Van Ranst, Jurgen Vercauteren, Kristel Van Laethem, **Anne-Mieke Vandamme**. Predictors of

HIV-1 transmitted drug resistance and transmission networks in the Leuven cohort. 3rd BREACH Symposium. Brussels, Belgium. November 21-22, 2014. Poster.

544. Sousa João Dinis de, **Vandamme Anne-Mieke** and Müller Viktor. Syphilis and chancroid as novel factors potentially driving HIV emergence. 3rd BREACH Symposium. Brussels, Belgium. November 21-22, 2014. Poster.
545. Winand Raf, Theys Kristof, Eusébio Mónica, Aerts Jan, Camacho Ricardo, Gomes Perpetua, **Vandamme Anne-Mieke**, Abecasis Ana. HIV-1 Transmitted Drug Resistance: New Insights Into the Transmissibility of SDRMs. 9th Benelux Bioinformatics Conference (BBC 2014), Kirchberg, Luxembourg, December 8th-9th, 2014. Poster.
546. **Vandamme A.-M.** Phylogenetic analysis in court: Microbial forensics. Bioinformatics Interest Group (BIG)-meeting, SymbioSys network, 10 Febr 2015, Leuven, Belgium. Invited speaker.